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Abstract
Infectious diseases and cancers have been the major cause of global death and disability
causing a significant impact on global health and economies. Enzyme-linked immunosorbent
assay (ELISA) is one of the most widely used laboratory diagnostic methods for infectious
diseases and cancer. ELISA detects proteins based on their binding to immobilized antibodies or
antigen. Even though most ELISAs performed today in 96-well plates are well suited for high
throughput assays, performing ELISA in low-resource settings is limited by several factors, such
as long incubation time, large volumes of precious reagents, and well-equipped laboratories.
Herein, we have developed multiple simple, miniaturized poly(methyl methacrylate) (PMMA)
and paper/PMMA hybrid microfluidic devices for the detection of infectious diseases and cancer
biomarkers in low-resource settings.
At first, we developed a surface modified PMMA microfluidic microplate, where the
protein was covalently bound either to the carboxylated PMMA surface using carbodiimide
chemistry or to the amine dense PMMA surface functionalized with polylysine. Immobilization
efficiency of proteins on the surface of the modified PMMA was remarkably increased due to the
covalent binding of the protein, thereby improving the sensitivity of ELISA and decreasing the
background noise. The surface modified PMMA microplate, where the protein can be covalently
immobilized within 20 min was used for the ultrasensitive multiplex detection of various
biomarkers including Immunoglobulin G (IgG), Hepatitis B surface antigen (HBsAg), and
Hepatitis B core antigen (HBcAg) with limits of detection (LODs) of 200 pg/mL, 180 pg/mL,
and 300 pg/mL, respectively. The results of the assay can be viewed by the naked eye or scanned
through a simple desktop scanner for quantitative analysis within 90 min as compared to 18
hours in traditional microplates. The surface modified microplate was found to be at least 10-fold
more sensitive than traditional microplates with much less reagent consumption.
To avoid the complicated surface modification steps, we also developed a novel
paper/PMMA hybrid microfluidic microplate using a porous, 3D paper in flow-through
microwells. The use of low-cost chromatography paper in the funnel-shaped microwells
vii

facilitated the rapid immobilization of protein within 10 min as compared to overnight
incubation in traditional microplates. In addition, it also helped in the efficient washing,
decreasing the background noise. The top reagent delivery channels can transfer reagents to
multiple microwells, avoiding repeated manual pipetting or the use of costly robots. Results of
these colorimetric ELISA could be observed by the naked eye within an hour. LODs of 1.3
ng/mL and 1.6 ng/mL for IgG and HBsAg were achieved without any specialized equipment,
which was comparable to commercially used microplate ELISA. Likewise, for the device to be
used in high-end laboratories and hospitals, the hybrid device was redesigned to make it
compatible with traditional microplate readers. Chemiluminescence ELISA of HBsAg, HBcAg,
and Hepatitis C virus core antigen (HCVcAg) was performed in the hybrid device with LODs of
50 pg/mL, 35 pg/mL, and 10 pg/mL, respectively, using commercial microplate reader to read
the device. Our hybrid device was found to be 100-fold more sensitive than 96-well commercial
microplate, even with the reduced amount of sample (5 µL as compared to 50 µL) and assay time
(1 hr compared to 18 hr).
To further increase the sensitivity of the device and to measure low-concentration
analytes, we developed a reusable, cost-effective, and eco-friendly PMMA/paper hybrid plugand-play (PnP) device for analyte enrichment and detection. The sample flowed back and forth
through the low-cost 3D paper substrate within PMMA channels, thereby, enriching the amount
of analyte adsorbed and dramatically decreasing the incubation time. After the enrichment assay,
the paper substrate can be replaced so that the device can be reused. LODs, 10-fold better than
commercial microplate reader and a wide linear range of five and six orders of magnitude was
obtained for IgG and HBsAg, respectively. Finally, we demonstrated the broader application of
our microfluidic approach by developing paper in PMMA pond hybrid microfluidic device for
simultaneous detection of cancer biomarkers including prostate-specific antigen (PSA) and
carcinoembryonic antigen (CEA). The porous 3D paper kept in between the flow-through
reservoir and pond, helped in rapid immobilization of protein and efficient washing, thus
increasing the sensitivity and decreasing the noise. Sandwich type immunoassay was performed
viii

accordingly in the hybrid device, where the reagent is delivered automatically to the papersubstrate through the reagent delivery channel. LOD of 0.32 ng/mL for CEA and 0.20 ng/mL for
PSA was obtained, which is sensitive enough to detect clinical cut off value of 5 ng/mL and 4
ng/mL for CEA and PSA, respectively.
We envisage that these simple polymer/paper hybrid microfluidic microplates can be
used in both underdeveloped and developed countries for low-cost, sensitive, and highthroughput bioassays of infectious diseases, cancer biomarkers, and other bio-molecules.
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Chapter 1: Introduction

•

This chapter introduces infectious diseases and cancer.

•

Current technologies for detection of disease biomarkers and their drawbacks are
described in this chapter.

•

The chapter also describes the application of microfluidic lab-on-a-chip for lowcost detection of disease biomarkers.

•

Finally, the research objectives are explained in the chapter.

1

1.1

Infectious diseases
Acute infectious diseases caused by pathogenic organisms such as bacteria, viruses,

fungi, and parasites have been a major cause of global death and high disability rates throughout
the human history, especially in underdeveloped and developing countries.7, 8 They can directly
or indirectly transmit from one person to another. Our defense against these diseases has been
facing problems like recognition of the pathogens or viruses’ species, strains, virulence factors,
and antimicrobial susceptibilities in a timely manner.9 We are currently in a very fragile balance
with respect to the continual emergence of new infectious diseases and the reemergence of old
infectious diseases, together with the potential for their global spread. The emergence of 335
infectious diseases between 1940 and 2004 in global human population has generated an
extremely significant impact on global health and economies.10, 11 Infectious diseases have been
one of the leading causes of death and out of 58.8 million annual deaths, roughly 25% (15.0
million) deaths are due to infectious diseases.7, 12

1.1.1

Hepatitis B virus
Hepatitis B virus (HBV), a DNA virus from Hepadnaviridae family, is capable of

establishing persistent reservoir in the form of covalently closed circular DNA in hepatocytes.
Permanent elimination of these viruses is extremely low.13 These viruses are highly transmissible
as they are extremely replicable which leads to assembly of concentrated viral particles in body
fluids and blood of the infected person. The continual presence of hepatitis B surface antigen
(HBsAg) for at least 6 months in serum is the diagnostic confirmation of chronic hepatitis B
(CHB), which is a necro-inflammation in the liver due to the extended presence of HBV.14 HBV,
which is one of the major causes of chronic hepatitis damage and hepatocellular carcinoma, has
approximately 2 billion infection cases with 1.2 million deaths every year.15, 16 5-15% of the
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people in developing and underdeveloped countries carry HBV.17 In addition, CHB is the leading
risk factor for hepatocellular carcinoma (HCC), which results in 746,000 deaths per year.18 There
is a high ecological correlation between areas of HBV prevalence and HCC incidence and
mortality.19 To prevent the transmission of HBV, testing of HBsAg has been recommended for
hemodialysis patients, pregnant woman, person exposed to HBV (e.g. infants born to HBVinfected mother, sex partners of infected persons, persons exposed to infectious blood or body
fluids), donors of blood, organs and tissues, HIV-positive persons, injection drug users, and highprevalence populations (high rate of endemic HBV).20 Marcellin et al. found that liver cirrhosis
was reversible with sustained suppression of HBV by long-lasting treatment with tenofovir in
patients with advanced fibrosis or cirrhosis.21 Early detection of biomarkers for HBV remains a
key to fight against the disease and resulting carcinoma.

1.1.2

Hepatitis C virus
Hepatitis C Virus (HCV), the causal agent for a chronic liver infection which was

originally identified as non-A non-B hepatitis, is a single-stranded RNA virus.22 It is a member of
the Flaviviridae family and has six major genotypes (1-6) and a series of subtypes. There is a
worldwide distribution of genotypes 1-3 while genotypes 4 and 5 appear predominantly in
Africa, and genotype 6 in Asia. It has been estimated that worldwide there were 54,000 deaths
and 955,000 disability adjusted life-years associated with an acute HCV infection.23 It has also
been assessed that 3-4 million persons are newly infected every year, 170 million people are
chronically infected and are at risk of developing liver disease including cirrhosis and liver
cancer. Each year 350,000 deaths occur due to all HCV-related causes.24 Out of 500,000 new
cases of liver cancer that occur each year, more than 100,000 (22%) are attributed to the
infection of HCV. HCV has been considered one of the major health problems of global concern
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because studies have shown that estimated 80% of acute hepatitis C can progress as a chronic
infection. Furthermore, 10–20% of HCV infection can develop complications of chronic liver
disease including liver cirrhosis, and finally, 1–5% develop liver cancer25.

1.2

Cancer
Cancer, the uncontrolled growth of abnormal cells in the body with the potential to

invade or spread to other parts of the body through the blood and lymphatic system, figures
among a leading cause of death worldwide accounting for 8.2 million deaths in 2012, according
to World Health Organization (WHO).26, 27 Cancerous cells often invade the surrounding tissues
and can metastasize to distant parts of the body through the blood and lymphatic system. Cancer
is the second leading cause of death in the US, exceeded only by heart disease, accounting for
nearly 1 of every 4 deaths.28 Besides, it is expected that annual cancer cases will rise from 14
million in 2014 to an astonishing figure of 22 million within next 2 decades. The majority of
countries with top incidence rates are developing countries, however, highest mortality rate
occurs in developing countries. The higher mortality in developing countries is due to late
diagnosis, barriers to diagnosis and medical care.29 Much of the burden of cancer such as
incidence, morbidity, and mortality mainly occurs in developing countries.30

1.2.1

Prostate Cancer
Prostate cancer begins as the cells in the prostate gland start growing uncontrollably and

are mostly adenocarcinomas. Prostate cancer is the fourth most common cancer if both sexes are
combined and the second most common cancer in men, and the most common cancer in men in
the developed countries.31 Worldwide, in 2012 an estimated 1.1 million people were diagnosed
with prostate cancer, which accounts for 15% of the cancers diagnosed in men. Out of 1.1
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million, nearly 70% (759,000) occurred in more developed regions. The total prostate cancer
mortality in men is estimated to be 307,000 which represents 6.6% of the total male cancer
mortality and is the fifth leading cause of death from cancer.32 Prostate cancer is primarily
considered as the disease of elderly men, as 85% of all the cases are diagnosed in men who are
older than 65 years. Similarly, 90% of all the deaths due to prostate cancer are in men over the
age of 65 years.33 Prostate cancer incidence remains highest in developed countries like
Australia, New Zealand and North America (largely because of the widespread practice of
prostate-specific antigen (PSA) testing and subsequent biopsy in those regions) and remains low
in the Asian population, eastern and South-Central Asia. Age, ethnic origin, and a positive family
history are the strongest known risk factors. Genes that cause prostate cancer can be inherited
and some of those genes show high penetrance. Advanced prostate cancer requires androgendeprivation treatment which can reduce symptoms in about 70–80% of patients but most tumors
relapse within 2 years to an incurable androgen-independent state.34

1.2.2

Colorectal cancer
Colorectal cancer starts in the colon or the rectum and usually begins as growth called a

polyp on the inner lining of the rectum or colon. The intestinal epithelium is a hotspot for
malignant transformations such as colorectal cancer because it has a very high turnover rate.
Although, there are some types of cancer which are known to run in certain families, however,
most cancers are not hereditary.35 Colorectal cancer is the second most common cancer in
women with around 614,000 cases, which is around 9.2% of total cancer cases. In men, it is the
third most common cancer with 746,000 cases, that is 10.0% of the total cases32. Incidence is
more common in developed regions (55%) such as Australia and New Zealand while lowest in
underdeveloped regions like Western Africa. However, mortality is higher in less developed
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region due to poor prognosis. Total mortality is estimated to be 694,000 per year in both sexes,
which is 8.5% of the total death due to cancer.32 According to a recent study, the global burden of
colorectal cancer is expected to increase by 60% to more than 2.2 million new cases and 1.1
million deaths by 2030.36

1.3

Current technologies for detection of disease biomarkers
A biomarker is a diagnostic indicator for assessing the risk or the presence of a disease. It

is a characteristic that can be measured and evaluated as an indicator of normal biological
processes, pathogenic processes or pharmacologic responses to a therapeutic intervention. It can
include mRNA expression profiles, circulating DNA and tumor cells, proteins, proteomic
pattern, lipids, metabolites, imaging methods or electrical signals. These signals/biomarkers may
be obtained from sources such as urine, blood, and tissues.37
In 1800s, it was found that identifiable microorganisms cause specific diseases, which led
to pathogen-specific medical diagnosis of today’s era. Microbiological culture in a laboratory
setting is commonly used as a significant approach to identify a variety of infectious diseases.38
However, limitations of microbiological culture including a long diagnostic time up to a week to
identify the organism and low-sensitivity especially for patients who have received antibiotic
pre-treatment limit their use.39-41 Gram stain is used as preliminary identification of bacterial
species but should be employed by combining the other diagnostic tools such as traditional
microbiological culture and molecular techniques. The sensitivity is low and the technique
requires well-trained personnel, as it is mostly limited by poor staining.42
Similarly, a biopsy is a procedure to remove a piece of sample or tissue from any
suspected part of the body to analyze in a laboratory for diagnosing cancer. A biopsy is usually
performed if there are any signs or symptoms of cancer or if an area of concern is noticed by the

6

doctor after X-ray or other scanning tests. Recent discoveries in the field of genetics and
molecular biology have revolutionized our understanding of cancer initiation and progression.
Likewise, the knowledge that “genetic changes drive cancer progression” has provided a variety
of molecular markers for early detection of cancer.43 Newer technologies have transformed the
field of molecular diagnosis for cancer.
Due to the high fatality and the high number of infections caused by untreated infectious
disease and cancer, especially in rural and resource-limited settings, a simple, low-cost, rapid,
and highly sensitive approach for immediate detection of infectious diseases and screening of
cancers is in great need. WHO has developed a list of general characteristics that make a
diagnostic test appropriate for resource-limited sites, abbreviated as ASSURED, and includes:
Affordable by those at risk, Sensitive, Specific, User-friendly, Rapid treatment and robust use,
Equipment-free, and finally Delivered to those who need it.44

1.3.1

Quantitative real-time polymerase chain reaction (qPCR)
Quantitative real-time polymerase chain reaction (qPCR) is a laboratory molecular

biology technique used to monitor and quantify the PCR amplification of the target DNA.
Detection can be achieved by using either non-sequence-specific fluorescent dyes that intercalate
with any double-stranded DNA or sequence-specific fluorescent dyes. PCR remains the most
widely adopted nucleic acid amplification method with applications in clinical, biological,
agricultural, environmental, and forensic analysis.

qPCR has been widely employed for

infectious disease diagnosis.46-48
Measurement of HBV DNA is a direct measurement of the viral load, which can show
the replication activity of the virus. HBV DNA assays can be carried out by real-time PCR. PCR
has a limit of detection (LOD) of 10–20 IU/mL. Serum HBV DNA concentrations range from
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undetectable to more than 10⁹ IU/mL during the course of chronic HBV infection.16 Hepatitis C
Virus RNA is detectable in serum as soon as 1 week after the initial exposure. Thus, nucleic acid
testing (NAT) remains the gold standard for diagnosis of HCV infection by PCR and is in routine
use.49
The laboratory setup for performing NAT requires expert technical staffs, expensive
reagents, dedicated procedure areas, and availability of pristine serum or plasma samples. In
addition, qPCR requires laborious and time-consuming sample preparation process such as DNA
purification, and specialized instruments in a well-equipped laboratory such as qPCR,
centrifuges, fluorescent microscopes, and so on, which limits the broad application of qPCR in
low-resource settings.

1.3.2

Enzyme-linked immunosorbent assay (ELISA)
ELISA, one of the most widely used laboratory methods in medical diagnostic and

research applications, is based on the binding of antibodies and antigens50. It is used for detecting
and quantifying substances such as peptides, proteins, antibodies, and hormones. ELISA can
detect the etiologic agents of diseases directly from clinical samples, which is very useful for
rapid detection of uncultivable or fastidious microorganisms. Depending upon the structure and
characteristics of target substances, ELISA can be performed in a variety of ways such as Direct,
Indirect, Sandwich, and Competitive ELISA as shown in Figure 1.1.1
For direct ELISA, the antigen or antibody to be measured is directly coated to the surface
of the plate. After blocking the unbound surface, an enzyme-tagged antibody is added (Figure
1.1). The plate is incubated, followed by the washing of any unbound antibodies. Finally, the
appropriate substrate for the enzyme is added and the signal is measured to determine the amount
of antigen/antibody.
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Figure 1.1: Schematic of different types of ELISA. (Source: Adapted with permission from
Aydin 2015. Copyright © 2015, Elsevier).1
In case of indirect ELISA, the antigen to be measured is first added to the surface of the
plate and blocked. The antibody against the antigen is then added to the plate so that the antibody
binds to the coated antigen (Figure 1.1). Afterward, a secondary antibody coated with the
enzyme is added, which binds with the primary antibody. Finally, a suitable substrate for the
enzyme is added to produce a signal that can be used to determine the amount of antigen.
For sandwich ELISA, capture antibodies are first added to the plate and blocked with
blocking buffer. Antigens to be measured are then added to the plate and incubated, followed by
washing to remove unbound antigens (Figure 1.1). Enzyme-tagged antibodies are then added to
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the plate followed by washing. After the addition of appropriate substrate, the signal is measured
to determine the amount of antigen.
Finally, in case of competitive ELISA, the surface of the well is coated with the antigenspecific antibody. The antigens to be measured (untagged sample) and enzyme tagged antigens
are placed into the plate simultaneously (Figure 1.1). The fixed amount of the tagged and
unknown concentration of the untagged antigen (sample) compete with each other to bind to the
antibody. After washing, the substrate is added and the signal is measured. Unlike other types of
ELISA, there is an inverse proportion between the concentration of the antigen and the signal.
During the past few years, commercial ELISA assays for the quantification of HBsAg
concentrations have been approved in Europe and many countries in Asia for the detection of
HBV.16 Similarly, for the detection of HCV, antigenic characterization has shown that the
Hepatitis C Virus core antigen (HCVcAg) has the potential for the diagnostic marker, and
several assays that rely on detecting the presence of the HCVcAg alone or in combination with
anti-HCV in serum or plasma have been developed commercially.49
ELISA has also been widely used for the detection of cancer biomarkers.
Carcinoembryonic antigen (CEA), is an important tumor marker responsible for clinical
diagnosis of over 95% of all colon tumors, 50% of breast tumors, as well as tumors of the lung,
pancreas, ovaries, and others of epithelial tissue origin, especially of the gastrointestinal tract,
and is widely measured using ELISA.51 Likewise, PSA level in the serum measured using ELISA
and digital rectal examination (DRE) are the recommended methods for the detection of prostate
cancer.33
Even though most ELISAs today which are performed in 96-well plates are well suited
for high throughput assays, they take several hours to complete because of the hour-long
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incubation and blocking time.52 Similarly, other critical issues include consumption of large
volume of precious samples and reagents, dependence on laboratory settings, making
conventional ELISA not suitable for Point of care (POC) detection. In addition, highly
complicated and specialized instruments have to be utilized to automate assays in a highthroughput format, like robotic pipettors, plate washers, and optical detectors. Furthermore, most
detection methods require bulky and expensive equipment, which further limits their application
in POC detection and in developing countries.

1.4

Microfluidic lab-on-a-chip
The microfluidic technique (Lab-on-a-chip (LOC), or micro total analysis system

(μTAS)) developed in the 1990s offer unique opportunities for various biomedical applications.53
It is a miniaturized system that can integrate one or several functional units in a small device.54
They are mostly produced by the microfabrication techniques. Due to the microliter volume of
the microchannels, there is a significant decrease in analysis time from hours to minutes and
minimal reagent consumption. It also allows integrated processing and analysis of complex
biological fluids with high efficiency and sensitivity in the healthcare settings, as well as the
possibility of rapid and multiplex detection.37, 55

1.4.1

Advantages and applications of microfluidic lab-on-a-chip
Microfluidic technology possesses remarkable features for simple, low-cost, and rapid

disease diagnosis, and analysis of complex biological fluids with high sensitivity for healthcare
application. Numerous microfluidic devices have been developed for biomedical applications.
These devices enable on-chip POC diagnosis and real-time monitoring of diseases from a small
volume of body fluids. They have the potential to act as a bridge to improve the global healthcare
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system with high efficiency and sensitivity, mainly for remote areas with scarce resources, such
as the underdeveloped and developing countries, and in emergency situations. Therefore, the
LOC technology has great potential to improve global health through the development of POC
testing devices.56, 57 Microfluidic LOC technology possesses several other remarkable features
which are discussed below:
(1) Microfluidic LOC is a miniaturized system. It is compact, portable, and consumes
much less space with the size of few square centimeters. The device can be easily carried to POC
settings such as the underdeveloped and developing countries and in emergency situations.
(2) Minimum volume of samples and reagents are required. The volume required ranges
from microliters to picoliters, which has significant importance as sample amount can be limited
at times (cancer biopsy, forensic analysis, detection of infectious diseases). It also helps to
reduce the cost by decreasing the volume of expensive reagents.
(3) Analysis time of the LOC devices is considerably faster as compared to traditional
methods. Fast analysis time is due to several factors including short diffusion distances, high
surface-to-volume ratios, increased effective contact areas and concentrations, etc.58
(4) Integration of several laboratory functions within a single miniaturized chip is one of
the most important features of LOC devices. This provides great flexibility to perform various
laboratory functions without the use of sophisticated instruments.
(5) High throughput of the assay remains another remarkable advantage of LOC over
conventional techniques. High throughput assay can be achieved in LOC devices due to the
massive parallelization and high-speed serial processing.
(6) Microfluidic lab-on-a-chip has a better process control as the device is very small and
different processes can be controlled in a better way.
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(7) Concentration gradients and controllable diffusion can be easily achieved by the use
of gradient generator or different kind of substrates and valves.
(8) Finally, the LOC devices are quite economical as compared to traditional methods as
it avoids the use of expensive and sophisticated instruments.
Because of all these significant features, numerous microfluidic devices have been
developed for various applications including:
(1) Biomarker detection in disease diagnosis and biochemical analysis (cancers,
infectious diseases, and other cardiovascular diseases, single-cell analysis);
(2) Environmental monitoring;
(3) Food safety analysis;
(4) Synthesis of chemicals and nanomaterials;
(5) Synthesis of pharmaceutical drugs and drug carriers;
(6) Drug discovery and controlled drug delivery; and
(7) 3D cell culture, organ-on-a-chip, and organism-on-a-chip.37, 55, 58-67

1.5

Substrates for microfluidic platform fabrication
In the early stage of microfluidics, microfluidic devices were predominantly made with

methods borrowed from microelectronics field and involved materials such as glass, quartz or
silicon. Although glass and silicon have good performance in chemical and thermal resistance,
they have expensive and complicated fabrication process, require cleanroom facility, and have
low biocompatibility. In addition, silicon is a high-cost material and not feasible for optical
detection, which further limits the fabrication and applications of silicon-based microfluidic
devices. Silicon and glass are more expensive and less flexible to work with, as compared to
polymers (e.g. polydimethylsiloxane (PDMS), poly(methyl methacrylate) (PMMA)).68-75 Most of
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the polymers have good optical properties similar to glass, but their fabrication (e.g. soft
lithography) does not have stringent requirements on cleanroom facility, which makes polymerbased microfluidic devices widely used.76, 77 Within the past few years, paper-based microfluidic
devices have debuted as a lower-cost microfluidic platform.65, 78 The choice of material depends
on the research application, detection system, fabrication facility, cost, and other factors such as
resistance to different chemicals, thermal conductivity, dielectric strength and sealing properties.

1.5.1

Polydimethylsiloxane (PDMS)
PDMS is among the most commonly used elastomers for microfluidic devices as it is

optically transparent, elastic, and cures at low temperature. It can bind to itself and to a range of
other materials after being exposed to air plasma. The ease and low cost of fabrication as well as
its ability to be cast in high resolution increase its advantages. In contrast to other thermoplastic
materials, PDMS is gas permeable, which makes it compatible with cell culture. PDMS is an
ideal substrate for applications of microfluidic 3D cell culture and organ-on-a-chip.79-81 PDMSbased microfluidic devices have been employed for various applications.82-84 There are different
methods available for the fabrication of PDMS devices including soft lithography, casting,
injection molding, imprinting, hot embossing, and laser ablation.62, 76, 85
Although PDMS is highly suitable for cost-effective microfluidic platforms, there are
some limitations of PDMS as well. PDMS swells in organic solvents and low molecular weight
organic solutes. It cannot withstand high temperature and has low mechanical resistance.

1.5.2

Poly(methyl methacrylate) (PMMA)
PMMA is another extensively used thermoplastic that serves as an economical alternative

to glass and silicon-based microfluidic platforms. PMMA is low-cost, optically transparent, and
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is compatible with a variety of chemical and biological reagents. They have moderately high
mechanical properties. PMMA is easy to fabricate and economical for mass production and does
not require long fabrication and curing time. PMMA devices can be fabricated easily by cutting
the pattern using a CO2 laser cutter followed by bonding with an adhesive or heat to form 3D
devices. Multilayered devices can be completely fabricated and made ready for testing in as little
as several hours.87 All these properties make PMMA a widely used substrate for the fabrication
of microfluidic devices with a variety of applications.88-90
PMMA devices can be fabricated using various methods such as hot embossing or
imprinting, laser ablation, injection molding, and soft lithography.37 Hot embossing and laser
ablation are two generally used micromachining techniques.75, 86 Silicon stamps are the more
commonly used embossing tools for the fabrication of these polymeric microfluidic devices. A
typical hot embossing setup consists of a force frame, which delivers the embossing force via a
spindle and a T-bar to the boss or the embossing master. The microstructures are then transferred
from the master to the polymer by stamping the master into the polymer by heating above its
glass transition temperature (Tg) under vacuum.91 Alternatively, polymer devices can be
imprinted at room temperature with elevated pressure. The master structure is pressed into the
thermoplastic substrate with a force (e.g. 20–30 kN in the case of PMMA) depending on the type
and size of the substrate along with the feature to be imprinted.91 Finally, the master and the
substrate are isothermally cooled to a temperature just below Tg and then separated. The
resulting plastic microchannel dimensions are the exact mirror image of the silicon stamp when
devices are hot embossed.
Laser ablation is also one of the rapid methods for the fabrication of microfluidic
devices.92, 93 Using this technique, the polymer is exposed to a high-intensity laser beam, which
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evaporates the material at the focal point by photo-degradation or thermal-degradation or a
combination of the two. A pulsed laser is typically used, so that each laser shot will ablate a
defined amount of material, depending on the material type and absorption properties, laser
intensity, wavelength, and a number of passes made across the channel. This process leads to the
rough surface of the laser-ablated microchannels and has a rippled appearance, which depends
upon the absorption of the polymer at excimer wavelength. Very high temperature is reached
during ablation and particles are ejected from the substrate creating a void, with small
particulates on the surface of the substrate material while other decomposition products become
gases (carbon dioxide and carbon monoxide). Laser ablation may be achieved in two ways. A
polymer substrate can be exposed to a laser through a mask. A mask is usually made from the
material that does not have significant absorption at the laser wavelength used. In the mask-less
process, which is more commonly used, a polymer substrate is placed on a movable stage and
either the focused laser beam or the substrate is moved across in the x and y-direction as defined
in the desired pattern to create the microstructure in the polymer substrate.
The major limitation of PMMA is the requirement of surface modification for
immobilization of different kinds of sensors and biomolecules.

1.5.3

Paper
Paper-based testing strips for testing pH, diabetes, and pregnancy have been

commercially available for decades. Whitesides group introduced paper-based microfluidic
devices as a low-cost platform for bioassay and since then paper has been widely used in the
field of microfluidics.94 Paper is a thin sheet of material that is generally produced by pressing
together cellulosic or nitrocellulose fibers.78 The biodegradable paper can transport liquids via
capillary effect. Paper, as a low-cost material, has abundant cellulose fibers with three-
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dimensional (3D) microstructures. Paper has good stackability, which allows the formation of 3D
structures for complex assays. The high surface to volume ratio provided by the macroporous
structure in paper improves the immobilization of protein and DNA biomarkers, allowing fast
detection.
Fabrication of paper-based devices is simple and does not require the use of clean-room
facilities. They can be fabricated both in 2D and 3D for either horizontal or vertical flow without
the requirement of the clean room.95 Fabrication of the paper-based devices can be subdivided
into two categories: (i) construction of hydrophobic barriers, and (ii) two-dimensional cutting.
Constructing hydrophobic barriers in the hydrophilic paper matrix is one of the
commonly used methods to prepare paper-based analytical devices. In this way, reagents and
analytes can be made to flow in a certain path, preventing the mixing and spreading across the
surrounding paper surface and achieve multiplex assays, without the issue of crosscontamination. Hydrophobic barriers can be created on the paper through either a physical
deposition or a chemical modification method.96, 97 A number of different fabrication methods
have been developed to fabricate paper-based devices, such as fast photolithography,2, 94 waxbased fabrication techniques,96, 98 saline UV/O3 patterning,99 flexographic printing,100 and alkenyl
ketene dimer (AKD) printing.97
Paper-based devices have some limitations such as poor performance in flow control.
They are not transparent, so it may cause some problem in optical detection. In addition, repeated
washing in paper-based devices may lead to the leakage of reagent through hydrophobic barriers.
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Figure 1.2: Procedure for FLASH fabrication of microfluidic devices in the paper. (A)
Schematic of the method. (B) Designs for channels were printed directly onto paper. (C) FLASH
paper was exposed to UV light. (D) The photoresist-impregnated paper was removed from the
transparency film and black construction paper. (E) The paper was baked on a hotplate. (F) After
developing the paper in acetone and 70% isopropyl alcohol, the microfluidic devices are ready
for use. The dotted lines indicate the edges of the paper. (Source: Adapted with permission from
Martinez et al., 2008. Copyright © 2008 RSC).2
FLASH (Fast Lithographic Activation of SHeets) or photolithography is an extensively
used fabrication technology for constructing hydrophobic barriers in paper-based devices.2
FLASH requires a UV lamp, a printer, and a hotplate along with a photoresist such as SU-8 and
other organic solvents (Figure 1.2). In this technique, a photoresist is first poured onto a piece of
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paper, spread evenly and baked on a hotplate at 130 °C for 5–10 min to evaporate propylene
glycol monomethyl ether acetate (PGMEA) from the photoresist. Then, the paper is covered with
a photomask and exposed to UV light. After incubation in an oven, the chromatography paper is
washed in acetone, followed by rinsing with isopropyl alcohol. The paper-based device is ready
to use after drying.
Another way to create a paper-based microfluidic device is 2D cutting. Paper channels
are cut through computer-controlled X–Y knife plotters or CO2 laser cutters, and then fixed to
suitable plastic cassettes to form hybrid devices.101 Nitrocellulose, conventional photocopy paper
or chromatography paper can be used. Thuo et al. described the use of embossing and a “cutand-stack” method to develop microfluidic devices from a paper.102 They demonstrated that fluid
flow in these devices was similar to open-channel microfluidic devices and cut layer generated
3D systems.

1.5.4

Hybrid microfluidic platforms
Each substrate has its own advantages and disadvantages. PMMA and PDMS are

transparent and rapidly delivers reagents to different regions. With very good optical properties
and high performance in flow manipulation, they have been widely used in microfluidic bioapplications.81, 83, 103, 104 However, these polymers require complicated surface modification to
immobilize biosensors and other biomolecules such as antibodies and enzymes. On the contrary,
paper-based devices can rapidly immobilize biosensors and other biomolecules but do not offer
high performance in flow control especially over a long distance. Paper is not transparent leading
to difficulties in optical detection, though there are efforts to develop the optically transparent
paper.105, 106 Hybrid devices can take advantages of various substrates while eliminating some
limitations of certain substrates. Li group developed the first PDMS/paper hybrid microfluidic
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biochip integrated with aptasensors for simple, one-step, and multiplex pathogen detection.107
Paper in this hybrid device acted as the substrate for facile immobilization of aptamerfunctionalized nano-biosensors without complicated surface modification. Lactobacillus
acidophilus was detected with the LOD of 11.0 cfu/mL within 10 minutes. Two infectious
foodborne pathogens (Staphylococcus aureus and Salmonella enterica) were simultaneously
detected with the hybrid device. Recently, Dou et al. fabricated another PDMS/paper hybrid
microfluidic platform integrated with loop-mediated isothermal amplification for detection of
meningitis-causing bacteria (Figure 1.3).3 It was interesting that they found the hybrid device
provided more stable performance than non-hybrid devices over a period of 2 months.
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Figure 1.3: Chip layout of the PDMS/paper hybrid microfluidic device. (a) 3D illustration of the
schematic of the chip layout. The chip consists of one top PDMS layer, one middle PDMS layer,
and one glass slide for reagent delivery, LAMP reaction, and structure support, respectively. A
chromatography paper disk is situated inside each LAMP zone to preload LAMP primers. (b) A
photograph of the hybrid microfluidic device for infectious disease diagnosis. (c) A cross-section
view of the LAMP zone illustrating the principle of the LAMP detection. (Source: Adapted with
permission from Dou et al., 2014. Copyright © 2014, ACS).3
1.6

Immunoassay on microfluidic devices
Although conventional microplates are widely used in hospitals and clinics, they have

several limitations as discussed in Section 1.3.2. To address those issues, microplate-format
microfluidic devices have been developed for immunoassays. For instance, Kai et al. developed
a 96-well microfluidic microplate for ELISA with improved sensitivity and reduced sample
volumes.52 The microplate was fabricated with clear polystyrene through injection molding. Each
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well was connected to a microfluidic channel on the opposing face of the substrate via a through
reservoir at bottom of the well. The ELISA on this microfluidic microplate took less time and
consumed less reagents as compared to conventional ELISA, but it still required a fluorescence
microplate reader. Sapsford et al. developed a miniaturized 96-well microfluidic chip for
portable ELISAs with colorimetric detection.124 The 96-well ELISA chip was micro-machined
using clear acrylic and polycarbonate (PC) bound together by double-sided tape. Although the
reagent consumption was less than conventional ELISA and a portable detector
(electroluminescence semiconductor strip with a charge coupled device (CCD)) was used,
overnight incubation and manual fluid handling were required. Similarly, Sun et al. fabricated a
miniaturized 96-well device for immunological detection, assembling six layers of PMMA core
and five PC layers.125 They performed electrochemiluminescence ELISA of staphylococcal
enterotoxin B (SEB) using a CCD detector. The microfluidic device required a complicated
functionalization and device assembling steps along with long incubation time to complete the
assay. Overall, all these devices require either long incubation time, surface functionalization or
complicated detection systems.

1.6.1

Immunoassay on paper-based devices
With the emergence of paper-based devices in recent years, various POC analyses,

including paper-based ELISAs have been developed.94, 126, 127 Paper-based ELISA takes advantage
of the high specificity of ELISA and low cost, easy-to-use paper-based devices. Whitesides and
his colleagues performed ELISA in a 96-microzone plate fabricated in the paper.128 Although it
was faster and less expensive, sensitivity was lower than conventional ELISA. Similarly, Li et al.
performed electrochemical ELISA on the paper-based microfluidic device. Electrodes were
screen-printed on the surface of the paper to perform the ELISA of IgG achieving a sensitivity
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similar to conventional ELISA.129 Murdock et al. used 96-well paper-based ELISA for the assay
of human performance biomarker.130 They used complicated and time-consuming conjugation
steps to perform enzyme-free ELISA using gold nanoparticles. Wang et al. performed
chemiluminescence ELISA of tumor markers on a paper-based device (6 x 3 zones). Chitosan
coating and glutaraldehyde cross-linking were required to covalently immobilize antibodies to
perform bioassay for tumor markers.131 Yang et al. fabricated quantum dot-based immunechromatography test strip for the detection of alpha-fetoprotein. It required a time consuming and
exhausting preparation of quantum dots (QD) and QD-antibody conjugates.132 Zhou fabricated
paper-based colorimetric bio-sensing platform for the detection of glucose and protein
biomarkers. 3-aminopropyltriethoxysilane (APTES) modified filter paper cross-linked with
glutaraldehyde was used as the substrate.133 Gold nanoparticles were then adsorbed on the paper
substrate for the absorption of primary antibody. Next, glucose oxidase modified gold nanorod
was prepared as detection anti-PSA antibody. The major drawbacks were a long and tiresome
modification and conjugation steps. Lei et al. performed paper-based immunoassay (8 x 6 zones)
for detection of influenza.134 One of the limitations of the paper-based device is the requirement
of highly sensitive dyes. Other limitations in paper-based ELISA include low-performance in
flow control and the need of repeated micropipetting for adding reagents and washing all the
zones, which is really time-consuming and limits its application for high-throughput detection. In
addition, the repeated washing steps in the micro-zones lead to spreading of the reagents over the
hydrophobic areas, which is one of the serious problems faced in paper-based devices.

1.6.2

Immunoassay on PMMA devices
Polymers such as PMMA require complicated surface modification procedures to

immobilize biosensors and other biomolecules such as antibodies and enzymes. Darain et al.
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activated the PMMA surface with O2 plasma and functionalized it with APTES for stable
antibody immobilization.109 The on-chip ELISA was detected using fluorescence microscopy.
Zhou et al. treated the PMMA under ultrasonic water bath and oxygen plasma before coupling
the capture antibody by the use of EDC reagent.135 Yu et al. developed quantum dot-linked
immune-diagnostic assay where myeloperoxidase antibodies were covalently linked to PMMA
after treating it with polyethylene glycol followed by glutaraldehyde.136 Liu et al. modified the
PMMA using PEI for electrochemical detection of a biomarker of neurological disease.137
Similarly, Liu et al. modified PMMA using PEI to determine trace level of α-fetoprotein and
hepatocellular carcinoma biomarkers.114 Yang et al. performed sandwich ELISA of
Staphylococcal Enterotoxin B by functionalizing antibody with carbon nanotube before
immobilizing it to the PMMA.138 All of these assays require complicated surface modifications
including

PEI

treatment,111,

114

APTES

treatment,109

and

carbon

nanotube

(CNT)

functionalization.125 In addition, they require expensive instruments like fluorescence
microscopy.109, 111

1.7

Research objectives
The goal of this research is to develop low-cost hybrid microfluidic diagnostic platforms

for rapid and sensitive detection of infectious disease and cancer biomarkers.
We have combined highly sensitive ELISA and low-cost microfluidic platform based on
polymer/paper hybrid substrate for rapid and POC detection. We first modified the surface of the
PMMA for the low-cost detection of disease biomarkers. Then, we developed paper/polymer
hybrid device to get rid of complicated surface modification of PMMA for the detection of
infectious diseases including hepatitis B and C virus and cancers including prostate cancer and
colorectal cancer. The organization structure of this dissertation can be seen in Figure 1.4.
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Chapter 3 introduces a simple method of functionalization of PMMA with Polylysine to
be used as the microfluidic substrate for ELISA with high amine density. Chapter 4 introduces an
alternate method to covalently bind the protein to carboxylated PMMA surface using
carbodiimide chemistry. Immobilization efficiency of proteins on the surface of the modified
PMMA was remarkably increased due to the covalent binding of the protein thereby improving
the sensitivity of ELISA and decreasing the background noise. The modified microplate can
immobilize protein within 20 min with much less reagent consumption and results of the assay
can be viewed by the naked eye or scanned through a simple desktop scanner for quantitative
analysis within 90 min. Simultaneous detection of IgG, HBsAg, and HBcAg was performed in
the surface modified PMMA with LODs in the range of 190-360 pg/mL without any specialized
equipment like microplate reader. Surface modified microplates by either method were found to
be at least 10-fold more sensitive than commercial ELISA kits.
Although the surface modified PMMA had good sensitivity and can be used in POC
settings, the complicated surface modification was still required. To get rid of these time
consuming and complicated surface modifications, we developed the hybrid microfluidic
microplate. In chapter 5, development of a simple, miniaturized paper/PMMA hybrid
microfluidic microplate for low-cost, high throughput, and POC infectious disease diagnosis is
discussed. One of the important features of the hybrid device is the funnel-shaped microwells.
The novel use of porous paper in the flow-through funnel-shaped microwells facilitates rapid
antibody/antigen immobilization avoiding complicated surface modifications. The flow-through
microwells also ensure efficient washing, decreasing the background noise. The top reagent
delivery channels can simply transfer reagents to multiple microwells thus avoiding repeated
manual pipetting to all the microwells and costly robots. IgG and HBsAg were quantitatively
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analyzed with good reliability in human serum samples. For the device to be used in the settings
of laboratories and hospitals, the hybrid device was further redesigned to make it compatible
with traditional microplate readers. Chemiluminescence ELISAs of different infectious disease
biomarkers including HBsAg, HBcAg, and HCVcAg were performed and the results could be
analyzed using commercial microplate reader. The sensitivity was found to be around 100-fold
better as compared to commercial 96-well plate ELISA.
To increase the sensitivity of the colorimetric hybrid device, we developed a reusable,
cost-effective, and eco-friendly PMMA/paper hybrid plug-and-play (PnP) device through analyte
enrichment, which is discussed in Chapter 6. The PMMA device has multiple slots where a prepatterned paper substrate can be inserted. The sample flows back and forth through the low-cost
3D paper substrate within the PMMA channels thereby enriching the amount of analyte adsorbed
and dramatically decreasing the incubation time from several hours to a few minutes. After the
enrichment assay, the paper substrate can be simply plugged out of the device and the device can
be reused. The LOD of 200 pg/mL for IgG and 270 pg/mL of HBsAg were observed, which is at
least 10 times more sensitive than commercial ELISA kits. In addition, a wide linear range of
five and six orders of magnitude was obtained for IgG and HBsAg, respectively.
We further demonstrated the broader application of our hybrid device for detection of
cancer biomarkers including PSA and CEA in Chapter 7. A single pre-patterned paper-based
substrate can be kept over the pond-shaped structure of the hybrid device. The device has a
similar flow-through reservoir as discussed in Chapter 5 but the manual addition of papersubstrate to all the microwells is avoided. We further modify the ELISA assay by adding the
capture antibody before adding the sample antigens, thus increasing the sensitivity and reducing
the background noise of the assay. LODs of CEA and PSA were found to be 0.32 ng/mL and
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0.20 ng/mL, respectively, which were 10-fold more sensitive than the clinical cut off value of 5
ng/mL and 4 ng/mL for CEA and PSA, respectively. Chapter 8 presents the concluding remarks
and future directions of the research work.
In summary, the low-cost PMMA and paper/polymer hybrid microfluidic microplates
that we developed have great potential for POC diagnosis of a wide range of infectious diseases
and cancer biomarkers, especially in low-resource settings such as developing countries where
financial and medical resources are extremely limited. In addition, the device can also be used in
high-end hospitals and laboratories for various bioassays.

Figure 1.4: The structure of this dissertation.
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Chapter 2: Experimental

•

This chapter introduces chemicals and materials used in the research projects.

•

Fabrication of paper/polymer hybrid microfluidic microplates is described in this
chapter.

•

The data analysis is demonstrated in this chapter.
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2.1

Chemicals and materials
Microfluidic biochip fabrication materials: PMMA was purchased from McMaster-Carr,

Los Angeles, CA; Whatman #1 chromatography paper was purchased from Sigma, St. Louis,
MO. SU-8, 2010 was purchased from Microchem, Newton, MA.
Surface modification of polymer: Polylysine, sodium hydroxide, and dimethylsulfoxide
(DMSO) were purchased from Sigma Aldrich, St. Louis, MO. Glutaraldehyde was purchased
from Amresco, Solon, OH. Isopropyl alcohol was purchased from J.T. Baker, Center Valley, PA.
N-hydroxysulfosuccinimide was purchased from Thermo Scientific, Rockford, IL. 1-ethyl-3-(3dimethylaminopropyl) carbodiimide hydrochloride was purchased from Advanced ChemTech,
Louisville, KY. Sulfuric acid was purchased from Alfa Aesar, Ward Hill, MA.
ELISA: IgG from rabbit serum, Tween 20, albumin from bovine serum, anti-rabbit IgGalkaline

phosphatase,

polyclonal

anti-carcinoembryonic

antigen,

monoclonal

anti-

carcinoembryonic antigen, prostate-specific antigen, serum from normal human male AB
plasma, 5-bromo, 4-chloro, 3-indoyl phosphate + Nitroblue tetrazolium (BCIP/NBT) liquid
substrate, and Phosphate Buffer Saline (PBS) were purchased from Sigma Aldrich, St. Louis,
MO. HBsAg protein (subtype ad) was purchased from Fitzgerald Industries International Inc.,
Acton, MA. Polyclonal anti-HBsAg was purchased from Novus Biologicals, Littleton, CO.
Hepatitis B virus core antigen, anti-hepatitis B virus core antigens, anti-rabbit IgG-HRP, and
supersignal ELISA pico chemiluminescent substrate were purchased from Fisher Scientific,
Hampton, NH. Cy3-labeled IgG whole molecule was purchased from Jackson Immunoresearch
Laboratories Inc., West Grove, PA. Carcinoembryonic antigen, Hepatitis C virus core antigen,
anti-hepatitis C virus core antigen, polyclonal anti-PSA, and monoclonal anti-PSA were
purchased from Abcam, Cambridge, MA. Ultrapure Milli-Q water (18.2 MΩ.cm) obtained from
a Millipore water purification system, Bedford, MA was used in all assays and reagent
preparation unless otherwise noted.
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2.2

Fabrication of polymer and paper/polymer hybrid microfluidic biochips

2.2.1

Fabrication of PMMA devices
The PMMA devices used in this study were designed by using Adobe Illustrator CS5 and

micro-machined using laser cutter (Epilog Zing 16, Golden, CO). In the mask-less laser ablation,
the PMMA substrate was placed on a stage and the focused laser beam was moved across in xand y- directions as defined in the designed pattern. Desired channels and wells were created on
the PMMA with the ablation of the PMMA by laser.
2.2.2

Two-level laser fabrication of PMMA devices
Since the power and the speed of the laser cutter can affect the depth of microstructures,

in order to achieve the desired depth, we first systematically investigated the relationship
between the depth, power, and the speed of the laser cutter, as shown in Fig. 2.1. It can be seen
that with the increase of the power for a 30 W CO2 laser in the raster mode, the structure depth
increased correspondingly. Additionally, the laser cutter speed also affects the fabrication depth.
The faster the laser’s speed, the shallower is the depth of microstructures. Thus, the percentage
power and the speed required for cutting PMMA was empirically determined. As seen from Fig.
2.1, the speed of 10% and power of 50% could completely pass through a 2-mm thick PMMA
layer creating a reservoir. Similarly, for a 1.5 mm thick PMMA, the speed of 10% and the power
of 35% could be used. Based on the data from Fig. 2.1, different structures with desired depth
can be created on the PMMA of different thickness.
2.2.3

Fabrication of paper/polymer hybrid microfluidic microplates
Pieces of chromatography paper were also designed using Adobe Illustrator CS5 and cut

using a laser cutter. For a paper/polymer hybrid microfluidic microplate, the pieces of
chromatography paper can be manually placed inside each microwell, as a 3D surface for
ELISA. Alternatively, chromatography paper can also be placed just over the middle layer of the
PMMA with microwells, so that the paper pieces directly fall to each microwells in the middle
layer during laser cutting, so that there is no need to place the chromatography paper manually to
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all the wells. For the PnP hybrid device, paper substrate can be inserted into the slot of the device
once it is cut with a laser cutter. Similarly, for a paper in polymer pond device, a single paper
substrate can be kept over the pond before binding different layers of the device.

Figure 2.1: Laser ablation of PMMA at different speeds and powers for two-level
microfabrication of funnel-shaped microwells. The graph shows the depth of microwells
achieved by speed of 10%, 20%, 30%, 40%, and 50%, respectively at different power
percentages of a 30 W laser in the raster mode.
2.2.4

Assembly of the paper/polymer hybrid microfluidic microplates
To assemble the hybrid device, different PMMA layers were overlapped together as in

the design. The layers were then clamped between two layers of glass slabs and kept in an oven
at 115–120 0C for 35 minutes. The chip could be used once it cooled down to the room
temperature. Different PMMA layers could be separated after the assay by applying pressure
between the joints so that the device can be reused after cleaning.
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2.3

Data analysis

2.3.1

Colorimetric assay
Once the substrate for ELISA was added, the chip was incubated for the required time.

The chip was then scanned using a portable flatbed scanner (CanoScan LiDE 700F, Canon). The
average brightness of each test zone was obtained by measuring the gray value using the ImageJ
software, distributed for free by NIH (http://rsb.info.nih.gov/ij/download.html). The signal of an
individual microwell was calculated as the average of the intensity values of respective pixels.
RGB images can be converted to the gray scale using the formula, gray = (red + green + blue) ⁄
3. The display range in ImageJ from minimum to maximum is scaled from 0 to 255. After the
average brightness value was measured using ImageJ, it was subtracted from the maximum value
(255) to get the corrected brightness value, which was then used for data analysis. The value
obtained with a concentration of 0 pg/mL in PBS was defined as the background.
2.3.2

Fluorescence microscope and fluorescence intensities
A highly sensitive Nikon Ti-E fluorescence microscope (Melville, NY) equipped with a

motorized stage and a cooled charge-coupled device (CCD) camera was employed for
fluorescence detection and confirmation of immobilization of IgG on the surface of the modified
PMMA and the paper surface. As Cy3-linked IgG was immobilized on the surface of the PMMA
and the paper substrate, a Cy3 optical filter was used for the fluorescence detection. Fluorescence
intensities of the images of the devices were then measured using the provided software.
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Chapter 3: Simple Polylysine-based Surface Modified Poly(methyl
methacrylate) Microfluidic Device for the Detection of Hepatitis B Virus

•

This chapter introduces a polylysine-based modification of PMMA for covalent
immobilization of proteins.

•

Modified PMMA microplates can immobilize proteins within 20 min and the
results of the assay can be seen by the naked eye without using any specialized
instruments.

•

A rapid and sensitive quantitative detection of infectious diseases can be achieved
within 90 min.

•

Immunoassays for the simultaneous detection of IgG, HBsAg, and HBcAg were
performed in the surface modified microfluidic devices.
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3.1

Introduction
Worldwide, infectious diseases are the leading cause of death and mortality. Unlike other

diseases which can result from multiple interacting risk factors, single agent causes most of the
infectious diseases; the identification of which leads not only the control measures but treatment
measures as well.12 This underlines the need for accurate surveillance and the development of
new strategies for fast, rapid, and sensitive detection of infectious diseases for their control.
ELISA is the most widely used laboratory assay for the detection of disease biomarkers but is
limited by long incubation periods, consumption of significant volume of samples and reagents,
and the requirement of laboratory settings.52, 144 Low-cost and highly sensitive device for the
detection of infectious diseases are needed, especially in resource-limited settings.
As described in Section 1.4, microfluidic devices with features including high surface-tovolume ratio, portability, and integrated processing results in low-cost, minimal reagent
consumption, and rapid bioanalysis of complex biological fluids.37, 62, 146, 147, 152 Different kinds of
substrates including PDMS, PMMA, and paper have been used as microfluidic substrates for the
detection of infectious diseases as described in Section 1.5.55, 148, 153 PMMA is a low-cost, rigid,
and transparent substrate, which is easier to fabricate and mass-produce than PDMS.149 It also
offers better performance under mechanical stress as compared to PDMS. PMMA substrate has
been used to perform ELISA but it shows low sensitivity, as hydrophobic PMMA surface lacks a
functional group to immobilize proteins and thus require surface modifications and complex
detection techniques.110
There is a growing demand to develop easy, fast, sensitive, and preferably inexpensive
detection platform for qualitative and quantitative testing in POC settings. Xu et al. developed a
silicon-based microfluidic device with a complicated micromachining technology to detect HBV
using micro-piezoelectric immunoassay.139 In addition to the requirement of a class-100 clean
room, it required impedance analyzer to measure resonant frequency, although the device had the
LOD of 0.1 ng/mL. Kamińska et al. developed surface-enhanced Raman scattering (SERS)based microfluidic device for HBV detection, which required complicated fabrication and
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modification of the device, and immune-Au nanoflowers.140 In addition, the polycarbonate-based
device required a diode laser, a microscope, and a CCD detector. Akama et al. developed a
droplet-free digital ELISA for detection of HBsAg.141 Tyramide substrate reacted with
horseradish peroxidase (HRP) labeled with an immune-complex on beads releasing fluorescence
signal, which could be counted digitally. The beads were either detected by microscopy or flow
cytometry and cannot be used for POC settings. Shen et al. developed an electrochemical method
for detecting HBsAg using copper-enhanced gold nanoparticle tag and magnetic nanoparticles. It
required complicated and time-consuming preparation of antibody-colloid gold conjugates,
magnetic

Fe3O4

nanoparticles,

APTES-bound

and

aldehyde-functionalized

magnetic

nanoparticles in addition to nearly a 16 hr long assay, as required for conventional ELISA and
cannot be used in POC settings.142 Lee et al. devised a microfluidic disc fabricated from PMMA
and performed immunoassay of HBsAg and anti-HBs by using carboxylated and aminated
polystyrene beads. However, the device was only as sensitive as conventional ELISA.143 Tsai et
al. fabricated a thin channel magnetic immunoassay device, which required a centrifuge, syringe
pump, and modified functional particles that needed to be counted for the preparation of
calibration curve.6 The thin channel consisted of a cut-out Mylar spacer sandwiched between a
plastic and a glass plate. These devices either require specialized instruments and complicated
preparation methodologies or are not very sensitive. With the development of nanoparticles and
microfluidic devices, portability, integrated processing, and rapid bio-analysis have been more
effective and low-cost.144-147 But to date, the development of a POC microarray platform for
multiplex detection, using the miniaturized system, which is as sensitive, effective, and robust as
those based on ELISAs and PCR is still a challenge.37, 55, 148, 149
Sensitivity and background noise of the biochemical assays is profoundly affected by the
total activity and the way of interaction of the specific protein bound to the surface of the assay
substrate109. In addition, the way of interaction is very sensitive towards their environment and
can easily lose their activity as they are brought in close proximity to the solid surfaces110.
Surface chemistry including treatment with oxygen plasma and strong bases/oxidizers are
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necessary for the immobilization of proteins to polymers like PMMA as they lack the functional
groups to bind proteins.112 PMMA surface can be modified by the introduction of carboxyl (COOH), hydroxyl (-OH), or amine (-NH2) reactive groups, which can be further reacted for the
immobilization of the protein.110
Functionalization of PMMA with amine groups has been reported but consists of too
many steps and yielded a low amine density or involves unstable intermediates and nonenvironment friendly solvents.4 Brown et al. characterized the surface modification of PMMA
microfluidic devices for their adhesion properties.4 PMMA surface which was modified using air
plasma, acid catalyzed hydrolysis, and aminolysis (using ethylenediamine), were used to
determine if covalent and or hydrogen bonds between modified PMMA substrate and cover plate
increase the adhesion. Llopis et al. studied the surface modification of PMMA microfluidic
devices for high-resolution separation of single-stranded DNA.113 They created amine-terminated
PMMA surface by a chemical or photochemical process by using ethylenediamine. Methacrylic
acid was then covalently linked and used as a scaffold to produce linear polyacrylamides (LPAs).
It helped them increase the efficiency of separation of single-stranded DNA electrophoretically.
Liu et al. modified the base-treated PMMA by immersing PMMA in poly(ethyleneimine) (PEI)
followed by treatment with glutaraldehyde.114 The modified PMMA chip fabricated by hotembossing machine was used for electrochemical detection of α-fetoprotein (AFP), a
hepatocellular carcinoma biomarker but required a syringe pump and an electrochemical
workstation. Bai et al. studied the surface modification of PMMA to enhance the antibody
binding on the polymer-based microfluidic device to perform ELISA. They found that the PEI
modified PMMA was 10 times more active in binding antibodies as compared to those without
treatment or treated with a small amine-bearing molecule, hexamethylenediamine (HMD).111
They performed the ELISA of IgG with a similar detection limit as the conventional 96-well
plate. PMMA was functionalized for various purposes including ELISA but only provided low
amine density resulting in higher LOD.111 High amine density polylysine has not been used for
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the modification of PMMA to covalently bind the antibodies. In addition, complex detection
techniques with expensive instruments have been used.
In response to aforementioned challenges, we have developed a polylysine modified
microfluidic microplate. Proteins were covalently bound to the surface of the microfluidic
microplate to perform a sensitive, rapid, and high-throughput multiplex assay of biomarkers of
infectious diseases. 64-microwell microplate with an 8´8 series, designed according to standard
384-well ELISA plates with the same X-axis and Y-axis offset but with reduced diameters and
depths was fabricated with a laser cutter so that the working volume could be decreased to 5 µL.
Covalent binding of the antibody to surface modified PMMA resulted in significant
improvement of sensitivity and decrease in the background noise as compared to traditional
microplates. Proteins could be immobilized in the surface modified PMMA within 20 min as
compared to overnight incubation in traditional microplates. Results of the ultrasensitive assay
with a minimal reagent can be viewed by the naked eye within 90 min or scanned through a
desktop scanner for quantitative analysis without the use of any sophisticated instruments.
Simultaneous multiplex detection of IgG, HBsAg, and HBcAg was performed with the LODs of
200 pg/mL, 180 pg/mL, and 300 pg/mL, respectively, which are at least 10-fold more sensitive
compared to traditional ELISA.154
3.2

Experimental

3.2.1

Chemicals and materials
All chemicals and materials are listed in Section 2.1.

3.2.2

Design and fabrication of the microfluidic microplate
The chip used in this study was designed in Adobe Illustrator CS5 and micro-machined

using a Laser cutter. The wells in the PMMA layer were designed according to the dimension of
standard 384 well plates. As seen from Figure 3.1, the X-axis and Y-axis offset are 4.5 mm (d),
which, is the length between the centers of 2 wells. The position of the first well corresponds to
A1 of a microtiter plate. A1 row offset (distance from the top edge of the microplate to the center
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of wells in 1st row) of the chip is 8.99 mm (a), similar to 384 well microtiter plates. In addition,
A1 column offset (distance from the side edge of the microplate to the center of wells in 1st
column) of 12.13 mm (b) is also same as a microtiter plate. The diameter of each well was
reduced to 3.6 mm (c).
3.2.3

Covalent modification of the PMMA surface
The PMMA microplate was functionalized using two different methods, where

aminolysis of the PMMA surface was performed using polylysine followed by activation using
glutaraldehyde for the covalent modification of antigen. (Figure 3.1B). In the first method, the
PMMA microplate was sonicated for 5 min in 40% by volume of aqueous 2-propanol solution.
After the PMMA microplate was dried, it was immersed in 0.2% (v/v) polylysine in DMSO for
20 min at room temperature followed by rinsing in 2-propanol solution. Finally, the aminated
PMMA microplate was immersed in a glutaraldehyde solution (1% v/v) at room temperature for
30 min. Glutaraldehyde, which acts as a cross-linker form the Schiff base with the amine group
of polylysine. The glutaraldehyde activated PMMA microplate was washed once with PBS and
used for the immobilization of antigen/antibody by forming Schiff base at the other end of
glutaraldehyde. In the second method, the PMMA microplate was immersed in a 1 N sodium
hydroxide (NaOH) solution at 55 0C for 30 min followed by immersing in 0.2% aqueous
polylysine solution at room temperature with pH of 7 for 1 hr. After the aminolysis, PMMA was
immersed for 30 min in 1% v/v glutaraldehyde solution at room temperature. The surface
modified PMMA was then used for the immobilization of antigen/antibody and further for
ELISA procedure after washing it with PBS.
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Figure 3.1: Microfluidic platform design and surface modification. (A) Photograph of the actual
device with a black background with A1 row offset (a), A1 column offset (b), the diameter of the
well (c), and X-axis and Y-axis offsets (d). (B) Schematic of the covalent modification of
PMMA using polylysine.
3.2.3

FTIR analysis
FTIR-spectroscopy was used for the structural analysis and verification during the

process of surface modification of PMMA. PMMA was first cut into small square pieces of 1 cm
´ 1 cm by using a laser cutter. Then, the PMMA was laser ablated to obtain wells with a
diameter of 3.6 mm. The FTIR spectra were recorded by an FTIR spectrometer, PerkinElmer
Spectrum 100. The FTIR spectra were recorded after each modification steps for both the
modification procedure to characterize specific functional groups. FTIR spectra were taken for
pristine PMMA, polylysine modified PMMA (PMMA + Polylysine), glutaraldehyde cross-linked
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PMMA (PMMA + polylysine + glutaraldehyde), and antibody immobilized PMMA (PMMA +
polylysine + glutaraldehyde + antibody).
3.2.4

Protein immobilization validation
Unspecific absorption of protein leads to a reduction of functional sites and increase in

the background signal. Wells were created in PMMA sheets using a laser cutter. 20 µg/mL of
Cy3 IgG were added to the surface modified PMMA (both methods), plasma treated PMMA, and
pristine PMMA to see the protein immobilization efficiency. Cy3 IgG was not added to one set
of PMMA to record the background fluorescence of PMMA. For plasma treatment of PMMA,
the laser ablated PMMA was placed in a plasma cleaner (PDC-32G, Harrick Plasma, NY, USA)
for 1 min. PMMA devices were incubated for 20 min with Cy3 IgG, then washed three times
with phosphate buffered saline with Tween 20 (PBST) before measuring the fluorescence
intensity, which was accomplished using a Nikon Ti-E fluorescence microscope.
3.2.5

ELISA of HBV biomarkers
The surface modified PMMA was used for the ELISA of different biomarkers for

infectious diseases including IgG, HBsAg, and HBcAg. For the ELISA of IgG, the rabbit IgG
was used as the analyte. 5 μL of IgG between the concentration from 0.1 ng/mL to 100 μg/mL
(in 10 mM, pH 8.0 PBS) were then added to each microwells. Each concentration had eight
replicas along the same column of the chip. IgG solutions were prepared from the stock solution
of 2mg/mL IgG. The chip was incubated at room temperature for 20 min. Following the reaction,
5 μL of Bovine Serum Albumin (4.5 % BSA w/v in PBS + 0.05% Tween 20) was added for 20
min to block the unreacted surface of the PMMA. Next, the chip was thoroughly washed with 5
μL of washing buffer PBST (10 mM, pH 7.4 PBS+ 0.05% Tween 20) to get rid of unbound
proteins. After washing, 5 μL of enzyme-linked antibody, i.e., anti-rabbit IgG-Alkaline
phosphatase (6 µg/mL) was added and incubated at room temperature for 7 min. Finally, the chip
was thoroughly washed with PBST for three times and 5 μL of the substrate (BCIP/NBT) was
added. The substrate, which was initially light yellow in color, was converted to insoluble dark
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purple NBT diformazan as the product which could be observed visually with the naked eye.
Following 10 min of incubation with the substrate, an office scanner was used to scan the chip.
Quantitative detection was carried out using the free software, ImageJ by measuring the
brightness value of each wells of the chip.

Figure 3.2: Schematic of the approach of immunoassay of HBsAg on the surface modified
PMMA microplate, comprising of eight steps: (1) Immobilizing antigen on the surface of
modified PMMA, (2) Blocking, (3) Washing, (4) Binding of enzyme conjugated antibody, (5)
Washing, (6) Addition of secondary antibody, (7) Washing, (8) Addition of the substrate, and (9)
Enzymatic production of insoluble NBT diformazan.
HBsAg and HBcAg were also tested for the detection of HBV and a similar assay
procedure as IgG was followed. For the detection of HBsAg, first, the antigen (i.e. HBsAg) was
immobilized on the modified surface of the PMMA (Figure 3.2). After the antigen was incubated
for 20 min, blocking buffer was added for another 20 min. The incubation was followed by a
thorough washing with PBST and addition of anti-HBsAg for another 20 min. Finally, after
washing it with PBST, a sandwich-structure immunoassay was formed by the addition of ALPlabeled anti-rabbit IgG. Like the detection of HBsAg, for the detection of HBcAg, anti-HBcAg
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was added after the initial immobilization of HBcAg. Finally, ALP-labelled anti-rabbit IgG was
added to form a sandwich immunoassay. The chip was scanned 10 min after the addition of the
substrate BCIP/NBT in both cases.
3.2.6

Multiplex detection of HBsAg and HBcAg
Here, the device was used for multiplex detection of HBsAg and HBcAg. The first

column was negative control with PBS and no antigen. HBsAg was immobilized in the second
and third columns, HBcAg was immobilized on the fourth and fifth columns, while both HBsAg
and HBcAg were immobilized in the sixth, seventh, and eighth columns. The concentration of
capture antigen was 200 ng/mL of HBsAg or 200 ng/mL of HBcAg except for the sixth column
where 100 ng/mL of each capture antigen was added. Different combinations of antigens were
incubated for 20 min and then blocking buffer was added for another 20 min followed by
thorough washing with PBST. After that, anti-HBsAg was added in second, fourth, and seventh
columns; anti-HBcAg was added in third, fifth, and eighth columns while both anti-HBsAg and
anti-HBcAg were added in first and sixth columns. After the primary antibodies were incubated
for 20 min, the ALP-labelled secondary antibody was added and incubated for another 7 min.
Finally, the device was scanned using a simple office scanner, 10 min after the addition of the
substrate.
3.2.7

Anti-interference test for the detection of HBsAg
Real world samples such as blood serum, urine, and cerebrospinal fluid, contain various

complex ingredients consisting of different biomolecules with a wide range of concentrations. A
high anti-interference capability is required to screen varieties of disease biomarkers, as these
biomolecules may interfere the detection of target proteins. The various columns in the surface
modified device were used for anti-interference experiments, where HBsAg was detected with
and without various interfering proteins. The first four columns from the left were the negative
control without the analyte (HBsAg) and consisted of 1 μg/mL HBcAg, 100 ng/mL CEA, 250
μg/mL BSA, and 10 ng/mL PSA, respectively. Fifth, sixth, and seventh columns had 1 μg/mL
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HBcAg, 100 ng/mL CEA + 10 ng/mL PSA, and 250 μg/mL BSA, respectively along with 200
ng/mL of HBsAg. The eighth column had 200 ng/mL of HBsAg. Different combinations of
antigens were incubated for 20 min at the room temperature followed by blocking with the
blocking buffer for 20 min. After thorough washing with washing buffer, anti-HBsAg was added
followed by washing and addition of ALP-labelled secondary antibody for 7 min. Finally, the
device was scanned 10 min after the addition of the substrate.
3.3

Results and discussion

3.3.1

FTIR characterization of PMMA surface modification
FTIR characterization was performed after every step of PMMA modification, starting

from pristine PMMA to identify different functional groups. As we can see from the FTIR
spectrum of the pristine PMMA in Figure 3.3, C–O–C stretching vibration showed a distinct
absorption band from 1,150 cm−1 to 1,250 cm−1. Similarly, two bands for the α-methyl group
vibrations were seen at 1,387 cm−1 and 750cm−1. Characteristic absorption vibration of PMMA
was represented by the band at 986 cm−1 along with the bands at 1,063 cm−1 and 841 cm−1.
Presence of the acrylate carboxyl group could be confirmed by the band at 1,723 cm−1. Bending
vibration of the C–H bonds of the -CH3 group could be attributed to the band at 1,435 cm−1.
Finally, two bands at 2,995 cm−1 and 2,951 cm−1 could be assigned to the C–H bond stretching
vibrations of the –CH3 and –CH2- groups, respectively. This spectrum correlated well with the
FTIR spectrum of PMMA that has been documented in the literature.155
Some major changes could be observed in the spectrum of PMMA after modification
using method 1 (Figure 3.3A). The presence of Amide I (1652 cm−1), Amide II (1533 cm−1) and
C-N stretch, as well as substantially less intense methyl ester bands after the treatment of PMMA
with polylysine, showed that the PMMA was aminated by polylysine. This data suggest
PMMA’s ester bond was replaced by the amide bond of polylysine as seen in literature for
amine-modified PMMA.155 The aminated PMMA was further treated with glutaraldehyde as seen
from C=O (1637 cm−1) and C-N (1442 cm−1) stretch vibration to covalently bind the antibody to
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the PMMA surface. We could see strong absorption for Amide I (1646 cm−1) and Amide II (1555
cm−1) after the addition of the antibody, which indicated the covalent binding of the antibody to
the modified PMMA surface.

Figure 3.3: Characterization of the polylysine-based surface modification of PMMA. (A) FTIR
analysis of the modified PMMA surface (modification method #1). (B) FTIR analysis of
modified PMMA surface (modification method #2).
Some major changes were also observed in the spectrum of PMMA after the treatment
with NaOH to form hydroxyl groups followed by treatment with polylysine to get aminated
PMMA (method# 2, Figure 3.3B). The presence of Amide I (1617 cm−1), Amide II (1534 cm−1)
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and C-N (1435 cm−1) stretch after the treatment of PMMA with polylysine showed that the
PMMA was aminated by Polylysine. Also, we could observe the CH2 stretching mode of
vibration at 2933 cm−1 and V1 proton mode band of the peptide at 3239 cm−1. The aminated
PMMA was further treated with glutaraldehyde as seen from C=O (1637 cm−1) and C-N (1440
cm−1) stretch vibration to covalently bind the antibody to the PMMA surface. We could observe
strong absorption for Amide I (1643 cm−1) and Amide II (1541 cm−1) after the addition of the
antibody, which indicated the covalent binding of the antibody to the modified PMMA surface.

Figure 3.4: Characterization of the polylysine-based surface modification of PMMA by
fluorescence microscopy. The bar graph shows the fluorescence intensity of Cy3 immobilized on
different surfaces of PMMA.
3.3.2

Confirmation of protein immobilization
Fluorescence microscopy was used to investigate the modification and the differences in

immobilization of antibody between the modified PMMA and the pristine PMMA. Figure 3.4
shows that polylysine modified PMMA (both method 1 and 2) gave around seven-fold higher
fluorescence intensity as compared to pristine PMMA indicating the increase in efficiency of
immobilization of the antibody. Method #1 (Ply/DMSO) had a slightly higher intensity as
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compared to method #2 (Ply/NaOH), but the increase in intensity/immobilization was
insignificant. We could also observe a three-fold increase in fluorescence intensity of polylysine
modified PMMA as compared to plasma treated PMMA. The blank represented the small
background fluorescence intensity of PMMA without the addition of Cy3 IgG. The result
showed that the immobilization efficiency of protein was significantly increased, confirming the
surface modification of the PMMA which may ultimately lead to the increase in the sensitivity of
ELISA.
3.3.3

ELISA of biomarkers for HBV
To demonstrate the feasibility of detection of HBV biomarkers, we first performed the

colorimetric ELISA for the detection of IgG using the surface modified PMMA microplate. IgG
which is the most common antibody in the human blood can be used for diagnosis of
autoimmune hepatitis and Neuromyelitis Optica.156, 157 We performed ELISA of IgG with 10-fold
diluted concentrations ranging from 100 μg/mL to 0.1 ng/mL. Each of the microwells just
required 5μL of the sample and each concentration had 8 repeats as seen from Figure 3.5. The
chip was scanned using a simple office scanner, 10 min after the addition of the substrate. The
brightness value of each spot was then measured by ImageJ as described in Section 2.3.1. We
could observe that the intensity of the purple color increased from left to right in Figure 3.5A, as
the concentration increased from 0.1 ng/mL to 100 μg/mL. The purple color got saturated as the
concentration increased higher than 10 μg/mL, leading to the plateau in the calibration curve.
Figure 3.5B shows the calibration curve for the detection of IgG by plotting corrected brightness
against the concentrations of IgG. The LOD is defined as the concentration value that generates a
signal three standard deviation (SD) above the blank value. The fitted curve of IgG in the surface
modified PMMA microplate (#1 method) was linear from 102 pg/mL to 106 pg/mL with a linear
regression of y = 9.72 log (x) + 98.95 (R2 = 0.98). The LOD of IgG in the surface modified
PMMA microplate (#1 method) was found to be 200 pg/mL.
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Figure 3.5: Detection of IgG in the surface modified PMMA microplate (#1 method). (A)
Scanned image of enzymatic converted substrate in different columns of the chip with
concentrations from left to right: blank, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1 μg/mL, 10
μg/mL, and 100 μg/mL, respectively. (B) The sigmoidal curve of the corrected brightness of IgG
over a concentration range of 102 pg/mL to 108 pg/mL.

Similar to the detection of IgG by using the surface modified PMMA (#1 method), the
calibration curve of IgG in surface modified PMMA microplate (#2 method) was linear over the
range of 102 pg/mL to 107 pg/mL with saturation above 107 pg/mL and the linear regression of y
= 12.26 log (x) + 42.49 (R2 = 0.98). The LOD of IgG in the surface modified PMMA microplate
(#2 method) was found to be 140 pg/mL (Figure 3.6) which was almost similar to #1 method.
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The LOD of IgG was found to be more than 10-fold sensitive as compared to commercial 96well microplate ELISA (LOD, 1.6 – 6.25 ng/mL) without the use of any specialized instrument
like microplate reader.154 In addition, our device just required 5 μL of sample and 90 min of
assay time compared to 50-100 μL of sample and 18 hr of assay time in a traditional microplate.
Our surface modified device is also more sensitive as compared to the APTES modified PMMA
(12 hr incubation time and LOD of 0.12 μg/mL),109 the paper-based device (54 f/mol/zone),128
and our previous hybrid device (LOD, 1.6 ng/mL).5 Bai et al. also used amine bearing
poly(ethyleneimine) to modify the PMMA but got LOD only comparable to a 96-well plate and
linear dynamic range from 5 to 500 ng/mL even with the use of fluorescence microscope.111
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Figure 3.6: Detection of IgG in the surface modified PMMA microplate (#2 method). (A)
Scanned image of enzymatic converted substrate in different columns of the chip with
concentrations from left to right: blank (PBS), 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1
μg/mL, 10 μg/mL, and 100 μg/mL, respectively. (B) The sigmoidal curve of the corrected
brightness of IgG over a concentration range of 102 pg/mL to 108 pg/mL.
For the detection of Hepatitis B virus, HBsAg and HBcAg were tested. HBsAg has been
mainly used for the diagnosis and remission of hepatitis B.158, 159 It can be seen from the figure
that the purple color intensity increased with the increased concentration of HBsAg (Figure 3.7).
As observed in the calibration curve of IgG, the purple color intensity got saturated at higher
concentration of HBsAg, starting from 34 μg/mL. The calibration curve of HBsAg on the surface
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modified PMMA microplate (#1 method) was linear over the range of 34´101 pg/mL to 34´106
pg/mL with a linear regression of y = 13.13 log (x) + 75.1 (R2 = 0.98). The LOD of HBsAg on
the surface modified PMMA (#1 method) was found to be 180 pg/mL.

Figure 3.7: Detection of HBsAg in the surface modified PMMA microplate (#1 method). (A)
Scanned image of enzymatic converted substrate in different columns of the chip with
concentrations, from left to right: blank (PBS), 0.34 ng/mL, 3.4 ng/mL, 34 ng/mL, 340 ng/mL,
3.4 μg/mL, 34 μg/mL, and 340 μg/mL, respectively. (B) The sigmoidal curve of the corrected
brightness of ELISA of HBsAg over a concentration range of 34´101 pg/mL to 34´107 pg/mL.
Similarly, the calibration curve of HBsAg on the surface modified PMMA microplate (#2
method) was linear over the range of 34´101 pg/mL to 34´106 pg/mL with saturation at 34
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μg/mL. The calibration plot had a linear regression of y = 16.46 log (x) + 74.9 (R2 = 0.98). The
LOD of HBsAg in the surface modified PMMA microplate (#2 method) was found to be 160
pg/mL (Figure 3.8). The LODs obtained from both methods of surface modification was found to
be similar. Besides, the LOD of our surface modified device was found to be more sensitive than
commercial ELISA kits, HBsAg assay by Yazdani et al. (LOD of 0.7 ng/mL), and our previous
hybrid device with LOD of 1.3 ng/mL.5, 160 Our LOD was similar to Xu et al. (LOD of 0.1
ng/mL) micro-piezoelectric immunoassay that required experiment in a class-100 clean room
and an impedance analyzer.139
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Figure 3.8: Detection of HBsAg in the surface modified PMMA microplate (#2 method). (A)
Scanned image of enzymatic converted substrate in different columns of the chip with
concentrations, from left to right: blank (PBS), 0.34 ng/mL, 3.4 ng/mL, 34 ng/mL, 340 ng/mL,
3.4 μg/mL, 34 μg/mL, and 340 μg/mL, respectively. (B) The sigmoidal curve of the corrected
brightness of ELISA of HBsAg over a concentration range of 34´101 pg/mL to 34´107 pg/mL.
ELISA of HBcAg and all other subsequent ELISA were performed in the surface
modified PMMA (#1 method) because the LOD for both the modification methods were similar
but modification method #1 was more time efficient (1 hr) compared to the modification method
#2 (2 hr). For ELISA of HBcAg, different concentrations of HBcAg between 0.1 ng/mL to 10
μg/mL were evaluated. As we can observe from Figure 3.9, the color intensity increased slightly
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at lower concentration up to 1 ng/mL after which the intensity increased rapidly until 1 μg/mL,
after which the intensity increased slightly. The calibration curve of HBcAg in surface modified
PMMA microplate (#1 method) was linear over the range of 103 pg/mL to 107 pg/mL with a
linear regression of y = 14.7 log (x) + 15.5 (R2 = 0.98). The LOD of HBcAg on the surface
modified PMMA microplate was found to be 300 pg/mL (Figure 3.9) which was more sensitive
than commercial ELISA kits.154

Figure 3.9: Detection of HBcAg in the surface modified PMMA microplate. (A) Scanned image
of enzymatic converted substrate in different columns of the chip with concentrations from left to
right: blank, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1 μg/mL, and 10 μg/mL, respectively.
(B) The sigmoidal curve of the corrected brightness of HBcAg over a concentration range of 102
pg/mL to 107 pg/mL.
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3.3.4

Multiplex detection of HBsAg and HBcAg
To demonstrate that the surface modified PMMA microplate has an efficient multiplex

biomarker sensing capability, the surface modified PMMA microplate was used for simultaneous
colorimetric detection of biomarkers for HBV (HBsAg and HBcAg). As shown in Figure 3.10,
the first column was negative control without any antigen, hence no color was developed.
Second and third columns were for the detection of HBsAg while fourth and fifth columns were
for the detection of HBcAg. Third and fourth columns didn’t develop color, as they didn’t have
the respective antibody against the antigen but second and fifth columns developed color as they
had their respective antibody. This also acted as specificity test, as HBsAg could only bind to
anti-HBsAg (2nd column) and not anti-HBcAg (3rd column). Sixth, seventh and eight columns
had both antigens i.e. HBsAg and HBcAg. All of them developed color as they had their
respective antibody or the mixture of both antibodies. Figure 3.10 shows the multiplex detection
of biomarkers including HBsAg and HBcAg, as well as the specificity test of different
biomarkers in the surface modified PMMA microplate.
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Figure 3.10: Multiplex assay of HBsAg and HBcAg in the surface modified PMMA microplate.
Scanned image of the enzyme-catalyzed substrate (A) and bar plot of the corrected brightness of
the scanned image (B). From left to right: immobilized probe, none (1), HBsAg (2) and (3),
HBcAg (4) and (5), and HBsAg + HBcAg (6), (7), and (8), respectively. Test: From left to right:
solution containing, anti-HBsAg and anti-HBcAg (1) and (6), HBsAg (2), (4), and (7), and
HBcAg (3), (5), and (8). “a” and “b” shows that the data are significantly different from each
other at p = 0.05.
3.3.5

Anti-interference test for the detection of HBsAg
The detection assay needs to have a high anti-interference capability to screen various

infectious diseases as the serum contains complex ingredients consisting of different proteins
with a wide range of concentrations that may interfere the detection of target proteins. So, anti-
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interference experiments were performed in various columns of the modified PMMA. The
experiment shows the detection of 200 ng/mL of HBsAg with and without various
concentrations of interfering proteins (1 μg/mL HBcAg, 100 ng/mL CEA, 250 μg/mL BSA, and
10 ng/mL PSA). As shown in the Figure 3.11, first four columns didn’t contain HBsAg, while
the last four columns contained 200 ng/mL of HBsAg with various concentrations of interfering
proteins. In the absence of HBsAg, there was no development of color in first 4 columns of the
device from the left. Furthermore, the color intensity for the detection of 200 ng/mL of HBsAg in
the presence of different interfering proteins (column 5, 6, and 7) was similar to the detection of
200 ng/mL of HBsAg without the interfering proteins (column 8). It demonstrates that even
1,250 times concentrated interfering proteins could not influence the specific detection of
HBsAg in the surface modified PMMA microplate.
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Figure 3.11: Anti-interference test for the detection of HBsAg in the surface modified PMMA
microplate. The scanned image of the chip after the assay (A) and the corrected brightness of the
scanned image of ELISA in the chip (B). Left four columns: Detection of 0 ng/mL of HBsAg in
1µg/mL of HBcAg (1), 100 ng/mL CEA (2), 250 µg/mL BSA (3), and 10 ng/mL PSA (4),
respectively. Right four columns: Detection of 200 ng/mL of HBsAg in 1µg/mL HBcAg (5), 100
ng/mL CEA + 10 ng/mL PSA (6), 250 µg/mL BSA (7), and PBS (8), respectively. “a” and “b”
shows that the data are significantly different from each other at p = 0.05.
3.4

Summary
In summary, we have developed a novel polylysine-based surface modification method to

functionalize PMMA microplate for enhanced covalent binding of the protein to perform an
ultrasensitive immunoassay for various biomarkers. Amine dense polylysine was used to

57

introduce amine groups onto PMMA surface while the glutaraldehyde acted as a cross-linker
ultimately increasing the immobilization efficiency of the protein within a short period of time
(20 min compared to overnight incubation in traditional methods). The surface modified PMMA
was able to improve the sensitivity of the assay without using the complex detection system.
LODs of 200 pg/mL, 180 pg/mL, and 300 pg/mL were obtained for IgG, HBsAg, and HBcAg,
respectively, which were at least 10-fold more sensitive than traditional microplate readers. In
addition, a wide linear range of detection, dramatically low reagent consumption, and a short
assay time of 90 min was achieved. The basic system used here can perform 8 × 8 or 7 × 8
assays but the design can simply be modified to perform as many experiments and repeats as
desired. In future, the study may lead to a simple, ultrasensitive, and POC device for the
simultaneous detection of low concentration biomarkers in a very low sample volume of
different body fluids such as saliva, tear, urine or serum. The device may find broad applications
in biochemical assays and clinical diagnosis, especially in low-resource settings and developing
nations.
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Chapter 4: Detection of Biomarkers for Hepatitis B Virus in Surface
Modified PMMA Microplates with Carbodiimide Chemistry

•

This chapter introduces carbodiimide chemistry-based modification of PMMA for
covalent immobilization of proteins.

•

Surface modified PMMA microplate can immobilize proteins within 20 min and
results of the assay can be seen by the naked eye without using any specialized
instruments.

•

A rapid and sensitive quantitative detection of infectious diseases can be achieved
within 90 min.

•

Immunoassay for the detection of HBV was performed in the surface modified
PMMA microplate with the LODs of 360 pg/mL and 380 pg/mL for HBsAg and
HBcAg, respectively.
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4.1

Introduction
One of the most initial plans for the treatment of HBV is the screening or the diagnosis of

the virus and the antiviral treatment of the infected people before it develops into an advanced
liver disease or cirrhosis. According to Toy et al., it is economically beneficial to prevent or
delay progression by antiviral treatment and cost-effective diagnosis for CHB related liver
diseases owing to the increased cost of the disease management.161 In addition, United States
Preventive Task Force recommends that screening is beneficial for the population at high risk for
HBV infection as they found convincing evidence that early antiviral treatments are effective in
improving clinical outcomes of HBV infected patients.162 The control of infection due to HBV
has been a burdensome task, especially in under-developed countries due to limited access to
diagnostics and antiviral treatment resulting from high costs and deficient infrastructures in
healthcare systems.163 The currently available diagnostic technologies are not suitable for POC
settings as they are tiresome, consume a large volume of samples, require overnight incubation
and expensive resources. There is a growing demand to develop easy, fast, sensitive and
preferably inexpensive HBV detection platform for qualitative and quantitative testing in POC
settings.144-147 But to date, the development of a POC microarray platform for multiplex detection
using the miniaturized system, which is as sensitive, effective, and robust as those based on
ELISAs and PCR is still a challenge.37, 55, 148, 149
Varieties of challenges need to be mastered to develop highly sensitive and specific POC
device for viral analysis in blood samples. Viral biomarkers’ concentration is extremely low at
early stages and to improve signal-to-noise ratio, enrichment may be needed164 or the device
substrate may need to be modified to increase the sensitivity. Acid/base catalysis or plasma/UV
treatment followed by carbodiimide conjugation can also be used to immobilize proteins on the
PMMA surface. Brown et al. performed acid catalysis using sulfuric acid and other surface
modifications for bonding and characterization of PMMA. Nugen et al. developed a PMMA
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biosensor for electrochemical detection of nucleic acids. PMMA surface was treated with UV to
get carboxylic acid functional groups, which were then conjugated, to cystamine using
carbodiimide chemistry.115 Plasma treatment provides modification with less surface roughening
and degradation and does not involve toxic solvents to generate reactive functional groups.
Surface aging of the polymer after the plasma treatment is a major drawback as the resultant
functional groups are not stable and results are difficult to repeat.116 Carbodiimide chemistry has
been widely used for the conjugation of proteins to various substrates including quantum dots,117
nanoparticles,118 carbon nanotubes,119 poly(l-lactide-co-glycolide) (PLGA) nanospheres,120 and
other biomacromolecules.121, 122 Khnouf et al. found that carbodiimide chemistry resulted in more
than twice the bonding efficiency of the protein to the PDMS microchannel as compared to
passive binding.123 Although carbodiimide chemistry has been widely used for the
immobilization of protein to varieties of the substrate, it has not been reported for the covalent
binding of antigen/antibody onto the acid/base catalyzed PMMA surfaces.
Therefore, we have developed a simple 64-microwell surface modified PMMA
microfluidic microplate where the protein is covalently bound to the modified surface for rapid,
sensitive and high-throughput multiplex detection of biomarkers of HBV. 8 ´ 8 series of
microwells designed according to standard 384 well plates were created on the PMMA surface
by laser ablation. The X-axis and Y-axis offset were kept like the standard 384-well plate while
the diameter and the depth of the wells were reduced. We performed the acid catalysis of the
PMMA to obtain carboxyl functional groups followed by carbodiimide chemistry for the crosslinking of the protein onto the carboxylated PMMA surface. The modification method yielded
significantly better results for immunoassay as compared to the plasma treated and pristine
PMMA. Covalent binding of proteins not only enhanced the binding efficiency of protein but
also improved the immunoassay sensitivity and decreased the background noise. In addition,
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rapid and ultrasensitive detection of the disease biomarkers could be completed within 90 min in
this microplate as compared to more than 16 hr in traditional 96-well microplates. The assay
does not require a large volume of expensive reagents and sophisticated instruments as results
can be seen with the naked eye. A simple desktop scanner can be used to scan the device for
quantitative analysis. Multiplex detection of IgG, HBsAg, and HBcAg was performed as a proofof-concept and LODs of 190 pg/mL, 360 pg/mL, and 380 pg/mL were obtained for IgG, HBsAg,
and HBcAg, respectively, which were more sensitive than commercial ELISA kits.154
4.2

Experimental

4.2.1

Chemicals and materials
All chemicals and materials are listed in Section 2.1.

4.2.2

Design and fabrication of microfluidic microplate
The chip (Figure 4.1) used in this study was designed in Adobe Illustrator CS5. The

device was then fabricated using a Laser cutter. The laser cutter moved in x- and y-direction as
defined in the pattern to erode the material creating the microwells according to the dimension of
the standard 384-well plate as discussed in Section 3.2.2. As seen from Figure 4.1A, both the Xaxis and Y-axis offset are 4.5 mm (d). A1 row offset of the chip is 8.99 mm (a) and A1 column
offset of the chip is 12.13 mm (b) similar to the 384-well microtiter plate. The diameter of each
well of the chip is 3.6 mm (c) which is smaller than the diameter of 384-well microtiter plate.

62

Figure 4.1: Surface-modified PMMA microplates. (A) Photograph of the actual device showing
different dimensions with A1 row offset (a), A1 column offset (b), the diameter of the well (c),
and X-axis and Y-axis offsets (d). (B) 3D image of PMMA microplate with 8 ´ 8 wells. (C)
Schematic of the covalent modification of PMMA using carbodiimide chemistry.
4.2.3

Surface modification of the PMMA microplate to covalently link antibodies
The surface of PMMA can be functionalized by different methods to increase the

immobilization efficiency of different biomolecules including proteins and DNA without a
change in its transparency and original mechanical properties. Base and acid hydrolysis can be
used to generate carboxylic acid functional groups.4, 116 Here, for the generation of the carboxylic
acid functional groups, PMMA was first sonicated for 5 minutes in 40% aqueous 2-propanol
solution. PMMA was dried and then submerged in 3M sulfuric acid at 60 0C for 20 minutes.
After that, PMMA was rinsed first with water, then with 2-propanol and dried (Figure 4.1).
Carbodiimide compounds have been used to activate carboxylic acid to directly conjugate to the
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primary amines of different biomolecules for various purposes including analysis by highperformance liquid chromatography or fluorescent labeling. In this method, 1-ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride (EDC) was used to obtain an intermediate Oacylisourea which is quite unstable in aqueous solution. Sulfo- N-hydroxysuccinimide (SulfoNHS) was added to improve efficiency and create dry-stable (amine-reactive) intermediate. First
of all, carboxylated PMMA was taken and EDC/NHS solution (0.35 M EDC + 0.1 M NHS) was
added and incubated for 20 minutes (Figure 4.1C). After 20 min, the PMMA was washed with
PBS. Protein was then added to the EDC/NHS modified PMMA microplate and incubated for 20
min so that there is a covalent amide bonding between the protein and the modified PMMA
surface.
4.2.4

Characterization of the surface modification
The structure of PMMA after each step of surface modification and protein

immobilization was analyzed by FTIR-spectroscopy to confirm the formation of certain
functional groups on the surface of PMMA. First of all, PMMA was cut into small square pieces
of 1 cm ´ 1 cm by using the laser cutter followed by ablation of well with a diameter of 3.6 mm.
The FTIR spectra were recorded after each modification steps, viz. pristine PMMA (without any
modification), acid-catalyzed hydrolysis of PMMA (PMMA + H2SO4), carbodiimide crosslinking (PMMA + H2SO4 + EDC/NHS), and finally protein immobilization (PMMA + H2SO4 +
EDC/NHS + IgG antibody).
4.2.5

Confirmation of immobilization of proteins
Surface modification for the covalent binding of the protein to the modified surface thus

increasing the amount of immobilized antibody was confirmed using a fluorescence microscopy.
Once the PMMA was modified using EDC/NHS, 20 µg/mL of Cy3 IgG was added to the
PMMA surface and incubated for 20 minutes. Similarly, 20 µg/mL of Cy3 IgG was added to
pristine PMMA and plasma treated PMMA for 20 minutes. PMMA was then washed with PBST
for three times. Fluorescence intensity was measured before and after washing with PBST.
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4.2.6

Detection of biomarkers of HBV
The surface modified PMMA microplate was first used for the detection of IgG followed

by detection of HBV using HBsAg and HBcAg. To perform the ELISA of IgG, serially diluted
IgG ranging from 100 μg/mL to 0.1 ng/mL were prepared from a stock solution of 2mg/mL IgG.
Different concentrations of IgG were pipetted to the chip (5 μL/well) having eight replicates
along each column. After the chip was incubated with primary antibody, the assay procedure
similar to detection of IgG as discussed in Section 3.2.5 was followed.
For the detection of HBV, similar assay procedures were followed and two biomarkers
HBsAg and HBcAg were analyzed. To detect HBsAg, the antigen i.e., HBsAg was immobilized
on the surface modified PMMA for 20 min followed by the addition of blocking buffer and antiHBsAg, respectively. Finally, ALP-labelled anti-rabbit IgG was added followed by the addition
of BCIP/NBT. Similarly, for the detection of HBcAg, anti-HBcAg was added after the
immobilization of HBcAg. ALP-labeled anti-rabbit IgG was added followed by the addition of
the substrate. The microplate was scanned by a desktop scanner 10 min after the addition of the
colorimetric substrate.
4.2.7

Multiplex immunoassay for detection of HBsAg and HBcAg
The surface modified PMMA can be used for simultaneous colorimetric detection of

eight different biomarkers with eight replicas in eight columns of the microplate or simply be
modified into 96- or 384-wells microplate. Herein, the device was used for simultaneous
multiplex detection and specificity test of HBsAg and HBcAg as discussed in Section 3.2.6.
4.2.8

Evaluation of cross-reactivity
A detection assay needs to have a high anti-interference capability while having a

minimum or no cross-talk and cross-reactivity to screen various infectious diseases as the
biological samples contain complex ingredients of proteins with a wide range of concentrations.
So, the anti-interference experiment was performed to evaluate the cross-talk and cross-reactivity
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in the various columns of the modified PMMA microplate as discussed in Section 3.2.7. The
microplate was scanned 10 min after the addition of the substrate.
4.3

Results and discussion

4.3.1

Characterization of surface modification
FTIR was used to characterize the modification of the PMMA microplate after each step.

FTIR spectra of the pristine PMMA was analyzed first. As we can see from the FTIR spectrum
of the PMMA in Figure 4.2, there were distinct absorption bands for different functional groups
of PMMA as discussed in Section 3.3.1. The spectrum of the PMMA corresponded very well
with the documented one in the literature for the FTIR spectrum of the PMMA.155, 165
We could observe some major changes in the FTIR spectrum of PMMA once its surface
was modified (Figure 4.2A). The first step in the modification involved the acid catalysis of
PMMA with H2SO4 to create a carboxyl functional group on the surface of the PMMA. The split
C=O stretch vibration for the acrylated (1724 cm−1) and non-acrylated (1699 cm−1) carboxyl
group indicated the formation of carboxyl functional groups at the surface of the PMMA.
EDC/NHS method was then used to treat the carboxylated PMMA to obtain the amine-reactive
sulfo-NHS ester, indicated by the S=O (1347 cm−1) asymmetric stretch, S-O (853 cm−1) stretch
and S=O (1152 cm−1) symmetric stretch. Strong absorption for Amide I (1558 cm−1) and Amide
II (1646 cm−1) was observed after the addition of the antibody, which indicated the covalent
binding of the antibody to the modified PMMA surface by the formation of an amide bond.
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Figure 4.2: Characterization of the surface modified PMMA microplate. (A) FTIR analysis of
surface modified PMMA. (B) Fluorescence intensity of Cy3 IgG immobilized on the surface of
the pristine and surface modified PMMA.
4.3.2

Cross-linking of proteins to the surface modified PMMA microplate
The main aim of surface modification of PMMA was to increase the immobilization

efficiency of the protein to the surface of PMMA, which could ultimately lead to increase in the
sensitivity of the ELISA and decrease the background signal. To access the modification of the
PMMA microplate and observe the differences in immobilization of antibody between the
pristine and surface modified PMMA, a fluorescence microscopy was used. It can be seen from
Figure 4.2B that EDC/NHS modified PMMA showed the highest fluorescence intensity, which
was at least 10-fold higher than the pristine PMMA indicating the increase in efficiency of
immobilization of the antibody. We could also observe a 5-fold increase in fluorescence intensity
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of EDC/NHS modified PMMA as compared to the plasma treated PMMA. The blank
represented the small background fluorescence intensity of PMMA without the addition of Cy3
IgG. Figure 4.2B showed that the proposed modification and cross-linking of protein onto the
modified PMMA surface was quite stable within 20 min of incubation as the immobilization
efficiency is remarkably enhanced as shown by the enhancement of fluorescence intensity of
surface modified PMMA as compared to the pristine and plasma treated PMMA.
4.3.3

Detection of HBV using surface modified PMMA
Herein, the surface modified PMMA microplate was used for detection of IgG followed

by the detection of biomarkers for HBV. Figure 4.3 shows the standard fitted curve of 10-fold
diluted IgG sample from 100 μg/mL to 0.1 ng/mL and one negative control with PBS performed
in the surface modified PMMA microplate. We could observe from Figure 4.3A that there was
the minimum development of color for the negative control as there was no IgG. The purple
color intensity for detection of IgG increased from lower concentration (0.1 ng/mL) to higher
concentration (10 μg/mL) and got saturated after 10 μg/mL, as there was no significant increase
in the intensity of purple color with higher concentrations. Figure 4.3B shows the calibration
curve for the detection of IgG as corrected brightness versus the concentration of IgG. The
calibration curve of IgG in the surface modified PMMA microplate was found to be linear over
the range of 102 pg/mL to 108 pg/mL with a linear regression of y = 17.86 log (x) + 9.57 (R2 =
0.98). The LOD of IgG in the surface modified PMMA microplate was found to be 190 pg/mL.
The surface modified PMMA microplate required just 90 min of assay time, 5 μL of sample, and
a simple desktop scanner to read the result as compared to 18 hr of assay time, 50-100 μL of
sample, and specialized instrument like microplate reader in the conventional commercially used
microplate. The LOD of IgG was still found to be more than 10-fold sensitive as compared to the
commercial 96-well microplate ELISA (LOD, 1.6–6.25 ng/mL)154 because of surface
modification of PMMA and higher efficiency of protein immobilization in our microplate. The
surface modified device was also found to be more sensitive as compared to APTES modified
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PMMA (LOD of 0.12 μg/mL),109 poly(ethyleneimine) modified PMMA (comparable to a 96well plate and linear dynamic range from 5 to 500 ng/mL even with the use of fluorescence
microscope),111 superparamagnetic beads for molecular analysis (LOD of 10 ng/mL),166 paperbased device (54 fmol/zone),128 and PMMA/paper hybrid device (LOD, 1.6 ng/mL).5

Figure 4.3: Detection of IgG in the surface modified PMMA microplate. (A) Scanned image of
enzymatic converted substrate in different columns of the chip with concentrations from left to
right: blank, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1 μg/mL, 10 μg/mL, and 100 μg/mL,
respectively. (B) The sigmoidal curve of the corrected brightness of IgG over a concentration
range of 102 pg/mL to 108 pg/mL.
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Two different biomarkers, HBsAg and HBcAg were used for the detection of HBV. For
the detection of HBsAg, 10-fold diluted samples of HBsAg ranging from 340 μg/mL to 0.34
ng/mL were prepared by diluting a stock solution of 3.4 mg/mL of HBsAg. Antigens were
immobilized in 8 ´ 8 microarrays of the microplate with eight replicas of each concentration as
performed in IgG. Figure 4.4 shows that the purple color intensity increased from left to right as
the concentration of HBsAg increased from 0.34 ng/mL to 34 μg/mL. As we could observe from
the fitted curve in Figure 4.4 the corrected brightness for the detection of HBsAg reached a
plateau after 34 μg/mL and there was no more increase in purple color intensity value when the
concentration was increased further. The calibration curve of HBsAg (corrected brightness vs
concentration of HBsAg) in the surface modified PMMA microplate was linear over the range of
34´101 pg/mL to 34´106 pg/mL with a linear regression of y = 11.05 log (x) + 91.76 (R2 = 0.98).
The LOD of HBsAg in the surface modified PMMA microplate was found to be 360 pg/mL.
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Figure 4.4: Detection of HBsAg in the surface modified PMMA microplate. (A) Scanned image
of enzymatic converted substrate in different columns of the chip with concentrations, from left
to right: blank, 0.34 ng/mL, 3.4 ng/mL, 34 ng/mL, 340 ng/mL, 3.4 μg/mL, 34 μg/mL, and 340
μg/mL, respectively. (B) The sigmoidal curve of the corrected brightness of ELISA of HBsAg
over a concentration range of 34´101 pg/mL to 34´107 pg/mL.
Like the detection of IgG and HBsAg, the detection for HBcAg was performed in the
surface modified PMMA microplate but with 8´7 arrays microplate for the 10-fold diluted
concentrations of HBcAg from 10 μg/mL to 0.1 ng/mL. Rapid increase in color intensity was
observed with the increased concentration of the analyte (HBcAg) after initial slight increase
from PBS to 0.1 ng/mL. In case of HBcAg, saturation of color intensity was not observed, as the
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highest concentration measured was 10 μg/mL (Figure 4.5). The calibration curve of HBcAg in
the surface modified PMMA microplate was found to be linear over the range of 102 pg/mL to
107 pg/mL with a linear regression of y = 14.07 log (x) + 29.64 (R2 = 0.98). The LOD of HBcAg
in the surface modified PMMA microplate was found to be 380 pg/mL. The LOD of the surface
modified PMMA microplate was found to be more sensitive than commercial ELISA kits,154
HBsAg assay by Yazdani et al. (LOD of 0.7 ng/mL),160 fully automated lab-on-a-disc (LOD 0.51
ng/mL),143 and paper/PMMA hybrid microfluidic device (LOD of 1.3 ng/mL).5 In addition, the
LOD of the surface modified PMMA microplate was found to be similar to Xu et al. (LOD of
0.1 ng/mL) which required experiment in a class-100 clean room.139
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Figure 4.5: Detection of HBcAg in the surface modified PMMA microplate. (A) Scanned image
of enzymatic converted substrate in different columns of the chip with concentrations from left to
right: blank, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1 μg/mL, and 10 μg/mL, respectively.
(B) The sigmoidal curve of the corrected brightness of HBcAg over a concentration range of 102
pg/mL to 107 pg/mL.
4.3.4

Multiplex immunoassay in EDC/NHS surface modified PMMA microplate
Simultaneous detection of HBsAg and HBcAg was performed in the carbodiimide-based

surface modified PMMA microplate to demonstrate that the device has an efficient multiplex
biomarker sensing capability. Figure 4.6 shows the multiplex detection of HBsAg and HBcAg in
the surface modified PMMA microplate. The first, third, and fourth columns did not produce
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color as they didn’t have the capture antigen for the respective antibody. All other columns
produced color as they had the capture antigen or the combination of capture antigens for the
respective antibody. Figure 4.6 showed the proficiency of the surface modified PMMA
microplate to perform multiplex detection of biomarkers including HBsAg and HBcAg as well
as the specificity for the detection of different biomarkers.

Figure 4.6: Multiplex detection of HBsAg and HBcAg in the surface modified PMMA
microplate. Scanned image of the enzyme-catalyzed substrate, (A) and bar plot of the corrected
brightness of the scanned image (B). From left to right: immobilized probe, none (1), HBsAg (2)
and (3), HBcAg (4) and (5), and HBsAg + HBcAg (6), (7), and (8), respectively. Test: From left
to right, solution containing, anti-HBsAg and anti-HBcAg (1) and (6), HBsAg (2), (4), and (7),
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and HBcAg (3), (5), and (8). “a” and “b” shows that the data are significantly different from each
other at p = 0.05.
4.3.5

Cross-reactivity test in the surface modified PMMA microplate
Evaluation of cross-talk or cross-reactivity remains one of the most important factors for

the development of potential multiplex detection platform. So, anti-interference test of the model
analyte, HBsAg was performed in the various columns of the surface modified PMMA
microplate. The test as shown in Figure 4.7 shows the anti-interference test for the detection of
HBsAg with and without various concentrations of interfering proteins. As shown in Figure 4.7,
the first four columns didn’t contain HBsAg and only contained interfering proteins so there was
no development of color. Moreover, the purple color intensity for the detection of 200 ng/mL of
HBsAg without the interfering protein (eighth column) was found to be similar to the detection
of 200 ng/mL of HBsAg in the presence of different interfering proteins (fifth, sixth, and seventh
column). The anti-interference test results showed that different interfering proteins with
concentration ranging from 10 ng/mL to 250 µg/mL could not interfere with the specific
detection of HBsAg.

75

Figure 4.7: Anti-interference test for the detection of HBsAg in the surface modified PMMA
microplate. The scanned image of the chip (A) and the corrected brightness of the scanned image
of ELISA (B) for the detection of HBsAg. From left to right: detection of 0 ng/mL of HBsAg in
the solution containing 1µg/mL HBcAg (1), 100 ng/mL CEA (2), 250 µg/mL BSA (3), and 10
ng/mL PSA (4), respectively and 200 ng/mL of HBsAg in 1µg/mL HBcAg (5), 100 ng/mL CEA
+ 10 ng/mL PSA (6), 250 µg/mL BSA (7), and PBS (8), respectively. “a” and “b” shows that the
data are significantly different from each other at p = 0.05.
4.4

Summary
We have developed a novel carbodiimide method to cross-link proteins onto the surface

of carboxylated PMMA microplate to improve the covalent binding of the antibody including
IgG, HBsAg, and HBcAg to perform a highly sensitive ELISA for the detection of various
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biomarkers. The use of EDC/NHS to cross-link the protein led to highly efficient immobilization
of antibody to the surface of PMMA microplate so that protein immobilization could be
accomplished within 20 min and the whole assay could be completed within 90 min. As a proofof-concept, simultaneous detection of IgG, HBsAg, and HBcAg was achieved with the LODs of
190 pg/mL for IgG, 360 pg/mL for HBsAg, and 380 pg/mL for HBcAg. The sensitivity of
ELISA was improved significantly without the use of any sophisticated instrument like a
microplate reader. A wide linear range of detection and 10-fold more sensitive detection limit
was achieved just with a simple desktop scanner. The results could be viewed with the naked eye
or smartphone can be used for quantitative detection. In addition, the reagent consumption is
minimum (5 μL/well) which can save the expensive reagent and limited amount of sample in
many cases. The basic design of the PMMA microplate used in the study had 8 × 8 or 7 × 8
assays-wells but the design can simply be modified to perform as many experiments and repeats
as desired and can simply be modified into 96- or 384-wells. The surface modified PMMA
microplate could find massive attention as a simple, high throughput, and POC detection system
in resource-limited settings where expensive diagnostic equipment like spectrophotometer is not
available. In future, the PMMA microplate with high protein immobilization efficiency may find
broad application as an ultrasensitive and multiplex biochemical assay or a clinical diagnosis
platform.
Two different methods were used for the modification of PMMA microplate. In the first
method, PMMA was functionalized with amine groups using polylysine followed by
glutaraldehyde for the cross-linking of the proteins to the modified PMMA surface. In the second
method, PMMA was acid hydrolyzed to obtain carboxyl functional groups followed by
carbodiimide chemistry (EDC/NHS) to link proteins to carboxylated PMMA. The modification
time for the polylysine-based method was 1hr using DMSO/polylysine and 2hr using
NaOH/Polylysine but only 45 min for the carbodiimide-based method. LODs for different
biomarkers was found to be similar to both the methods, however, modification time was less in
the carbodiimide-based method.
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Chapter 5: A Polymer/paper Hybrid Microfluidic Platform for Rapid
Quantitative Detection of Multiple Disease Biomarkers

Reproduced in part with permission from the Nature Publishing Group.
•

Parts of this chapter were published in Scientific Reports as a research article in
2016 (Sanjay, S. T., Dou, M., Sun, J., & Li, X. (2016). Scientific reports, 6,
30474).

•

This chapter introduces a versatile polymer/paper hybrid microfluidic platform for
detection of multiple disease biomarkers.

•

Novel use of porous paper in flow-through microwells facilitates rapid protein
immobilization

and

efficient

washing,

avoiding

complicated

surface

modifications.
•

The top reagent delivery channels can simply transfer reagents to multiple
microwells thus avoiding repeated manual pipetting and costly robots.

•

For the device to be used in the settings of laboratories and hospitals, the hybrid
device was redesigned to make it compatible with traditional microplate readers
as well.

•

For the chemiluminescence assay, the LODs of 20 pg/mL for IgG, 50 pg/mL for
HBsAg, and 10 pg/mL for HCVcAg were achieved.
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5.1

Introduction
Acute infectious diseases caused by various pathogenic microorganisms are usually

diagnosed by exhausting immunoassay tests like ELISA, immunofluorescence, western blotting,
and immunodiffusion along with PCR, flow cytometry and a wide range of other techniques.167169

Although there is a considerable progress in science and technology, rapid and sensitive POC

detection of diseases or biological agents in low-resource settings (e.g. high-poverty regions) is
still a challenge.170
As discussed in Section 1.4, microfluidic LOC devices possess astonishing features for
low-cost, simple, and rapid bioanalysis. These highly portable microfluidic devices with
integrated processing can analyze complex biological fluids including serum, urine,171 cells, and
cell lysates for various applications, such as detection of diseases,37, 172, 173 single cell analysis,174176

3D cell culture for tissue-based bioassays,61 forensic analysis,59 and a wide range of other

fields.62, 177-180
To address issues from conventional microplates, a few microplate-format microfluidic
devices have been developed for immunoassays as discussed in Section 1.7.52, 124, 125 Overall, all
these devices require either long incubation time, surface functionalization or complicated
detection systems. With the emergence of paper-based devices in recent years, various POC
analyses, including paper-based ELISAs have been developed.94, 126, 127 The limitations in paperbased ELISA include low-performance in flow control and the need of repeated micropipetting
for adding reagents and washing all the zones, which is time-consuming and limits its application
for high-throughput detection, especially in low-resource settings as discussed in Section 1.7.1.
Along with paper, some polymers such as PMMA have also been widely used for the
fabrication of microfluidic devices. Each substrate has its own advantages and disadvantages.
PMMA is transparent, rigid and rapidly delivers reagents to different regions. However,
polymers such as PMMA require complicated surface modification procedures to immobilize
biosensors and other biomolecules such as antibodies and enzymes. On the contrary, paper-based
devices can rapidly immobilize biosensors and other biomolecules but do not offer high
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performance in flow control especially over a fairly long distance. Hybrid devices can take
advantages of various substrates while eliminating some limitations of certain substrates as
discussed in Section 1.5.4. These types of hybrid devices have been used for various applications
including infectious diseases diagnosis.181-183
Herein, we have developed a simple miniaturized 56-microwell paper/PMMA hybrid
microfluidic ELISA microplate for rapid and high-throughput detection of infectious diseases. A
series of novel funnel-shaped PMMA microwells have been created by laser ablation of PMMA,
wherein a paper substrate can be placed to complete ELISA within an hour. The introduction of
3D micro-porous paper with the high surface-to-volume ratio in microwells of this hybrid
microplate facilitated rapid immobilization of antibody/antigen and also avoided complicated
surface modifications. The top reagent delivery channels along with the vertical flow-through
microwells in the middle PMMA layer can simply transfer reagents to multiple microwells, thus
avoiding repeated manual pipetting and washing steps into each well in conventional ELISA or
the use of costly robots. All the reagents/analytes pass through the 3D matrix of the paper surface
from the funnel-shaped microwells. This design not only provides efficient washing but also
increases the opportunities for analytes to be rapidly and efficiently captured, thus resulting in
higher detection sensitivity. ELISA of IgG and HBsAg were performed in the hybrid device and
LODs comparable to commercial ELISA kits were obtained by using an office scanner, without
the use of any specialized instruments like a microplate reader.
5.2

Experimental

5.2.1

Chemicals and materials
All chemicals and materials are listed in Section 2.1.

5.2.2

Design and fabrication of microfluidic platform
The chip used in this study was designed by using Adobe Illustrator CS5 and micro-

machined using the laser cutter. Since the funnel-shaped microwells involve different depths,
multi-level fabrication is needed. Although photolithography is one of the most widely used
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fabrication techniques to fabricate microfluidic devices, it is difficult, expensive and complicated
to create a microfluidic device with different depths.94, 184, 185 On the contrary, laser ablation is a
rapid prototyping method for the fabrication of microfluidic devices. By applying different
intensities, microstructures with different depths can be readily fabricated. Therefore, we
developed a simple laser ablation method to create the funnel-shaped microwells, which can be
completed within minutes, without using any photomask. As shown in Figure 5.1a, the
microfluidic device consists of three different layers. The topmost layer, the fluid delivery layer,
is used to deliver all the assay reagents and also forms the cover for the microwells in the assay
plate (middle layer). Each of the channels connected to different inlet reservoirs of upper layer
delivers reagents to 7 microwells in the middle layer. Pieces of chromatography paper were
placed inside each microwell. The middle layer contains funnel-shaped (Figure 5.1c) microwells
with an upper diameter of 2 mm and a lower diameter of 0.3 mm, wherein a paper disk can be
placed, as shown in the cross-section view of the device from Figure 5.1b. The 0.3 mm diameterlower microwells are placed just below the upper microwells of the middle layer and helps to
hold the paper in place and minimize the chances of backflow of the reagents. Just underneath
the bottom of the assay microwells, is attached the outlet system. The outlet channels are
connected to a single outlet microwell, which acts as an outlet reservoir once a negative pressure
is applied. Arrows in Figure 5.1b shows the direction of the flow of reagents.
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Figure 5.1: Chip design of the PMMA/paper hybrid microfluidic microplate. (a) 3D schematic of
the exploded view of the hybrid device. (b) Cross-section view of the chip. The chip consists of
three PMMA layers. The top layer (I) for fluid delivery consists of inlet reservoir ‘1’ and fluid
distribution channel ‘3’. The middle layer (II) for incubation consists of 56 unique funnel-shaped
microwells, with upper microwell ‘4’ and lower microwell ‘6’, with paper disks ‘5’ placed in
between. The lowermost layer (III) for fluid removal consists of an outlet channel ‘7’, which
leads to a common outlet reservoir ‘8’. (c) 3D exploded view of the funnel-shaped microwell. (d)
Photograph of the actual assembled device with water and different colored dyes in alternate
columns.
5.2.2

Colorimetric detection of IgG and HBsAg using the hybrid device
The hybrid device can be used for a wide range of bioassays. Figure 5.2 illustrates the

main steps for the IgG detection by on-chip ELISA using the hybrid device. The primary
antibody IgG (0.1 ng/mL-100 μg/mL in 10 mM, pH 8.0 PBS) was introduced to the chip from
different inlet reservoirs in the first layer of the chip. After the chip was incubated with the
primary antibody for 10 minutes, the unreacted paper surface was blocked with a blocking buffer
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for another 10 minutes. After washing with PBST, anti-rabbit IgG-alkaline phosphatase (6
µg/mL) was added for another 7 min. Then, the final wash was done with the washing buffer for
three times. Finally, the substrate (BCIP/NBT) was added. After a 10-minute incubation,
different layers of the chip were separated, and the middle layer was scanned with a scanner after
another 15 minutes.

Figure 5.2: Schematic illustration of the approach of immunoassay on the hybrid device,
comprising six steps: (1) Immobilizing antibody on paper, (2) Blocking, (3) Washing, (4)
Binding of enzyme conjugated antibody, (5) Washing, and (6) Enzymatic production of insoluble
NBT diformazan.
Regarding HBsAg detection, a similar assay procedure was followed. The main
difference was that the first step was to immobilize the antigen, i.e., HBsAg, followed by
addition of anti-HBsAg, and finally forming a sandwich-structure immunoassay by the addition
of ALP-labelled anti-rabbit IgG.
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5.2.3

Rapid detection of HBsAg in human serum
To validate the reliability of the developed hybrid microfluidic microplate and to test its

feasibility for real human sample detection, HBsAg was spiked in normal human serum. 10 µL
of varying concentrations of HBsAg were spiked into 1.0 mL human serum which was prediluted 3 folds using PBS to get the final concentrations of 3.4 ng/mL, 34 ng/mL, 0.34 µg/mL,
and 3.4 µg/mL, respectively. After mixing thoroughly, the spiked samples were used for the
rapid detection of HBsAg, following steps similar to the detection of standard HBsAg prepared
in PBS buffer and spike recoveries were calculated.
5.2.4

Rapid detection of HBcAg and HCVcAg
Herein, for the detection of HBV, first, different concentrations of HBcAg (1 ng/mL-100

μg/mL) were pipetted to the chip through the inlet microwells in the top reagent delivery layer.
After blocking the device with blocking buffer for 10 min, anti-HBcAg was added followed by
washing with PBST and addition of the ALP-linked secondary antibody for 7 min. Finally,
BCIP/NBT substrate was added after washing the chip three times with PBST. The chip was
incubated for 10 min and scanned by a common desktop scanner. The brightness value of the
scanned chip was then measured by the software ImageJ.
Regarding the detection of HCV, a similar assay protocol as HBcAg was followed. First,
HCVcAg was immobilized on the paper substrate of the hybrid device followed by the addition
of blocking buffer and anti-HCVcAg. Finally, ALP-labelled anti-rabbit IgG was added followed
by the addition of the substrate. Washing was required after each step similar to the detection of
HBcAg.
5.2.5

Colorimetric multiplex detection of HBsAg and HBcAg
To demonstrate the feasibility of multiplex detection in the hybrid microfluidic

microplate, two biomarkers for HBV were used as model analytes. Colorimetric detection of
HBsAg and HBcAg was performed in the device as described in Section 3.2.6. Different
combination of capture antigens was added to the device followed by the addition of the
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blocking buffer and the primary antibody. After the addition of primary antibody, the ALPlinked secondary antibody was added. Finally, 10 min after the addition of BCIP/NBT substrate,
the chip was scanned with the scanner.
5.2.6

Colorimetric anti-interference test
To establish a device as an efficient infectious diseases detection platform, the detection

assay in the device needs to show a high anti-interference capability. So, the anti-interference
assay was performed in different columns of the hybrid microfluidic microplate to detect
HBsAg. Different kinds of capture antigens were immobilized on the paper surface as described
in Section 3.2.7. After the addition of the capture antigen, blocking buffer was added in all the
columns followed by the addition of anti-HBsAg. Finally, the secondary antibody linked with
alkaline phosphatase and the substrate was added before scanning the device with a scanner.
5.2.7

Rapid chemiluminescent detection of infectious diseases
Chemiluminescence detection of IgG in the hybrid microfluidic microplate was carried

out similar to the colorimetric detection of IgG in the device. The major difference in the assay
protocol was the use of the HRP-linked secondary antibody in chemiluminescence assay instead
of ALP-linked secondary antibody in the colorimetric assay. Similarly, the substrate used in the
assay was Supersignal® ELISA Pico chemiluminescent substrate (peroxide + luminol +
enhancer) instead of BCIP/NBT. Finally, after the completion of the assay, the device was read
using a microplate reader instead of a desktop scanner. Briefly, IgG was pipetted to the inlet
microwells of the hybrid chip. The device was incubated for 10 min and the unreacted paper
surface was blocked with blocking buffer for another 10 minutes. After washing with the
washing buffer, HRP-linked secondary antibody (0.4 µg/mL) was added. It was then incubated
for another 7 min followed by washing for three times. Finally, the substrate for the HRP was
added. After incubating the substrate for 2 min, the chemiluminescent intensity was read at 425
nm by a spectrophotometer.
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Regarding the chemiluminescence detection of HBsAg, a similar assay protocol as IgG
was followed. First, HBsAg was immobilized on the paper substrate of the hybrid microfluidic
microplate followed by the addition of the blocking buffer and anti-HBsAg. Finally, HRPlabelled anti-rabbit IgG was added followed by the addition of the chemiluminescent substrate.
Similarly, detection of HBcAg and HCVcAg were performed with their respective antibodies.
5.2.8

Chemiluminescence multiplex detection of HBsAg and HBcAg
To demonstrate the feasibility of multiplex chemiluminescent detection in the hybrid

microfluidic microplate, similar to the colorimetric detection, the assay of HBsAg and HBcAg
were performed in the hybrid device. The assay procedure was similar to that of colorimetric
multiplex detection; the only difference being the addition of HRP-linked secondary antibody
instead of an ALP-linked secondary antibody. After the completion of the assay, the
chemiluminescent substrate was added and the device was scanned after 2 min with a
spectrophotometer at 425 nm.
5.2.9

Chemiluminescence anti-interference test
To demonstrate that the chemiluminescent detection assay in the hybrid device has a high

anti-interference capability, the anti-interference assay was performed in various columns of the
hybrid device, similar to the colorimetric assay as described in Section 5.2.6. Instead of ALPlinked secondary antibody, HRP linked-secondary antibody was added. The device was scanned
by a spectrophotometer, 2 min after the addition of the chemiluminescent substrate.
5.2.10 Rapid chemiluminescent detection of HBsAg & HCVcAg in human serum
All the previous assays in this chapter were performed in the hybrid microfluidic
microplate with pure protein in PBS. However, for the validation of the reliability of the
proposed chemiluminescence assay, the detection of the biomarkers was performed in normal
human serum samples. The feasibility of the assay was tested by spiking different concentrations
of HBsAg and HCVcAg in normal human serum samples as the biomarkers for HBV and HCV,
respectively. The human serum samples were diluted 3 folds using PBS. 10 µL of different
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concentrations of HBsAg were spiked in 990 µL of the diluted human serum to get the final
concentrations of 3.4 ng/mL, 34 ng/mL, 0.34 µg/mL, 3.4 µg/mL, and 34 µg/mL, respectively.
Similarly, 10 µL of different concentrations of HCVcAg were spiked in 990 µL of the diluted
human serum to get the final concentrations of 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, and
1µg/mL, respectively. The hybrid microfluidic microplate was used for the rapid
chemiluminescence detection following similar procedure and incubation time as mentioned in
Section 5.2.7. After the assay, chemiluminescence intensity was measured and the spiked
recoveries were calculated for each samples.
5.3

Results and discussion

5.3.1

Cross-contamination test
After the assembly of the hybrid microfluidic microplate, cross-contamination test was

performed, as microwells were connected through channels at the bottom layer. For the crosscontaminations test, fluorescein isothiocyanate (FITC) was added to alternate columns of the
device, while Milli Q water was added in the adjacent columns. As seen from the fluorescent
image (Figure 5.3), the high fluorescent intensity was only observed in the alternate column (a, c,
e, and g) where FITC was added; there was no fluorescence in adjacent columns (b, d, f, and h).
The result shows that there was no cross contamination or leakage within different columns. To
confirm this, different colored dyes were similarly passed into the alternate columns, with water
in the adjacent columns. Similar results were obtained with colors showing up only in the
alternate columns and clear background in the adjacent columns (Figure 5.1d). This further
confirmed that there was no cross-contamination between the adjacent columns.
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Figure 5.3: Cross contamination/leakage test for the hybrid chip. Fluorescence was observed in
columns a, c, e, and g where FITC was added, but not in columns b, d, f, and h, where Milli-Q
water was added.
5.3.2

Rapid immobilization of protein
Because of the novel introduction of paper in this hybrid microfluidic microplate,

antigen/antibody can be quickly immobilized within 10 minutes as compared to overnight
incubation in conventional microplates.128 Cy3-labeled IgG was used to assess rapid
immobilization of antibody on the paper surface. Different concentrations of Cy3-labeled IgG
(100, 50, 25, and 12.5 μg/mL) were introduced into alternate columns of the device, and PBS in
the adjacent columns for 10 minutes. After washing, from Figure 5.4a, we can see the decreasing
intensity of fluorescence in the alternate columns (from left to right), with the decrease in
concentration of IgG. There was no fluorescence in the adjacent columns where PBS was added.
The assay confirms the rapid immobilization of proteins within 10 min.
Yet, in another experiment, the blocking buffer (4% BSA + 0.05% Tween 20) was added
to one column and PBS to another to test the effectiveness of the blocking buffer. After 10
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minutes, Cy3-labeled IgG was added to both and incubated for 10 more minutes followed by
washing three times with PBST. Figure 5.4b shows that blocking buffer can be used to
effectively block the paper surface. Minimal fluorescence can be seen in the column where
blocking buffer was added before the addition of Cy3-labeled IgG.

Figure 5.4: Rapid immobilization of antibodies (a) and effectiveness of blocking buffer (b) for
ELISA on the hybrid device. (a) Fluorescence image of Cy3-labeled IgG immobilized on the
hybrid device. Different concentrations of IgG include; 100 μ g/mL, PBS, 50 μ g/mL, PBS, 25 μ
g/mL, PBS, 12.5 μ g/mL, and PBS, respectively, from left to right. (b) The mean fluorescence
intensity of 20 μ g/mL of Cy-3 IgG immobilized on the hybrid device with and without the
blocking buffer.
5.3.3

Optimization of incubation time for BCIP/NBT
It was observed that once BCIP/NBT was added to the chip, the substrate started to

produce an insoluble diformazan end product, which was purple in color and could be observed
visually (Figure 5.5). We observed that the lower concentration generated light purple color and
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the higher concentration of the analyte produced dark purple color. The color intensity
significantly increased to a certain time and then started fading away. To optimize the optimal
incubation, on-chip ELISA of IgG (from 1 ng/mL-1 μg/mL) was performed. The chip was
scanned every 5 minutes, starting from 10 minutes after the addition of BCIP/NBT. As seen from
Figure 5.5, the purple color started fading away after 30 minutes, which led to decrease in
corrected brightness value. In addition, lower signal/noise ratios (the noise was derived from the
column with PBS only) were observed starting at 30 minutes. Colour intensity of 20-minute
incubation was almost similar to that of 25-minute incubation, but 20-minute incubation had a
higher background noise. It can also be noticed that the deviation started increasing slightly after
25 minutes. Therefore, considering the signal/noise ratio, deviation, and the time required, 25
minutes incubation time was considered optimum and was used in subsequent experiments.

Figure 5.5: Optimization of the incubation time for BCIP/NBT. The graph shows the corrected
brightness value of the enzymatically-developed color as measured by ImageJ for different IgG
concentrations against the incubation time.
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5.3.4

Rapid quantitative detection of IgG
IgG is the most common type of antibody found in the human circulation (75% of serum

antibodies). The measurement of IgG can be a diagnostic tool for conditions like autoimmune
hepatitis.186 IgG levels are indicative of the immune status of diseases such as measles, mumps,
and rubella (MMR), hepatitis B virus, and varicella.187 In addition, IgG can serve as a specific
marker for Neuromyelitis Optica, an inflammatory demyelinating disease.188 Thus, we first
demonstrated the application of our hybrid microfluidic plate for rapid detection of IgG (0.1
ng/mL-100 μg/mL). For the on-chip ELISA, all reagents were loaded sequentially from the inlets
in the upper layer of the PMMA chip, the reagent delivery system. No external power or device
was used for the addition of reagents, except a micropipette. After ELISA was completed, the
result could be viewed by the naked eye, or a portable office scanner can be used to scan the
device. Figure 5.6a shows a scanned image for IgG detection from an office scanner. It was
found that the color intensity increased as the IgG concentration increased from 0.1 ng/mL to
100 μg/mL (from right to left) with the blank in the rightmost column. Signal intensities of the
scanned images were calculated using ImageJ. Figure 5.6b shows the calibration curve of IgG
over a concentration range of 1´102 pg/mL to 1´108 pg/mL. A sigmoidal curve (Figure 5.6b) was
observed over the whole concentration range, while the linearity lies between 1´103 pg/mL to
1´107 pg/mL (inset Figure 5.6b) with a linear regression of y = 18.35 log (x) + 48.74 (R2 = 0.99),
which illustrates a typical immunoassay characteristic.
The LOD for IgG was calculated to be 1.6 ng/mL based on 3 folds of standard
deviation (SD) above the blank value, which was comparable to commercial 96-well microplate
ELISA (LOD, 1.6-6.25 ng/mL).154 The conventional 96-well microplate ELISA not only
consumes more reagents (50-100 μL), and requires overnight incubation, but also rely on
specialized instruments like a microplate reader. However, our method only needs 5 μL samples,
and 1 h to complete the whole assay, without using any specialized instruments. As to PMMA
devices, they require complicated surface modification with APTES and long incubation time
(i.e. 12 hours), and the LOD was only 0.12 µg/mL even with a fluorescence microscope.109
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Although 96-zone paper-based ELISA did not require surface modification,128 it required timeconsuming repeated micropipetting, making it less user-friendly and incapable of highthroughput detection. Additionally, the LOD of paper-based ELISA was 54 fmol/zone, much
higher than that of our hybrid system (53.6 amol/zone), which might be attributed to efficient
washing from our hybrid system.

Figure 5.6: Rapid detection of IgG by on-chip ELISA on a hybrid microfluidic microplate. (a)
Partial scanned image of the microfluidic microplate with different IgG concentrations by an
office scanner: (1) 100 μ g/mL, (2) 10 μ g/mL, (3) 1 μ g/mL, (4) 100 ng/mL, (5) 10 ng/mL, (6) 1
ng/mL, (7) 0.1 ng/mL and (8) 0 ng/mL. (b) The sigmoidal plot of the corrected brightness of
microwells versus different IgG concentrations. The inset shows the calibration curve of IgG
where the range of linearity lies between 1 ng/mL to 1 × 104 ng/mL.
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5.3.4

Rapid quantitative detection of HBV
HBV infection is a major cause of chronic hepatic damage and of hepatocellular

carcinomas worldwide.17 HBsAg, a serological biomarker for an HBV infection, can diagnose
acute and chronic hepatitis B virus.189-191
Slightly different from the IgG detection, the ELISA for the detection of HBsAg and
HBcAg was based on a sandwich-type immunoassay. As illustrated in the inset of Figure 5.7b,
the antigen HBsAg was first immobilized on the paper surface in the hybrid microfluidic
microplate, followed with reactions with the primary antibody (i.e. rabbit anti-HBsAg) and the
secondary antibody goat anti-rabbit IgG conjugated with ALP. After the formation of the
sandwich structure, the enzymatic reaction between ALP and the colorimetric substrate
BCIP/NBT produces the purple color, similar to IgG detection. Different concentrations of
HBsAg ranging from 0.34 ng/mL to 340 μg/mL were analyzed by the hybrid microfluidic
microplate. Figure 5.7a shows a scanned image for HBsAg detection from an office scanner.
The purple color intensity increased with increasing concentrations from 0.34 ng/mL to 340
μg/mL (from right to left) with the blank in the rightmost column. Figure 5.7b shows the
calibration curve of HBsAg over a concentration range from 3.4´102 pg/mL to 3.4´108 pg/mL. A
sigmoidal curve (Figure 5.7b) was observed over the whole detected concentration range as in
IgG. In case of HBsAg, the range of linearity was observed between 3.4´102 pg/mL to 3.4´107
pg/mL (inset Figure 5.7b) with a linear regression of y = 17.37 log (x) + 56.71 (R2 = 0.99). The
LOD for HBsAg was found to be 1.3 ng/mL, comparable to commercial ELISA kits.192
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Figure 5.7: Detection of HBsAg by ELISA on a hybrid microfluidic microplate. (a) Partial
scanned image of the microfluidic microplate with different HBsAg concentrations by an office
scanner: (1) 340 μg/mL, (2) 34 μg/mL, (3) 3.4 μg/mL, (4) 340 ng/mL, (5) 34 ng/mL, (6) 3.4
ng/mL, (7) 0.34 ng/mL, and (8) 0 ng/mL. (b) The sigmoidal curve of the corrected brightness of
HBsAg over a concentration range from 3.4 × 102 pg/mL to 3.4 × 108 pg/mL. The upper inset is
the schematic of the colorimetric ELISA for detection of HBsAg, where a primary antibody
(rabbit anti-HBsAg) and an ALP-conjugated secondary antibody (goat anti-rabbit IgG) are used
together to form a sandwich-type immunoassay. The lower inset shows the calibration curve of
HBsAg where the range of linearity lies between 0.34 ng/mL to 3.4 × 104 ng/mL.
As seen from Figure 5.8A, ELISA of HBcAg was performed in the hybrid microfluidic
microplate with concentrations ranging from 1 ng/mL to 100 μg/mL. As seen from the corrected
brightness value from Figure 5.8B, it can be observed that the color intensity increased till 10
μg/mL, after which it started to saturate. The calibration curve of HBcAg was linear over the
range of 1 ng/mL to 1 ´ 104 ng/mL, after which there is a plateau with no more increase in purple
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color intensity. The linear regression of y = 10.36 log (x) + 29.32 (R2 = 0.98) was observed with
the LOD of 1.1 ng/mL, comparable to commercial ELISA kits.192
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Figure 5.8: Detection of HBcAg in a hybrid microfluidic microplate. (A) Scanned image of the
microfluidic microplate with different HBcAg concentrations by an office scanner ranging from
1 ng/mL to 100 μg/mL and a negative control (PBS). (B) The sigmoidal curve of the corrected
brightness of HBcAg over a concentration range from 1 ng/mL to 105 ng/mL.
5.3.5

Rapid quantitative detection of HCVcAg

Different concentrations of HCVcAg ranging from 0.1 ng/mL to 10 μg/mL were analyzed by the
hybrid microfluidic microplate for the detection of HCV. Figure 5.9A shows a scanned image
for HCVcAg detection from an office scanner. The figure clearly shows that the purple color
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intensity increased with increased concentrations of HCVcAg from 0.1 ng/mL to 10 μg/mL
(from left to right) with the blank in the leftmost column. Figure 5.9B shows the calibration
curve of HBcAg over a concentration range from 0.1 ng/mL to 1 ´ 104 ng/mL. A sigmoidal
curve (Figure 5.9B) was observed over the whole detected concentration range. No plateau was
observed in the color production as the maximum concentration of HCVcAg was only 10 μg/mL
and the range of linearity was observed between 0.1 ng/mL to 10 μg/mL with a linear regression
of y = 11.24 log (x) + 41.76 (R2 = 0.98). The LOD of HCVcAg was found to be 0.8 ng/mL. The
sensitivity of the hybrid device was comparable to commercial ELISA kits192 and slightly better
than nano-composite modified electrochemical immunosensor (LOD of 1 ng/mL).193
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Figure 5.9: Colorimetric detection of HCVcAg in a paper/PMMA hybrid microfluidic
microplate. (A) Scanned image of enzymatic converted substrate in different columns of the chip
with concentrations from left to right: blank (PBS), 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL,
1 μg/mL, and 10 μg/mL respectively. (B) The sigmoidal curve of the corrected brightness of
HBcAg over a concentration range of 0.1 ng/mL to 104 ng/mL.
5.3.6

Colorimetric Multiplex detection of HBsAg and HBcAg in the hybrid device
For the demonstration of the efficiency of multiplex detection of various biomarkers in

the hybrid microfluidic platform, simultaneous colorimetric detection of biomarkers of hepatitis
B virus i.e., HBsAg and HBcAg were performed. As we observed from Figure 5.10A, there was
no color development in the first column as it was negative control (PBS) without any antigen.
Second and fifth columns developed color as they had respective antibody for the capture
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antigen, but third and fourth columns didn’t develop color as they didn’t have the respective
antibody against the capture antigen. This assay also showed high specificity for anti-HBsAg and
anti-HBcAg as they could only bind to their respective antigen. All the last three columns (sixth,
seventh, and eighth) developed color as they had both the capture antigen i.e., HBsAg and
HBcAg. Figure 5.10B shows the bar graph for the corrected brightness for different columns of
the hybrid microfluidic microplate.

Figure 5.10: Colorimetric multiplex assay of HBsAg and HBcAg on a paper/PMMA hybrid
microfluidic microplate. Scanned image of the enzyme-catalyzed substrate, (A) and bar plot of
the corrected brightness of the scanned image (B). From left to right: immobilized probe, none
(1), HBsAg (2) and (3), HBcAg (4) and (5), and HBsAg + HBcAg (6), (7), and (8), respectively.
Test: From left to right, solution containing, anti-HBsAg and anti-HBcAg (1) and (6), HBsAg
(2), (4), and (7), and HBcAg (3), (5), and (8). “a” and “b” shows that the data are significantly
different from each other at p = 0.05.
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5.3.7

Colorimetric anti-interference test of HBsAg in the hybrid device
The anti-interference assay showed that there was no interference or cross-reaction of the

target protein with other proteins and biomolecules present in the matrix. Figure 5.11 shows the
detection of 200 ng/mL of HBsAg with and without various concentrations of interfering
proteins (HBcAg, CEA, BSA, and PSA). There was no production of purple color in the first
four columns from the left as anti-HBsAg did not bind with any of the interfering proteins (1
μg/mL HBcAg in the first column, 100 ng/mL CEA in the second column, 250 μg/mL BSA in
the third column, and 10 ng/mL PSA in the fourth column). As seen from Figure 5.11B, the color
intensity for the detection of 200 ng/mL of HBsAg in the presence of different interfering
proteins (column 5, 6, and 7) was similar to the detection of 200 ng/mL of HBsAg without the
interfering proteins (column 8). It demonstrated that even 1,250 times concentrated interfering
proteins did not influence the specific detection of HBsAg in the hybrid microfluidic microplate.
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Figure 5.11: Colorimetric anti-interference test for the detection of HBsAg in a paper/PMMA
hybrid microfluidic microplate. The scanned image of the chip (A) and the corrected brightness
of the scanned image of ELISA in the hybrid device (B) for the detection of HBsAg. The left
four columns are for detection of 0 ng/mL of HBsAg in the solution containing 1µg/mL HBcAg
(1), 100 ng/mL CEA (2), 250 µg/mL BSA (3), and 10 ng/mL PSA (4), respectively. The right
four columns are for the detection of 200 ng/mL of HBsAg in 1µg/mL HBcAg (5), 100 ng/mL
CEA + 10 ng/mL PSA (6), 250 µg/mL BSA (7), and PBS (8), respectively. “a” and “b” shows
that the data are significantly different from each other at p = 0.05.
5.3.8

Rapid quantitative detection of HBsAg in human serum samples
To validate the analytical accuracy and to determine its feasibility for detection of real

human samples of HBV, normal human serum was spiked with different concentrations of
standard HBsAg. Four different concentrations of HBsAg (3.4 ng/mL, 34 ng/mL, 0.34 µg/mL,
100

and 3.4 µg/mL) within the range of linearity and above the LOD were chosen for spiking and
recovery tests. As can be seen from Table 5.1, the intensity of purple color increased from lower
concentrations to higher concentrations of the spiked human serum samples, consistent with
ELISA results using standard HBsAg (Figure 5.7). The analytical recoveries of the serum
samples ranging from 91.1-109.1 % were obtained and were within the acceptable criteria for
bio-analytical validation.194, 195
Table 5.1: Detection of HBsAg spiked in human serum sample by colorimetric ELISA on a
hybrid microfluidic microplate.

5.3.9

Chemiluminescence ELISA on the hybrid microfluidic microplate
For the device to be used in high-end laboratories and hospitals, the hybrid device was

redesigned to make it compatible with traditional microplate readers (Figure 5.12). The
microwells in the hybrid device were designed according to the dimensions of the standard 384

101

well plates as discussed in Section 3.2.2. Chemiluminescence ELISA of IgG, HBV, and HCV
was performed in the hybrid device. Once the chemiluminescence substrate for ELISA was
added to the chip, the chip was incubated for two minutes. The chip was then scanned using
microplate reader M3 (Molecular Devices, San Jose, CA). Since the dimensions of the chip were
similar to the 384-wells microplate, the desired area of scanning was chosen from the standard
384-wells microplate. The chemiluminescence intensity of SuperSignal® ELISA Pico
Chemiluminescent substrate was measured at 425 nm to draw the calibration curve.

Figure 5.12: Photographs of the PMMA/paper hybrid microfluidic microplate consisting of three
different layers. The top layer for fluid delivery consists of inlet reservoirs and fluid distribution
channels. The middle layer consists of 64 funnel-shaped microwells where paper disks can be
inserted. The lowermost layer for fluid removal consists of outlet channels which lead to a
common outlet reservoir.

102

5.3.10 Optimization of incubation time for chemiluminescence substrate
Once the chemiluminescence substrate was added to the hybrid device, after washing the
device three times with PBST following the addition of enzyme-linked secondary antibody,
chemiluminescence was measured. To optimize the incubation time of the substrate to get the
maximum signal, kinetic ELISAs were performed for 30 min after the addition of the substrate
and reading was taken every 30 seconds. Chemiluminescence signal was measured using a
microplate reader after the completion of the assay. On-chip ELISA was performed at three
different concentrations, 1 ng/mL, 1 μg/mL, and 100 μg/mL of IgG along with the negative
control. As we can see from Figure 5.13 the chemiluminescence intensity increased until 2 min
for higher concentration (1 μg/mL and 100 μg/mL) and until 2.5 min for lower concentration (1
ng/mL) and then started to decrease rapidly. The increase in chemiluminescence intensity from 2
min to 2.5 min in lower concentration was not significant. The maximum signal to noise (PBS)
ratio was also observed at 2 min. Therefore, 2 min was considered as the optimum time for the
incubation of chemiluminescence substrate and reading was taken at 2 min after the addition of
the substrate.
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Figure 5.13: Optimization of the incubation time for the chemiluminescent substrate (luminol
and peroxide). Kinetic chemiluminescence ELISAs of different concentrations of IgG were
performed in the hybrid device for 30 min.
5.3.11 Rapid chemiluminescence detection of IgG
For the on-chip chemiluminescence ELISA of IgG in the hybrid microfluidic microplate,
all the reagents were loaded sequentially from the inlets in the upper layer of the hybrid device.
The reagents flowed through all the wells in the middle layer avoiding the manual pipetting to all
the wells. After ELISA was completed, the device was scanned using a microplate reader at 425
nm. Figure 5.14A shows the fitted sigmoidal curve for on-chip chemiluminescence detection of
IgG as chemiluminescence intensity versus the concentration of IgG. It can be seen from Figure
5.14A that the chemiluminescence intensity increased rapidly until the concentration reached 103
ng/mL, after which the intensity got saturated. Figure 5.14B shows the assay had a very wide
linear range of detection ranging from 0.01 ng/mL to 1 ´ 103 ng/mL with a linear regression of y
= 2389.4 log (x) + 11722 (R2 = 0.99). The LOD of IgG was found to be 20 pg/mL. The assay was
found to be 80-fold more sensitive as compared to our hybrid colorimetric device (LOD, 1.6
ng/mL) and 100-fold more sensitive than traditional microplate ELISA.5 Our device also has a
better sensitivity as compared to APTES modified PMMA (0.12 μg/mL),109 the paper-based
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device (54 f/mol/zone),128 and poly(ethyleneimine) modified PMMA using fluorescence
microscope.111

Figure 5.14: Rapid chemiluminescence detection of IgG in the hybrid microfluidic microplate.
(A) The fitted sigmoidal curve of the chemiluminescence intensity over a concentration range
from 0.01 ng/mL to 104 ng/mL and a negative control (PBS). (B) Calibration plot of IgG where
the range of linearity lies between 0.01 ng/mL to 1000 ng/mL.
5.3.12 Rapid chemiluminescence detection of HBsAg
Similar to on-chip chemiluminescence ELISA of IgG, chemiluminescence ELISA of
HBsAg was also performed in the hybrid microfluidic microplate. As we could observe from
Figure 5.15, chemiluminescence intensity of HBsAg increased with the increase in the
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concentration of HBsAg from 0.034 ng/mL to 3.4 ´ 104 ng/mL. Figure 5.15A shows the
sigmoidal fitted curve for the detection of HBsAg with chemiluminescence intensity against the
concentration of HBsAg. Figure 5.15B showed that the assay had very wide linear range of
detection ranging from 3.4 ´ 101 pg/mL to 3.4 ´ 107 pg/mL with a linear regression of y = 2415.8
log (x) + 10492 (R2 = 0.98). The LOD of HBsAg was found to be 50 pg/mL. The
chemiluminescence hybrid device was more sensitive than commercial ELISA kits, HBsAg
assay by Yazdani et al. (LOD of 0.7 ng/mL), and our previous colorimetric hybrid device with
LOD of 1.3 ng/mL.5, 160 Our device had better sensitivity than the device by Xu et al. (LOD of
0.1 ng/mL), which required experiment in class-100 clean room,139 capillary chemiluminescence
with a sensitivity of 0.3 ng/mL, and copper oxide nanoparticles and nanocomposite-based
chemiluminescence assay (LOD of 1.8 and 0.85 ng/mL).196, 197 The sensitivity was comparable to
gold nanoparticle-based chemiluminescence detection of HBsAg with LOD of 14 pg/mL.198

106

Figure 5.15: Rapid chemiluminescence detection of HBsAg in the hybrid microfluidic
microplate. (A) The fitted sigmoidal curve of the chemiluminescence intensity over a
concentration range from 0.034 ng/mL to 34 ´ 104 ng/mL and a negative control (PBS). (B)
Calibration plot of HBsAg where the range of linearity lies between 3.4 ´ 101 pg/mL to 3.4 ´ 107
pg/mL.
5.3.13 Rapid chemiluminescence detection of HBcAg
On-chip chemiluminescence ELISA of HBcAg was performed similar to the ELISA of
IgG and HBsAg in the hybrid microfluidic microplate. Figure 5.16A shows that
chemiluminescence intensity of HBcAg increased with the increase in the concentration of
HBcAg from 0.01 ng/mL to 103 ng/mL. There was no significant increase in the intensity from
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103 ng/mL to 104 ng/mL, which may indicate that the chemiluminescence intensity was getting
saturated. As seen in Figure 5.16A chemiluminescence intensity against the concentration of
HBcAg gave a sigmoidal fitted curve over the whole range of concentrations. Figure 5.16B
shows the assay had very wide linear range of detection ranging from 0.01 ng/mL to 1 ´ 104
ng/mL with a linear regression of y = 2349 log (x) + 10065 (R2 = 0.98). The LOD of HBcAg was
found to be 35 pg/mL which was similar to chemiluminescence detection of HBsAg.

Figure 5.16: Rapid chemiluminescence detection of HBcAg in the hybrid microfluidic
microplate. (A) The fitted sigmoidal curve of the chemiluminescence intensity over a
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concentration range from 0.01 ng/mL to 104 ng/mL and a negative control (PBS). (B) Calibration
plot of HBcAg where the range of linearity lies between 0.01 ng/mL to 104 ng/mL.
5.3.14 Rapid chemiluminescence detection of HCVcAg
Infection by hepatitis B and C virus cause acute and chronic liver disease and they can
coexist and result in fulminant hepatitis and HCC.199 Both the viruses are the causal agents for a
chronic liver infection. Therefore, after the completion of on-chip chemiluminescence ELISA for
the detection of HBV (HBsAg and HBcAg), detection of HCV was carried out using HCVcAg.
For the detection of HCVcAg, samples ranging from 104 ng/mL to 0.01 ng/mL were taken.
Figure 5.17 shows that there was minimum chemiluminescence intensity for the negative control
(PBS) and the chemiluminescence intensity of HCVcAg escalated with the increase in the
concentration of HCVcAg from 0.01 ng/mL to 103 ng/mL, after which a plateau can be observed,
indicating saturation of the chemiluminescence intensity. Chemiluminescence intensity against
the concentration of HCVcAg gave a sigmoidal fitted curve as seen in Figure 5.17A. Figure
5.17B shows that the assay had a wide linear range of detection ranging from 0.01 ng/mL to 1 ´
104 ng/mL with a linear regression of y = 2075.5 log (x) + 11569 (R2 = 0.99). The LOD of
HCVcAg was found to be 10 pg/mL. The device was found to be more sensitive than the labelfree immunosensor for HCVcAg detection (LOD of 0.17 ng/mL), nano-composite modified
electrochemical immunosensor (LOD of 1 ng/mL).193, 200 The LOD was comparable to gold
nanoparticle-enhanced microwell plate-based ELISA of HCV antibody with LOD of 122
pg/mL.201
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Figure 5.17: Rapid chemiluminescence detection of HCVcAg in the hybrid microfluidic
microplate. (A) The fitted sigmoidal curve of the chemiluminescence intensity over a
concentration range from 0.01 ng/mL to 104 ng/mL and a negative control (PBS). (B) Calibration
plot of HCVcAg where the range of linearity lies between 0.01 ng/mL to 104 ng/mL.
5.3.15 Multiplex chemiluminescence detection of HBcAg and HBsAg
Similar to the colorimetric multiplex assay, simultaneous chemiluminescence detection of
HBsAg and HBcAg was performed in the hybrid microfluidic platform. As we could observe
from Figure 5.18, there was minimum chemiluminescence intensity in the first column as it was
negative control (PBS) without any antigen. The second and fifth columns showed high
chemiluminescence intensity as they had respective antibody for the capture antigen but third
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and fourth columns showed minimum chemiluminescence intensity as they didn’t have the
respective antibody against the capture antigen. Last three columns (sixth, seventh, and eighth)
had high chemiluminescence intensity as they had both the capture antigen i.e., HBsAg and
HBcAg. The assay shows that multiple biomarkers can be detected at a same time in the hybrid
device. The device has a potential to detect eight different biomarkers in eight columns of the
hybrid chip.

Figure 5.18: Multiplex chemiluminescence assay of HBsAg and HBcAg in a paper/PMMA
hybrid microfluidic microplate. From left to right: immobilized probe, none (1st), HBsAg (2nd)
and (3rd), HBcAg (4th) and (5th), and HBsAg + HBcAg (6th), (7th), and (8th), respectively.
Test: From left to right, solution containing, anti-HBsAg and anti-HBcAg (1st) and (6th), HBsAg
(2nd), (4th), and (7th), and HBcAg (3rd), (5th), and (8th). “a” and “b” shows that the data are
significantly different from each other at p = 0.05.
5.3.16 Chemiluminescence anti-interference test for HBsAg
Similar to the colorimetric anti-interference assay, the on-chip chemiluminescence antiinterference assay for HBsAg was performed. The assay procedure was similar to the
colorimetric assay except for the secondary antibody (HRP-linked antibody instead of ALP111

linked antibody) and its chemiluminescence substrate along with the scanning method. Figure
5.18 shows that the first four columns are negative controls without any target protein (i.e.
HBsAg) and produce minimum chemiluminescence intensity, while the last four columns
contain 200 ng/mL of the target protein, HBsAg in the presence of other interfering proteins and
produced high chemiluminescence intensity. The chemiluminescence intensity of 200 ng/mL of
HBsAg was similar to the intensity of 200 ng/mL of HBsAg with different interfering proteins.
Similar to the colorimetric assay, it demonstrated that even 1,250 times concentrated interfering
proteins did not influence the specific detection of HBsAg in the hybrid microfluidic microplate.

Figure 5.19: Chemiluminescence anti-interference test for the detection of HBsAg on a
paper/PMMA hybrid microfluidic microplate. The left four columns: detection of 0 ng/mL of
HBsAg in the solution containing 1µg/mL HBcAg (1st), 100 ng/mL CEA (2nd), 250 µg/mL
BSA (3rd), and 10 ng/mL PSA (4th), respectively. The right four columns: detection of 200
ng/mL of HBsAg in 1µg/mL HBcAg (5th), 100 ng/mL CEA + 10 ng/mL PSA (6th), 250 µg/mL
BSA (7th), and PBS (8th), respectively. “a” and “b” shows that the data are significantly
different from each other at p = 0.05.
5.3.17 Chemiluminescence detection of HBsAg and HCVcAg in a human serum sample
To determine the feasibility for the detection of the real human sample and to validate the
analytical accuracy of the proposed chemiluminescence assay in the hybrid device,
112

chemiluminescence ELISA of HBsAg and HCVcAg was performed with the human serum
sample. For the chemiluminescence assay, normal human serum was first spiked with various
concentrations of standard HBsAg and HCVcAg. Five different concentrations of both HBsAg
(3.4 ng/mL, 34 ng/mL, 340 ng/mL, 3.4 μg/mL, and 34 μg/mL) and HCVcAg (0.1 ng/mL, 1
ng/mL, 10 ng/mL, 100 ng/mL, and 1 μg/mL) were taken. All the concentrations of HBsAg and
HCVcAg chosen for spiking and recovery tests were within the range of linearity and above the
LOD. We can see from Table 5.2 that the analytical recoveries of the serum samples obtained
ranged from 90.00–109.64 % and were within the acceptable criteria for bio-analytical
validation.194, 195
Table 5.2: Detection of HBsAg and HCVcAg spiked in human serum sample by
chemiluminescence ELISA on a hybrid microfluidic microplate.

5.4

Summary
We have developed a simple, portable, and POC paper/PMMA hybrid microfluidic

microplate for rapid and sensitive detection of infectious diseases and other bio-analytes. To the
best of our knowledge, this is the first report of paper/PMMA hybrid microfluidic device, which
draws more benefits from both substrates. The innovative use of 3D micro-porous paper in
funnel-shaped microwells of this hybrid microplate facilitated rapid immobilization of
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antibody/antigen and avoided complicated surface modifications. ELISA assays can be
completed within one hour, and results can be observed by the naked eye or scanned by an office
scanner for quantitative analysis. In addition, smartphone cameras can also be used to capture the
image and the signals can be processed using different applications or cloud-based systems57.
Although the basic system shown here can only perform 8 seven-repeated experiments (7x8
microwells), the design can be simply modified to perform as many experiments and repeats as
desired. For instance, the hybrid microfluidic microplate can be expanded to 96 wells or 384
wells according to different needs simply by increasing the number of wells and channels, where
the basic architecture remains the same. Without using any specialized laboratory equipment, the
LOD of 1.6 ng/mL for IgG was achieved, which is comparable to that of commercial ELISA kits
using spectrometers or microplate readers. The hybrid microfluidic microplate significantly
reduces the sample and reagent volume compared to commercial ELISA and shows great
promise as a POC device for rapid, sensitive, and quantitative detection of biomarkers, especially
in low-resource settings, such as small clinics, rural areas, border regions and developing
nations.
For the device to be used in the settings of laboratories and hospitals, the hybrid device
was redesigned to make it compatible with traditional microplate readers. The microwells in the
hybrid device were designed according to the dimensions of the standard 384-well plates so that
any commercial microplate reader can be used to read the device. Chemiluminescence assay of
different biomarkers was performed in the hybrid device and the LODs of 20 pg/mL for IgG, 50
pg/mL for HBsAg, 35 pg/mL for HBcAg, and 10 pg/mL for HCVcAg were achieved. The hybrid
device can be used in high-end laboratories and hospitals having microplate reader for detection
of infectious diseases and cancer biomarkers. As the device is around 100-fold more sensitive
than commercial 96- or 384-well plates, it can be used to detect a low-concentration analyte.
Because ELISA and microplates are widely used, this hybrid paper/PMMA microfluidic
microplate will have broad applications from biology and clinical diagnosis to various
biochemical analyses.
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Chapter 6: A Reusable PMMA/Paper Hybrid
Plug-and-Play Microfluidic Device for High-sensitivity Immunoassay

•

This chapter introduces a reusable, cost-effective, and eco-friendly PMMA/paper
hybrid plug-and-play (PnP) device for analyte enrichment and detection.

•

The sample flows back and forth through the low-cost 3D paper substrate within
the PMMA channels thereby enriching the amount of analyte adsorbed and
dramatically decreasing the incubation time.

•

The paper substrate can be replaced so that the device can be reused.

•

The sandwich-type immunoassay of IgG and HBsAg was performed in the hybrid
device with LOD of 200 pg/mL and 270 pg/mL, respectively which is at least 10
times more sensitive than commercial ELISA kits.

•

The hybrid PnP device can be used for low-cost, reusable, and reproducible
enrichment and detection of infectious diseases, cancers, and other biomolecules.
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6.1

Introduction
Infectious diseases caused by bacteria, viruses or fungi lead to around 13.2 million

deaths, which is 25% of the deaths worldwide and accounts for more than half of all the infant
deaths.202, 203 In addition, 95% of these deaths are due to the lack of cost-effective medical
interventions.204 Although advanced and sophisticated technologies including polymerase chain
reaction (PCR) and enzyme-linked immunosorbent assay (ELISA) are extensively used in
developed countries, they are not widely available in developing countries because of limited
funds and skilled manpower. These techniques along with other methods such as cell culture,
western blotting, and flow cytometry are often laborious and time-consuming. So, point-of-care
(POC) detection in resource-limited settings is still a challenge.170, 205144 Although ELISAs
performed in 96-well plates are the most commonly used laboratory methods, they require
overnight incubation, consume a large volume of valuable samples and expensive reagents, and
require laboratory settings with bulky and expensive robotic pipettors, plate washers, and optical
detectors.52, 145 Likewise, the other major problem is the detection of low-concentration analytes.
The ability to enrich biological samples such as proteins is important in bio-analysis and medical
diagnosis to increase the sensitivity of detection. In order to make LOC devices as competitive as
traditional techniques, the development of novel methods to improve detection limits and enrich
analytes for chip-based detection is required.206 One of the most important boons of preconcentration of samples before analysis is to improve the detection of low-concentration
analytes, typically faced in the real-world samples.206 Sample enrichment or pre-concentration
have been done on microfluidic devices either by electrophoretic methods or non-electrophoretic
extraction methods (liquid/liquid extraction, solid-phase extraction). Such techniques require
careful consideration of electrical behavior, background electrolyte composition, and ion
concentrations.207, 208 Likewise, complicated on-chip column-based chromatography method
followed by detection using mass spectroscopy has also been used for enrichment of
biomarkers.209 Carbon-based nanomaterials such as fullerenes, graphene, nanodiamonds, and
nanofibers have also been frequently utilized as adsorbents for sample pre-treatment and
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enrichment.210 Most of the developed techniques of analyte enrichment require complicated
synthesis and cross-linking steps along with expensive detection units and are not suitable in
POC settings.
Microfluidic devices fabricated by microelectromechanical systems (MEMS) technology
incorporate different fields including electronics, mechanics, optics, biological detection, and
sensors.147, 211 The small volume of micro-channels and high surface-to-volume ratios in these
low-cost and portable microfluidic devices, significantly decreases the analysis time and can
integrate various bio-sensing elements.6237 Microfluidic lab-on-a-chip (LOC) devices greatly
reduce the volume of samples and reagents, without compromising specificity and sensitivity.212
Disposable devices such as paper-based devices further reduce the cost of diagnosis. Paper-based
devices have been widely used as platforms for POC analysis.55, 128 Paper having a high surfaceto-volume ratio can rapidly immobilize different sensors and biomolecules, yet doesn’t require
clean room for fabrication, and can be easily disposed. Furthermore, it is abundant, inexpensive
and easy to use.55 Colorimetric paper-based devices are the most widely employed detection
platforms since the paper substrate offers a bright, high-contrast, and colorless background for
color change readings as described in Section 1.5.3. PMMA has also been widely used in LOC
devices due to its low cost of manufacturing and ease of use and fabrication as discussed in
Section 1.5.2. Likewise, it is bio-disposable, transparent, rigid, and can rapidly transfer reagents.
However, PMMA requires complicated surface modification for the immobilization of proteins
and immune-sensors. Darain et al. activated the PMMA surface with O2 plasma and
functionalized it with APTES for stable antibody immobilization.109 The on-chip ELISA was
detected using fluorescence microscopy with LOD of 0.12 µg/mL. Zhou et al. treated PMMA
under ultrasonic water bath and oxygen plasma before coupling the capture antibody with 1ethyl-3-(3-dimethylaminopropyl) carbodiimide reagent and required a pumping system and a
microplate reader.135 Yu et al. developed a QD-linked immune-diagnostic assay where
myeloperoxidase antibodies were covalently linked to PMMA after treating it with polyethylene
glycol followed by glutaraldehyde and required expensive fluorescence setup for detection.136
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Liu et al. modified the PMMA using PEI for electrochemical detection of a biomarker of
neurological disease and required an electrochemical workstation.137 Sun et al. performed
sandwich ELISA of staphylococcal enterotoxin B by functionalizing antibody with carbon
nanotube before immobilizing it to the PMMA.125 All of these assays require complicated and
time-consuming functionalization along with bulky and expensive detection systems and cannot
be used in POC settings.
Each microfluidic substrate has its own nobilities and drawbacks. The combination of
different substrates can enable integration of different functionalities, taking advantages of
different materials and excluding some limitations of certain materials. Recently hybrid
microfluidic devices have been broadly applied for diverse applications including detection of
infectious diseases and cell culture studies as discussed in Section 1.5.4.55, 148, 149, 213
In response to the aforementioned challenges, we have developed a simple reusable
PMMA/paper hybrid plug-and-play (PnP) microfluidic device for analyte enrichment and highly
sensitive immune-detection. The PMMA substrate has multiple laser-ablated slots where a prepatterned 3D microporous paper substrate can be plugged in. The sample flows back and forth
through the paper within the PMMA channel, hence increasing the amount of analyte
immobilized and decreasing the incubation time. After the enrichment assay through the 3D
matrix of the paper, paper substrate can be simply plugged out of the device to view the result
and a new paper substrate can be plugged in for the next assay. ELISA of IgG and HBsAg were
performed in the PnP hybrid microfluidic device and LODs of 200 pg/mL and 270 pg/mL were
obtained, respectively, without the use of any specialized detection system like the microplate
reader. Compared to regular paper-based and PMMA microfluidic devices, our hybrid method
showed significantly improved sensitivity and a wide linear range of five orders of magnitude for
IgG and six orders of magnitude for HBsAg. The sensitivity of the PnP device was at least 10
folds better than that the commercial ELISA kits.
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6.2

Experimental

6.2.1

Chemicals and materials
All chemicals and materials are listed in Section 2.1.

6.2.2

Design and fabrication of microfluidic platform
PnP hybrid microfluidic platform was designed with the aid of Adobe Illustrator CS5.

The PMMA chip was then fabricated with a laser cutter (Epilog Zing 16, Golden, CO) by maskless laser ablation where the beams of the laser move in x- and y-directions as devised in the chip
design. The final design of the PnP hybrid device was as shown in Figure 6.1. The hybrid PnP
microfluidic device has varying depths in each of the PMMA layers. Thus, we have used laser
ablation as a rapid alternative to the photolithography, where the high-powered laser removes the
material from the desired substrate as defined in the pattern.
The PnP hybrid device consists of three layers as shown in the 3D schematic of the
exploded device in Figure 6.1A, with top, middle, and bottom layers. The top and middle layers
consist of two inlet microwells, four slots, and two micro-reservoirs. Inlet microwells in the
middle layer are connected to the reservoir microwells via slots by microchannels in the middle
layer. Two sets of the two-replica assays can be performed in the shown device. The bottom
layer consists of four slots. Figure 6.1B shows a 3D view of the assembled PnP hybrid
microfluidic device, while Figure 6.1C shows the photograph of the actual assembled PnP hybrid
microfluidic device.
A reversible sealing of the PnP device was obtained by clamping different PMMA layers
together within glass slabs in an oven at 115-120 °C for 35 minutes. The PnP device can be used
for enrichment and assay after plugging the paper substrate in the slots after the chip cools down
to room temperature.
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Figure 6.1: Chip design of hybrid PnP device. (A) 3D schematic of the exploded PnP hybrid
microfluidic device with top, middle, and the bottom layer. (B) 3D view of the assembled PnP
hybrid microfluidic device. (C) The photograph of the assembled PnP hybrid microfluidic
device.

6.2.3

Optimization of parameters effecting colorimetric signals
ELISAs of different biomarkers were performed in the hybrid PnP microfluidic device.

Varieties of factors including flow rate, incubation time, and repeat time influences the
sensitivity of ELISA. A thorough study was performed to optimize the conditions of ELISA to
get a better result and sensitivity. Finally, the ELISA of IgG and HBsAg were performed with
the optimized conditions.
6.2.4

Optimization of the flow rates in the hybrid device
To determine the relationship between the flow rate and signal intensity, ELISA of IgG

was performed with different flow rates. Samples/reagents were injected into the microwells by
polyethylene tubing (BD Diagnostics, Sparks, MD) connected to a syringe pump (kdScientific,
Holliston, MA) and the inlet microwells to control the flow rate. 1 ng/mL of IgG and the
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negative control (PBS) were added to each inlet microwell present in the first layer. To optimize
the flow rate of the analyte, ELISA was performed with different flow rates (15 µL/min, 20
µL/min, 25 µL/min, 30 µL/min, and 35 µL/min). 50 µL of the analyte/PBS was added to the chip
with these different flow rates (so that each micro-zone receives 25 µL of the analyte). Once 50
µL of the analyte was added and incubated for 5 minutes, analyte was withdrawn back to the
syringe so that it flows through the paper surface within the channel. This process was repeated
for 5 times in order to maximize enrichment of the analyte onto the paper surface. After the
completion of the colorimetric assay, the flow rate with the highest net brightness (signal)
difference between the analyte and the negative control was taken as the optimum flow rate and
further experiments were done with the same flow rate.
6.2.5

Optimization of the incubation time and repeat times in the hybrid device
Incubation time was defined as the time of incubation after the analyte was completely

injected or withdrawn from the PnP hybrid microfluidic device in each repeat cycles. Incubation
time was optimized similar to the optimization of the flow rate. Once the analyte was completely
injected to the device or withdrawn from the device using the optimum flow rate, the paper
substrate was incubated for different times (0 min, 1 min, 3 min, 5 min, and 10 min) and the
process was repeated for 5 times. Finally, the colorimetric assay was completed to measure the
net brightness difference between the analyte and the negative control. For the optimization of
the repeat times, the complete injection and withdrawal of the analytes were repeated for several
times (1, 2, 3, and 4) with the optimized flow rate and incubation time. The signal intensities
were compared against repeat times after the assay and the repeat times with the highest net
brightness difference between the analyte and the negative control was considered as the
optimum repeat times.
6.2.6

Detection of IgG and HBsAg using the hybrid PnP microfluidic device
The hybrid PnP device was used for the detection of IgG and HBsAg. Standard samples

of IgG were prepared by diluting a stock solution of IgG (2 mg/mL in 10 mM, pH 8.0 PBS) to

121

different concentrations ranging from 0.1 ng/mL to 10 μg/mL. 50 µL of IgG/PBS was injected
into the hybrid PnP device from different inlet microwells in the top layer of the chip. The
analyte was injected from the syringe pump via polyethylene tubing to the inlet microwells at the
speed of 20 µL/min. The device was incubated for 3 min, then the analyte was withdrawn back
to the syringe pump at the same speed of 20 µL/min followed by incubation time of 3 min. The
injection and withdrawal of the analytes were repeated for 3 times with the same speed and
incubation time. After the enrichment step, the paper surface was blocked with a 4.5 % BSA to
block the non-specific binding sites. After incubating for 10 min, the device was washed with
washing buffer. 6 μg/mL of anti-rabbit IgG linked with alkaline phosphatase was added for 7
min, which was followed by a three-time wash with PBST. A light yellow colored BCIP/NBT,
which is a substrate for alkaline phosphatase was then added. The substrate produces a visually
observable purple color, the intensity of which depends on the concentration of the analyte.
Finally, the paper substrate was plugged out of the device after 10 minutes and scanned with a
scanner or an image cab be taken by a cell-phone camera.
For the on-chip enrichment and detection of HBsAg, a sandwich immunoassay was
performed with a procedure similar to IgG. HBsAg was first bound to the surface of the paper
followed by blocking the unreacted surfaces. Next, anti-HBsAg was added followed by the
addition of anti-rabbit IgG, which was linked with alkaline phosphatase. Unbound secondary
antibody in the sandwich structure was then washed with PBST and finally the colorimetric
substrate, BCIP/NBT was added.
6.2.7

Comparison of the PnP device with paper-based devices for the detection of HBsAg
For the detection of HBsAg in a paper-based device, 40-microzone-paper substrate with

an array (8 ´ 5) of circular zones was prepared and colorimetric ELISA ranging from 0.34
ng/mL-340 μg/mL was performed. 10 μL of different concentrations of HBsAg was first added
to each microzone and incubated for 10 min followed by blotting-dry by keeping the paper-based
device over a kimwipe (Kimtech, Roswell, GA). The paper substrate was then blocked with a
blocking buffer (5 μL per zone) for 10 min and washed with PBST. The paper-based device was
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blotted dry after each step. Anti-HBsAg was then added for 10 min followed by washing and the
addition of ALP-linked anti-rabbit IgG. Finally, BCIP/NBT was added after washing it three
times with PBST. The paper-based device was scanned with a desktop scanner for quantitative
measurement.
6.3

Results and discussion

6.3.1

Hybrid PnP microfluidic device
The PnP hybrid microfluidic device was designed to meet three specific requirements: (i)

generation of multiple slots with interconnected channels, where the paper substrate can be
placed so that the analyte can pass back and forth through the channel, rapidly immobilizing
more and more analyte in the porous paper substrate. (ii) the paper substrate which can be
plugged into the device to perform the assay (PnP) and be replaced with a new one for another
assay. (iii) a temporary reservoir to store the analyte so that all the analyte from the syringe can
pass through the slot.
Figure 6.2 explains the working principle of the PnP hybrid microfluidic device. As
shown in Figure 6.2A, the top layer (I) has inlet microwells (a) from which reagents/analytes can
be added. The top inlet microwell continues with microwell in the middle layer (II), which is
placed just below the inlet microwell so that the reagents can fall directly into the middle layer.
The microwell in the middle layer continues to the channels (c) in the middle layer through
which reagents flow towards the opposite end of the reservoir (d). The reagent flows through the
slots (e) where the paper substrate (f) is plugged in vertically as shown in Figure 6.2B. The
reservoir in the middle layer is open as a reservoir in the top layer with a smaller diameter (b).
The slot is open in the top and middle layer but it is closed towards the lower side of the bottom
layer so that the reagent does not fall down from the chip. The analyte passes through the paper
substrate and gets stored in the reservoir. The analyte is then withdrawn back to the syringe
pump through the paper substrate. The process is continued for a couple of times so that the
higher amount of sample could be immobilized to the surface of the paper.
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Figure 6.2: Working principle and cross-section view of PnP hybrid microfluidic device. The
figure shows the cross-section view of the PnP hybrid microfluidic device without the paper
substrate (A) and with the paper substrate (B). The top layer consists of inlet microwell (a) and
reservoir microwell (b). The middle layer consists of channels (c) and reservoir (d). Slots (e) pass
through the top, middle and half of the bottom layer where the paper substrate (f) can be plugged
in vertically. Scanned image of the SU-8 treated paper substrate before the immunoassay (C) and
after the immunoassay (D).
6.3.1

Optimization of the flow rates
The flow rate of the sample through the paper-strip affects the immobilization or the

enrichment efficiency of the analyte on the surface of the paper. Therefore, the optimum flow
rate of the sample which can immobilize maximum amount of analyte was determined. IgG was
chosen as the model analyte for optimization studies. IgG, the most prevalent antibody in the
human circulation can be used for diagnosis of Neuromyelitis Optica188 and autoimmune
hepatitis186 and is the major constituent of the secondary immune response to different kinds of
infectious agents.214 IgG levels in the human body also indicates the immune status of different
diseases including measles, mumps, and rubella (MMR), hepatitis B virus, and varicella.187 For
the optimization of the flow rate of the injection and the withdrawal of the sample, different flow
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rates of IgG (15 µL/min, 20 µL/min, 25 µL/min, 30 µL/min, and 35 µL/min) were tested. After
the completion of ELISA, the paper substrate was scanned and ImageJ was used to measure the
brightness value. As we could observe from Figure 6.3, there was a significant increase in the net
brightness difference between the analyte (1 ng/mL of IgG) and the negative control (phosphatebuffered saline, PBS) from 15 µL/min to 20 µL/min. The decrease in the net brightness
difference between the analyte and the negative control was observed from 20 µL/min to 35
µL/min. At 15 µL/min, the pressure may not be strong enough for the analyte to go through the
paper substrate properly. However, we hypothesized that with the flow rate higher than 20
µL/min, the analytes passed the paper substrate too fast, so they could not bind to the paper
surface properly. The flow rate of 20 µL/min, which gave the highest net difference between the
analyte and the negative control, was considered as the optimized flow rate and was used in the
following experiments.

Figure 6.3: Optimization of the flow rate of the analyte. The graph shows the relationship
between flow rate and the net brightness difference between the analyte and the negative control.
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6.3.2

Optimization of the incubation time and repeat times
Diagnostic devices which have higher sensitivity, but lower assay time are preferred.

Therefore, the minimum incubation time which can obtain the highest enrichment of the analyte,
ultimately leading to increase in sensitivity was determined in the optimization of incubation
time. Once the flow rate of the analyte was optimized, different incubation times (0 min, 1 min, 3
min, 5 min, 10 min) were evaluated to optimize the incubation time for the analyte. As seen from
Figure 6.4A, there was a slight increase in the net brightness difference between the analyte and
the negative control, from 0 min to 3 min. After 3 min of incubation time, there was no
significant increase in the net brightness difference. In addition, the standard deviation at 0 and 1
min was much higher as compared to 3 min. The incubation time of 3 min was considered as the
optimum incubation time as we could observe from Figure 6.4A, where the graph of net
brightness difference against incubation time showed plateau starting from 3 min. Therefore, the
incubation time of 3 min was used in all the subsequent experiments.
We also optimized the repeat time for the injection and withdrawal of the analyte to
determine the minimum repeat time with the maximum difference between the positive and
negative control so as to increase the sensitivity while achieving the minimum time possible. A
few repeat times may not be sufficient to enrich the analyte while too many repeats may
ultimately lead to washing off the immobilized analyte or more time consumption. The injection
and withdrawal of the analyte were repeated for several times (1 time, 2 times, 3 times, and 4
times). As we could observe from Figure 6.4B, the net brightness difference between the analyte
and the negative control increased with the increase in repeat times for up to 3 repeats. After 3
repeats, there was no significant increase in the net brightness difference as the graph of net
brightness difference against repeat time showed plateau starting from 3 repeats. It showed that
signal to noise difference reached a maximum at 3 repeats and any further increase in repeat time
did not increase the enrichment of analyte, so 3 repeats were enough to immobilize maximum
amount of analyte. Hence, the repeat times of 3 repeats were considered as optimum repeat times
and the same parameter was used in all the subsequent experiments.
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Figure 6.4: Optimization of incubation time and repeat times for immunoassay in PnP hybrid
microfluidic device. (A) The relationship between incubation time and net brightness difference
between the analyte and the negative control. (B) The relationship between repeat times and net
brightness difference between the analyte and the negative control.
6.3.3

Rapid quantitative detection of IgG in the hybrid PnP device
The hybrid PnP microfluidic device can be used for the enrichment and detection of

several disease biomarkers. We first performed the on-chip ELISA of IgG in our hybrid PnP
microfluidic device. Different concentrations of IgG ranging from 0.1 ng/mL to 10 μg/mL were
injected into the device using the syringe pump to perform the colorimetric ELISA. The result
was observed with the naked eye and a portable desktop scanner was used to scan the paper
substrate for quantitative analysis. Figure 6.5 shows the gray image scanned by the desktop
scanner for IgG immunodetection on the PnP hybrid microfluidic device along with its
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corresponding corrected brightness against the concentration of IgG. We could observe that the
brightness of the hydrophilic zones was directly related to the concentration of IgG. As seen
from Figure 6.5, the detection zone containing PBS had the brightest color and the detection
zone containing 107 pg/mL of IgG had the darkest color. The brightness of other concentrations
decreased from 102 pg/mL to 107 pg/mL, from left to right. ImageJ was used to measure the
average brightness/intensity of the signal from the scanned images. Similarly, a wide linearity
range was found over the whole concentration range from 102 pg/mL to 107 pg/mL with a linear
regression of y = 5.30 log (x) + 15.72 (R2 = 0.99). LOD of IgG using the hybrid PnP microfluidic
device was calculated to be 200 pg/mL based on 3 folds of SD above the blank value. Our device
is around 10-folds more sensitive compared to the commercial ELISA of IgG, which has LOD of
1.6–6.25 ng/mL.154 Our hybrid PnP device (200 pg/mL) was also more sensitive than the paperbased device,128 the modified PMMA (0.12 μg/mL),109 the complementary metal oxide
semiconductor (10 ng/mL),166 and the paper/polymer hybrid microfluidic microplate (1.6
ng/mL).215

Figure 6.5: Rapid detection of IgG by hybrid PnP microfluidic device. The figure shows a linear
plot of the corrected brightness of IgG over a concentration range from 102 pg/mL to 107 pg/mL.
The inset shows the gray image obtained by converting the RGB image of the paper substrate
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with different IgG concentrations. The RGB image was obtained by scanning the paper substrate
from an office scanner.
6.3.4

Rapid quantitative detection of HBsAg in the hybrid PnP device
HBV is a major cause of chronic hepatic damage and of hepatocellular carcinomas

worldwide17 and roughly 30% of world’s population show serological evidence of current or past
infection.16 216 25% of people acquiring HBV infection in childhood develop primary liver cancer
or cirrhosis when they grow up.217 HBsAg, a serological biomarker for an HBV infection,
appears 2-10 weeks after the exposure to HBV and persistence beyond 6 months is due to the
progression to chronic infection.16 Globally, 248 million individuals were estimated to be HBsAg
positive.218 HBsAg can diagnose acute and chronic hepatitis B virus189-191 and the titer indicates
the level of infection and severity of the disease.15, 191 Thus, HBsAg was used as the biomarker
for the detection of HBV. Figure 6.6A shows the image scanned by the desktop scanner for the
detection of HBsAg in the PnP microfluidic device. The detection zone with PBS showed the
brightest color and the one with 340 µg/mL HBsAg showed the darkest purple color, while the
purple color intensity of other concentrations increased from 0.34 ng/mL to 340 µg/mL. Signal
intensity of the scanned image was calculated by ImageJ and a calibration curve of HBsAg over
a concentration range from 34´101 pg/mL to 34´107 pg/mL was obtained (Figure 6.6B). In
addition, a wide linearity range was found over the whole concentration range from 34´101
pg/mL to 34´107 pg/mL with a linear regression of y = 10.89 log (x) + 33.16 (R2 = 0.99). LOD of
HBsAg using the hybrid PnP microfluidic device was found to be 270 pg/mL based on 3 folds of
SD above the blank value. Our device was more sensitive than the device developed by Yazdani
et al. for detection of HBsAg (LOD of 0.5 ng/mL, which was comparable to commercial ELISA
kits).160 This shows that the proposed method is more sensitive than the commercial ELISA kits
and the paper/polymer hybrid microfluidic microplate with a LOD of 1.3 ng/mL.215
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Figure 6.6: Rapid detection of HBsAg by hybrid PnP microfluidic device. (A) Scanned image of
the paper substrate with different HBsAg concentrations by an office scanner. (B) Linear plot of
the corrected brightness of HBsAg over a concentration range from 34 ´ 101 pg/mL to 34 ´ 107
pg/mL.
6.3.5

Comparison of the PnP device with paper-based devices for the detection of HBsAg
To compare the sensitivity of ELISA and the dynamic linearity range, ELISA of HBsAg

was performed in the paper-based device. Figure 6.7A shows the image scanned by the desktop
scanner for HBsAg immunodetection on the paper-based device. Similar to detection of HBsAg
on hybrid PnP microfluidic device, the intensity of the purple color increased from 0.34 ng/mL
to 340 µg/mL from left to right. However, the purple color intensity only increased slightly from
0.34 ng/mL to 3.4 ng/mL and then got saturated at 34 µg/mL. The intensity of the signal of the
scanned images was calculated using ImageJ as described before. Figure 6.7B is the calibration
curve of HBsAg over a concentration range from 34´101 pg/mL to 34´107 pg/mL. Unlike the
hybrid PnP device, the linearity range was only found in the concentration between 34´102
pg/mL and 34´105 pg/mL with a linear regression of y = 7.80 log (x) + 28.73 (R2 = 0.96). LOD of
HBsAg using the paper-based device was found to be 2.9 ng/mL, which was 10 folds higher than
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the hybrid PnP device. In addition, repeated washing steps required in ELISA led to decrease in
hydrophobicity of the paper surrounding the hydrophilic zone. Similarly, we observed that
repeated washing in the hydrophilic zone of the paper substrate led to spreading of the reagents
over the hydrophobic area, which may lead to cross-contamination. Finally, as seen from Figure
6.7A, analytes and color production in the paper-based device tend to agglomerate at the center
of the hydrophilic zone. In contrast, the adsorption of the analyte and hence the color production
in PnP hybrid microfluidic devices are distributed more evenly (Figure 6.6 A) compared to those
in the paper-based devices. In the absence of external force, water tends to form droplets because
of the surface tension and get agglomerated at the center of the hydrophilic zone, thus analytes
get adsorbed mostly at the center and hence the color production. The tendency to form the
droplet increases with the increase in storage time of SU-8 fabricated paper substrate as the
hydrophilic zones turns more hydrophobic. In contrast, even distribution of the analyte and color
production may be due to the repeated back and forth flow of the sample through the paper
substrate with the help of syringe pump, which increases the uniformity of protein absorption as
the analyte flows more uniformly and does not form droplets. This led to significant increase in
dynamic linearity range from 3 orders of magnitude (34´102 pg/mL to 34´105 pg/mL) in the
paper-based device, to 6 orders of magnitude (34´101 pg/mL to 34´107 pg/mL) in the PnP hybrid
microfluidic device.
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Figure 6.7: ELISA of HBsAg on the paper-based device. (A) Scanned image of the paper
substrate with different HBsAg concentrations by an office scanner. (B) Linear plot of the
corrected brightness of HBsAg over a concentration range from 34´101 pg/mL to 34´107 pg/mL.
6.4

Summary
The goal of this study was to develop a highly sensitive and eco-friendly device for the

enrichment and detection of disease biomarkers. We developed a simple and portable hybrid PnP
microfluidic device that takes advantages of both paper and PMMA substrates. The hybrid
device provides a unique and low-cost platform to carry out the colorimetric assay of different
biomolecules at very low reagent and sample volume. The hybrid PnP microfluidic device has
four important features as compared to regular paper-based or PMMA microfluidic devices. (i)
The entire sample passes back and forth through the paper substrate with a certain flow rate
enriching the amount of analyte immobilized, ultimately increasing the sensitivity of the device
so that low-concentration analyte typically faced in real-world samples can be measured. (ii) The
paper substrate can be replaced with a new substrate after the completion of the assay so that the
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main PMMA framework can be used for multiple times in this PnP microfluidic device. (iii)
Reagents/analytes can be easily and rapidly transferred through the microchannels to the paper
substrate, avoiding the slower flow in the paper-based device. The flow of the reagent can be
controlled through the use of syringe pump as the rate of flow of the analyte plays an important
role in the overall sensitivity of the device. (iv) Due to the unique installation of the 3D microporous paper substrate with high surface-to-volume ratio within the PMMA slot, proteins can be
rapidly immobilized within few minutes as compared to overnight incubation in traditional
microplates, which also avoids the complicated surface modification of PMMA.
The results of the assay could be viewed within 70 min with the naked eye or scanned by
a simple desktop scanner for quantitative analysis. Without the use of any specialized equipment,
LODs of 200 pg/mL for IgG and 270 pg/mL for HBsAg were achieved, which were at least 10
folds better than those using commercial ELISA kits. In addition, the hybrid device showed a
wide linear range of five orders of magnitude for IgG and six orders of magnitude for HBsAg.
The hybrid PnP microfluidic device can be used for the rapid enrichment and immobilization of
the analyte for highly sensitive and quantitative detection of infectious diseases, cancers, and
other bio-molecules. It also remarkably reduces the reagent volume and can be reused simply by
replacing the paper substrate. This hybrid PnP microfluidic device could be immensely valuable
in resource-poor settings including rural areas, small clinics, border regions, and developing
countries, where the expensive diagnostic equipment such as microplate readers is not easily
available.
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Chapter 7: A Paper in Polymer Pond (PiPP) Hybrid Microfluidic
Device for the Detection of Cancer Biomarkers

•

This chapter introduces a cost-effective paper in polymer pond (PiPP) hybrid
device for detection of cancer biomarkers.

•

Sandwich type immunoassays of cancer biomarkers including CEA and PSA were
performed with LODs of 0.32 ng/mL and 0.20 ng/mL, respectively.

•

The hybrid PiPP device can be used for low-cost and reproducible detection of
infectious diseases, cancer biomarkers, and other biomolecules.
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7.1

Introduction
Cancer, characterized by uncontrolled growth and spread of abnormal cells in the body

has been the leading cause of death as discussed in Section 1.2. Cancer also causes a tremendous
burden to the society in terms of economic cost. In addition, cancer survival rate is very low due
to late-stage diagnosis and limited access to adequate and standard treatment. Early detection of
cancer biomarker proteins holds immense potential for the effective toxicity monitoring and
successful treatment or personalized therapy.219 The major goal in the field is to develop reliable,
low-cost, and highly sensitive biomarker detection methods to indicate cancer risk or early
detection and classification of the tumor, so the patient can get appropriate treatment and be
monitored.220 Detection of infectious diseases, cancer biomarkers, and other biomolecules can be
done with high precision, sensitivity, and specificity in the laboratory which needs expensive
instrumentation, and well-trained personnel and requires tiresome sample preparation methods.
Conventional methods including ELISA, PCR, LC/MS are limited either by analysis time,
sample volume required, or complexity for routine diagnosis.
Miniaturization of the device using microfluidic LOC technology to develop POC
devices with a minimum volume of sample/reagent but with precision and sensitivity as that of
traditional instruments including PCR, flow-cytometer, and microplate ELISA is in great need.221
Different kinds of POC devices including agglutination and lateral flow assays are being
developed for immunoassay test but most of the time they are limited by the lack of quantitative
assay and multiplex analysis.222
As discussed in Section, 1.5.3, the paper is an inexpensive and widely used substrate with
the basic principle of creating hydrophilic microchannels and reaction surface surrounded by
hydrophobic patterning materials such as wax, polymers, and inks. Similarly, PMMA remains
another widely used substrate as mentioned in Section 1.5.2. It requires surface modification for
immobilization of the biomolecules. In contrast, paper-based devices can rapidly immobilize
biomolecules but do not offer high performance in flow control. Hybrid microfluidic devices
which can extract benefits from both the substrates are being used for different applications.
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Herein, we have developed a paper in PMMA pond (PiPP) hybrid microfluidic device for
low-cost detection of cancer biomarkers. Porous 3D paper with high surface-to-volume ratio kept
over the PMMA pond can easily immobilize capture antibodies within 10 min, thereby
decreasing the assay time to 1 hr compared to 16 hr in traditional microplates. Presence of the
pond-shaped structure avoids the addition of paper substrates to individual microwells
separately, as a single paper substrate cut by laser cutter as the shape of the pond can be added ti
the PiPP device. The flow-through pond also acts as outlet channels to direct the waste reagents
to the outlet microwell. The vertical flow-through reservoirs which pass through the paper
substrate to the outlet layer ensures maximum immobilization of the protein and efficient
washing, thereby increasing the sensitivity and decreasing the background noise. Simultaneous
sandwich type multiplex immunoassay of cancer biomarkers including PSA and CEA was
performed in the hybrid device and sensitivity better than traditional microplates was obtained
without the use of any sophisticated instruments like a microplate reader.
7.2

Experimental

7.2.1

Chemicals and materials
All chemicals and materials are listed in Section 2.1.

7.2.2

Microfluidic platform design and fabrication
The microfluidic device used in this study was designed in Adobe Illustrator CS5 and

fabricated using the laser cutter. As seen in Figure 7.1, the device consists of three different
PMMA layers. The top layer has eight different fluid delivery channels connected to each inlet
microwells. The reagents added from the top reagent delivery layer flow through the fluid
delivery channel into the six reservoirs (2 mm diameter) kept just below each channel in the
middle layer. The bottom layer of the device consists of interconnected pond-shaped structures.
Each pond-shaped structure (0.6 mm in height) in the same column is connected to each other.
Finally, all the outlets for the ponds are connected to a common horizontal outlet which has a
higher depth (1.5 mm) as compared to the vertical outlet channels so that the waste reagent does
not flow back to the same or different outlet channels. SU-8 treated paper is cut by laser cutter as
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the shape of the ponds and kept over the bottom layer, so that all the reservoir in the middle layer
fall just above the hydrophilic layer of the paper (3.5 mm diameter). In this way, the reagents
added from the inlet microwell flow through the channel to the six reservoirs below each channel
and pass through the paper into the outlet pond and to the outlet. All the reagents flow through
the hydrophilic paper layer so that maximum amount of protein gets immobilized onto the
surface of the paper substrate.

Figure 7.1: Paper on PMMA Pond hybrid device consisting of a top layer, middle layer, and
bottom pond layer with the paper substrate kept over the bottom pond layer. The top layer has
inlet microwells and reagent delivery channels. The middle layer has 6 ´ 8 reservoirs. The
bottom layer has pond-shaped structure connected to a common outlet channel leading to an
outlet microwell.
7.2.3

Optimization of the concentration of capture antibody
The immunoassay of CEA was performed with different concentrations of anti-CEA

capture antibody for the optimization of the concentration of capture antibody as shown in Figure
7.2. First, different concentrations of anti-CEA capture antibody (1 µg/mL, 5 µg/mL, 10 µg/mL,
15 µg/mL, 20 µg/mL, 25 µg/mL, and 30 µg/mL in 10 mM, pH 8.0 PBS) were added to the
hybrid device and incubated for 10 min. The device was then blocked with blocking buffer for
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another 10 min followed by washing with PBST. For one set of device positive sample antigen
(500 ng/mL of CEA) was added, while for the other, negative control (PBS) was added. After
incubating the positive and negative control for 10 min, the device was washed with PBST and
10 µg/mL of anti-CEA secondary antibody was added. The device was washed with PBST after
10-min incubation followed by adding of 10 µg/mL ALP-linked IgG for 7 min. Finally, the
device was washed for three times with PBST and colorimetric substrate BCIP/NBT was added.
The device was disassembled 10 min after the addition of the substrate and the bottom pond
layer with paper substrate was scanned using an office scanner. ImageJ was used to obtain the
brightness value which was used for further study.

Figure 7.2: Schematic of the approach of immunoassay of CEA on the paper in polymer pond
microfluidic device, comprising of ten steps: (1) Immobilizing of the capture antibody in the
paper substrate, (2) Blocking, (3) Washing, (4) Addition of CEA, (5) Washing, (6) Addition of
anti-CEA antibody, (7) Washing and addition of ALP-linked IgG, (8) Washing, (9) Addition of
the substrate, and (10) Enzymatic production of insoluble NBT diformazan.
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7.2.4

Optimization of the concentration of anti-CEA secondary antibody
Optimization of the concentration of anti-CEA secondary antibody was performed with

the optimized concentration of capture antibody. First, 20 µg/mL capture antibody was added to
the hybrid device and incubated for 10 min followed by blocking with blocking buffer for
another 10 min and washing with PBST. 500 ng/mL of CEA was added as a positive control and
PBS was added as a negative control. The device was washed with PBST after a 10-min
incubation. Different concentrations of anti-CEA secondary antibody (1 µg/mL, 5 µg/mL, 10
µg/mL, 15 µg/mL, and 20 µg/mL) were added to both the positive and negative control for 10
min and washed with PBST. ALP-linked IgG (10 µg/mL) was then added for 7 min and washed
for three times with PBST. Finally, BCIP/NBT was added for 10 min and the device was
disassembled to scan the bottom pond layer with the paper substrate using a simple office
scanner.
7.2.4

Optimization of the concentration of enzyme-linked secondary antibody
After the optimization of the concentration of capture antibody and the anti-CEA

secondary antibody, concentration of enzyme-linked secondary antibody (ALP-IgG) was
optimized. First, 20 µg/mL capture antibody was added to the hybrid device and incubated for 10
min followed by blocking with blocking buffer for another 10 min. The device was washed with
PBST followed by the addition 500 ng/mL of CEA as a positive control and PBS as a negative
control. The device was incubated for 10 min and washed with PBST followed by the addition of
10 µg/mL of anti-CEA secondary antibody. The device was then incubated for 10 min and
washed with PBST. Different concentrations of ALP-linked IgG (1 µg/mL, 3 µg/mL, 6 µg/mL, 9
µg/mL, 12 µg/mL, and 15 µg/mL) were then added for 7 min and washed for three times with
PBST. Finally, BCIP/NBT was added for another 10 min and the device was disassembled for
scanning.
7.2.5

Colorimetric detection of cancer biomarkers
The paper in PMMA pond hybrid device can be used for the detection of a wide range of

biomolecules. Herein, CEA and PSA were detected in the PiPP device with all the optimized
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concentrations of different antibodies. For the detection of CEA, 20 µg/mL of capture antibody
was added to the device and incubated for 10 min followed by blocking with blocking buffer for
another 10 min (Figure 7.2). Different concentrations of CEA (0.1 ng/mL, 1 ng/mL, 5 ng/mL, 10
ng/mL, 25 ng/mL, 50 ng/mL, and 100 ng/mL) were then added to the device and incubated for
10 min. The device was then washed with PBST followed by the addition of 10 µg/mL of antiCEA secondary antibody. 6 µg/mL of ALP-linked IgG was then added for 7 min and washed for
three times with PBST. Finally, BCIP/NBT was added for another 10 min and the device was
disassembled for scanning.
Similar to the detection of CEA, detection of PSA was performed by addition of 20
µg/mL of anti-PSA capture antibody and incubation for 10 min. After the substrate was blocked
with blocking buffer, different concentrations of PSA (0.1 ng/mL, 1 ng/mL, 5 ng/mL, 10 ng/mL,
25 ng/mL, 50 ng/mL, and 100 ng/mL) were added and incubated for another 10 min. Finally, the
anti-PSA secondary antibody (10 µg/mL) was added followed by the addition of ALP-linked IgG
(6 µg/mL). The device was scanned 10 min after the addition of the substrate, BCIP/NBT.
7.3

Results and discussion

7.3.1

Optimization of the concentration of capture antibody
Optimization of the concentration of capture antibody was carried out by performing the

immunoassay of CEA with varying concentrations of anti-CEA capture antibody. As seen from
Figure 7.3, the corrected brightness value of positive control (500 ng/mL of CEA) increased with
the increase in the concentration of capture antibody from 1 µg/mL to 20 µg/mL. It reached a
plateau at 20 µg/mL and remained constant with further increase in the concentration of the
capture antibody. For the negative control (PBS) the corrected brightness value remained
constant with the increase in the concentration of capture antibody from 1 µg/mL to 20 µg/mL.
As the concentration of capture antibody increased further from 20 µg/mL there was a slight
increase in the corrected brightness value (background noise). It could also be observed from
Figure 7.3 that the signal difference between the positive control and the negative control was
maximum at the capture antibody concentration of 20 µg/mL. Therefore, 20 µg/mL of capture
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antibody was considered as the optimum concentration and all the further assays were performed
with the same concentration.

Figure 7.3: Optimization of the concentration of anti-CEA capture antibody. The line graph
shows the corrected brightness value for the positive (500 ng/mL of CEA) and negative (PBS)
control with 10 µg/mL of anti-PSA secondary antibody and 10 µg/mL of ALP-linked IgG. The
bar graph shows the signal difference between the positive and negative control.
7.3.2

Optimization of the concentration of anti-CEA secondary antibody
The concentration of anti-CEA secondary antibody was optimized after the optimization

of the concentration of capture antibody. As seen from Figure 7.4, the corrected brightness value
of positive control (500 ng/mL of CEA) increased with the increase in the concentration of antiCEA secondary antibody from 1 µg/mL to 10 µg/mL after which it reached a plateau. The
average brightness value of positive control remained almost constant with concentration more
than 10 µg/mL. For the negative control (PBS) the corrected brightness value remained constant
with the increase in the concentration of capture antibody from 1 µg/mL to 10 µg/mL. As the
concentration of anti-CEA secondary antibody increased further from 10 µg/mL, there was a
rapid increase in the corrected brightness value (background noise). It could also be observed
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from Figure 7.4 that the signal difference between the positive control and the negative control
was maximum at the anti-CEA secondary antibody concentration of 10 µg/mL. Therefore, 10
µg/mL of anti-CEA secondary antibody was considered as an optimum concentration and all the
further assays were performed with 20 µg/mL of capture antibody and 10 µg/mL of anti-CEA
secondary antibody.

Figure 7.4: Optimization of the concentration of anti-CEA secondary antibody. The line graph
shows the corrected brightness value for the positive (500 ng/mL of CEA) and negative (PBS)
control with 20 µg/mL of capture antibody and 10 µg/mL of ALP-linked IgG. The bar graph
shows the signal difference between the positive and negative control.
7.3.3

Optimization of the concentration of enzyme-linked secondary antibody
The optimal concentration of ALP-linked IgG was optimized after the optimization of the

concentration of capture antibody and anti-CEA secondary antibody. As seen from Figure 7.5,
the corrected brightness value of positive control (500 ng/mL of CEA) increased with the
increase in concentration of ALP-linked IgG from 1 µg/mL to 6 µg/mL after which it reached a
plateau and remained almost constant with any further increase in concentration of ALP-linked
IgG from 6 µg/mL to 15 µg/mL. For the negative control (PBS) the corrected brightness value
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remained constant with the increase in the concentration of ALP-linked IgG from 1 µg/mL to 6
µg/mL. As the concentration of ALP-linked IgG increased further from 6 µg/mL to 15 µg/mL,
there was a rapid increase in the corrected brightness value (background noise). It could also be
observed from Figure 7.5 that the signal difference between the positive control and the negative
control was maximum at the ALP-linked IgG concentration of 6 µg/mL. Therefore, 6 µg/mL of
ALP-linked IgG was considered as the optimum concentration and all the further assays were
performed with 20 µg/mL of capture antibody, 10 µg/mL of anti-CEA secondary antibody, and 6
µg/mL of ALP-linked IgG.

Figure 7.5: Optimization of the concentration of ALP-linked antibody. The line graph shows the
corrected brightness value for the positive (500 ng/mL of CEA) and negative (PBS) control with
20 µg/mL of capture antibody and 10 µg/mL of anti-CEA secondary antibody. The bar graph
shows the signal difference between the positive and negative control.
7.3.4

Colorimetric detection of cancer biomarkers in PiPP device
Rapid ELISA of the cancer biomarkers including CEA and PSA was achieved in the

paper in PMMA pond hybrid device. Figure 7.6A shows the image scanned by a desktop scanner
for the detection of CEA in a PiPP hybrid microfluidic device. It could be observed from the
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figure that PBS showed the brightest color and 100 ng/mL CEA showed the darkest purple color,
while the purple color intensity of other concentrations increased from 0.1 ng/mL to 100 ng/mL.
After calculating the signal intensity of the scanned images by ImageJ, a calibration curve of
concentration of CEA against the corrected brightness was plotted as seen in Figure 7.6B. Inset
in Figure 7.6B shows that a linearity range was found over the clinically relevant range from 1
ng/mL to 100 ng/mL with a linear regression of y = 27.05 log (x) + 95.86 (R2 = 0.98). LOD of
CEA using the hybrid PiPP microfluidic device was found to be 0.32 ng/mL based on 3-fold of
SD above the blank value which was sensitive enough to detect the clinical cut off value of 5
ng/mL. Our device was more sensitive as compared to colorimetric immunoassay based upon
gold nanoparticles (LOD of 2.32 ng/mL) and distance-based assay on microfluidic paper (LOD
of 2 ng/mL).223, 224 The sensitivity was comparable to microfluidic electrochemical detection
(LOD of 0.20 ng/mL) and paper-based microfluidic device (LOD of 0.3 ng/mL).225, 226
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Figure 7.6: Rapid detection of CEA in a hybrid PiPP microfluidic device. (A) Scanned image of
the paper substrate after the assay with negative control (PBS) and different CEA concentrations
ranging from 0.1 ng/mL to 100 ng/mL by an office scanner. (B) Calibration curve for the
detection of CEA as corrected brightness against the concentration of CEA. Inset shows the
linear plot of the corrected brightness of CEA over a logarithmic concentration range from 1
ng/mL to 100 ng/mL.
Rapid colorimetric detection of PSA was carried out in the PiPP hybrid microfluidic
device similar to the detection of CEA using the same optimized concentrations of different
antibodies. Detection of PSA was performed in the range of 0.1 ng/mL to 100 ng/mL. Figure
7.7A shows the image scanned by a desktop scanner for the detection of PSA in a PiPP hybrid
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microfluidic device. It could be observed that PBS showed the brightest color and 100 ng/mL
PSA showed the darkest purple color. Figure 7.7B shows the calibration curve for the corrected
brightness of different concentrations of PSA. Inset in Figure 7.7B shows that a linearity range
was found over the clinically relevant range from 0.1 ng/mL to 100 ng/mL with a linear
regression of y = 16.26 log (x) + 116.74 (R2 = 0.988). LOD of PSA using the hybrid PiPP
microfluidic device was found to be 0.20 ng/mL based on 3-fold of SD above the blank value,
which is sensitive enough to detect the clinical cut off value of 4 ng/mL. The sensitivity of the
device was better than our previous nanoparticle-mediated bioassay using a thermometer (LOD
of 1 ng/mL) and colorimetric assay (LOD of 1 ng/mL).144, 145 Our device was also found to be
equally sensitive as the microfluidic electrochemical detector which required a syringe pump
(LOD of 0.20 ng/mL).225
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Figure 7.7: Rapid detection of PSA in a hybrid PiPP microfluidic device. (A) Scanned image of
the paper substrate after the assay with negative control (PBS) and different PSA concentrations
ranging from 0.1 ng/mL to 100 ng/mL by an office scanner. (B) Calibration curve for the
detection of PSA as corrected brightness against the concentration of CEA. The inset shows the
linear plot of the corrected brightness of CEA over a logarithmic concentration range from 1
ng/mL to 100 ng/mL.
7.4

Summary
The goal of this study was to develop a simple, POC paper in PMMA pond (PiPP) hybrid

microfluidic device for the detection of cancer biomarkers. We have developed a highly sensitive
colorimetric hybrid PiPP microfluidic device taking advantages of both the paper and PMMA
substrates. The presence of the 3D micro-porous paper substrate within the pond-shaped

147

structure of the hybrid device ensures that proteins are immobilized within a short period of time
without any complicated surface modifications, so that the assay can be completed within an
hour and observed by the naked eye or can be scanned by a simple desktop scanner for
quantitative analysis. A single paper substrate pre-fabricated using SU-8 can be added to the
pond due to the presence of interconnected pond-shaped structure, which avoids the addition of
paper substrate to individual microwells. Because of the presence of reagent delivery top layer
and flow-through reservoirs kept just over the paper substrate, manual addition of reagent into
each assay zone is eliminated. In addition, the flow-through reservoir aids in efficient washing
thus decreasing the background noise and increasing the sensitivity of the ELISA. After the
optimization of different antibodies, sandwich ELISA for cancer biomarkers including CEA and
PSA was performed without the use of any specialized equipment. LODs of 0.32 ng/mL for CEA
and 0.20 ng/mL for PSA were achieved, which were at least 10 folds better than commercial
ELISA kits. This hybrid PiPP microfluidic device could be immensely valuable in POC settings
for the screening of cancer biomarkers and may have wide application as a rapid, highly
sensitive, and quantitative detection of infectious diseases, cancers, and other biomolecules.
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Chapter 8: Conclusions and Perspectives

•

This chapter describes the concluding remarks and future directions of the
research work in this dissertation.
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8.1

Concluding remarks
Five PMMA and paper/polymer hybrid microfluidic microplates have been developed for

the detection of disease biomarkers. These devices provide low-cost, POC, and rapid detection of
diseases. In this dissertation, sensitive and specific detection of infectious diseases including
Hepatitis B and Hepatitis C and cancer biomarkers for Prostate and Colorectal cancer has been
successfully demonstrated using these microfluidic microplates. In conclusion:
1. Surface modified PMMA microplate could remarkably increase the efficiency of
surface immobilization of biomolecules including proteins in a short period of time
(20 min) due to covalent immobilization. Multiplex detection of various biomarkers
including IgG, HBsAg, and HBcAg were performed with LODs of 200 pg/mL, 180
pg/mL, and 300 pg/mL, respectively, which are 10-fold more sensitive than
traditional microplates.
2. Different substrates have their own advantages and limitations. Polymer/paper hybrid
microfluidic devices can draw more benefits from both the polymer and paper
substrates and avoid some of their limitations.
3. Introduction of the low-cost 3D paper substrate with a high surface to volume ratio
within the funnel-shaped, flow-through microwells in the paper/polymer hybrid
device ensures rapid immobilization of proteins within 10 min and efficient washing,
decreasing the background noise.
4.

The top reagent delivery channels in the hybrid device can transfer reagents to
multiple flow-through microwells, avoiding repeated manual pipetting to all the
microwells or the use of costly robots. LODs of 1.3 ng/mL and 1.6 ng/mL for IgG
and HBsAg were achieved without any specialized equipment, which were
comparable to commercially used microplate ELISA.

5. In addition, for the device to have wider applications in high-end laboratories and
hospitals, the hybrid device was redesigned to make it compatible with traditional
microplate readers. Chemiluminescence ELISAs of HBsAg, HBcAg, and HCVcAg
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were performed in the hybrid device with LODs of 50 pg/mL, 35 pg/mL, and 10
pg/mL, respectively, using commercial microplate reader to read the device. The
sensitivity was about 100-fold better than the traditional microplates.
6. To further increase the sensitivity of the colorimetric device to measure lowconcentration analytes, a reusable plug-and-play hybrid device was developed. The
sample flows back and forth through the 3D paper substrate within the PMMA
channels thereby enriching the amount of analyte adsorbed and dramatically
decreasing the incubation time. The paper substrate could be replaced so that the
device can be reused. LODs of 200 pg/mL and 270 pg/mL were obtained for IgG and
HBsAg, respectively, which were 10-fold better than commercial microplate readers.
A wide linear range of five and six orders of magnitude were obtained for IgG and
HBsAg, respectively.
7. The broader application of our microfluidic approach was further demonstrated by
simultaneous multiplex detection of cancer biomarkers including PSA and CEA with
high specificity and sensitivity. LODs of CEA and PSA were found to be 0.32 ng/mL
and 0.20 ng/mL, respectively, which were 10-fold more sensitive than the clinical cut
off value of 5 ng/mL and 4 ng/mL for CEA and PSA, respectively.
8. PMMA and paper/polymer hybrid microfluidic microplates demonstrated great
potential applications in both underdeveloped and developed countries for low-cost,
sensitive, and high-throughput bioassays of infectious diseases, cancer biomarkers,
and other bio-molecules.
8.2

Future directions

8.2.1

On-chip separation of blood plasma
Pure protein samples dissolved in PBS was used for the detection of Immunoglobulin G,

Hepatitis B surface antigen, Hepatitis B core antigen, Hepatitis C virus core antigen, Prostatespecific antigen, and Carcinoembryonic antigen in this dissertation. But, for the validation of the
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reliability of the proposed colorimetric and chemiluminescence assay, the detection of the
biomarkers was carried out in the real human serum sample. Blood serum is usually obtained by
using a centrifuge. After the clotting of blood at room temperature, serum is separated by
centrifuging at around 1,600 g for 15 min, which is not suitable for POC detection. There are
different kind of POC devices to separate serum from the blood which are commercially
available. But the on-chip separation of blood plasma followed by detection of disease
biomarkers within the single biochip would be ideal. Plasma could be separated within the
device by using different techniques such as placing a blood filtering membrane inside the inlet
microwell which can separate plasma from pure blood. Other techniques such as lateral
displacement and hydrodynamic flow separation could also be used but are relatively more
complicated than filtration. That kind of devices will find broader application in POC settings.
8.2.2

Test of clinical samples
As mentioned earlier the validation of the reliability of the proposed colorimetric and

chemiluminescence assay was performed by spiking the pure protein in human serum samples.
The hybrid and surface modified devices need to be further validated by testing clinical samples
of Hepatitis B, Hepatitis C, Prostate cancer, and Colorectal cancer. The data can be further
validated by performing the ELISA of these biomarkers using commercially available 96-well
ELISA kits. The data obtained from the microfluidic devices need to be compared statistically
with the standard method including PCR and microplate ELISA to see if the result matches the
performance of the established techniques. In addition, sensitivity, specificity, false positive, and
false negative values need to be calculated with preferably 50 or more clinical samples.
8.2.3

Field validation
The major aim of this kind of microfluidic devices is to have a broad application in POC

settings. Therefore, instead of conducting these assays in a clean and well-equipped laboratory
setting, field validation and testing of hepatitis B & C at a physician’s offices, a school/college
health center or other resource-limited settings is needed in the future. For instance, detection of
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hepatitis B could be directly performed in the field using patient’s blood sample in
underdeveloped places like African region. In this way, the utility of PMMA and paper/polymer
hybrid microfluidic microplates for detection of infectious diseases and cancer biomarkers can be
validated.
8.2.4

Mobile application for data analysis
All the colorimetric data analysis for different projects in this dissertation was

accomplished using a desktop-based ImageJ after scanning devices with a common office
scanner. For POC analysis, cell phone camera can be used to take the image of the device.
Although different kinds of application including an application based upon ImageJ is available
for data analysis, these applications are not user-friendly for our devices. It is difficult to measure
so many microwells using the cell phone based application. In future, it is better to develop the
application which can easily take a picture or upload the existing picture of our device with assay
result and give the final result in a user-friendly way. It would be ideal if the application could
recognize the pattern of the device and measure the value of all the microwells at a time.
8.2.5

Broad application of the hybrid devices
This dissertation demonstrates the application of several PMMA and paper/polymer

hybrid microfluidic microplates for the detection of disease biomarkers. By changing the capture
antibody, other pathogens that cause epidemics, such as Zika, foodborne pathogens,
chikungunya, cholera, and Ebola could be tested on the microfluidic devices for rapid POC
detection. Likewise, different kinds of cancer such as lung cancer and breast cancer could also be
detected at early stages using our microfluidic microplates. In addition, the hybrid microfluidic
devices should have a variety of applications, such as 3D cell culture, drug discovery and drug
test, chemical synthesis, and so on.
8.2.6

Panel-based detection of diseases
The hybrid device could be further modified to perform a panel-based detection of

different diseases. For instance, it could be simultaneously used for detection of viral sexually
153

transmitted diseases (STDs). Different kind of STDs can co-exist together and it could save a lot
of money and resources if different STDs including HIV, Herpes, hepatitis B virus could be
detected in a single chip. In future, different conditions could be optimized so that rapid 5 min
test can be performed with this kind of device.
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